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ABSTRACT
Elastin is an important component of the extracellular matrix that endows
cardiovascular tissue with the ability to extend and recoil repetitively. It has been shown
that elastin may be vulnerable to enzymatic degradation and calcification in certain
pathological cases. As a result, elastin degeneration may be associated with the failure of
tissue-derived cardiovascular devices, such as bioprosthetic heart valves, as well as the
development and progression of aortic aneurysms, a disease associated with progressive
connective tissue degeneration of the arterial wall. Therefore, an elastin stabilizing agent
may be beneficial for both applications. As such, our objectives for elastin stabilization
are two-fold: (1) in the case of tissue-derived cardiovascular implants, to develop a tissue
pretreatment targeting elastin stabilization that may significantly extend the clinical
durability of such devices, and (2) to hinder the progression of aortic aneurysm formation
by limiting elastin degradation with the delivery of therapeutic elastin stabilizing agents.
For both of these applications, we propose to stabilize elastin using tannins, a class of
naturally derived plant polyphenols known to interact with elastin.
In studies presented here, we have confirmed that tannins bind to elastin, resulting
in improved resistance to elastolytic degradation. This binding is effective within treated
porcine aortic wall, as suggested by the preservation of elastin through in vitro and in
vivo studies.

Tannin-mediated elastin stabilization also correlated into a decreased

propensity of aortic tissue to calcify in vivo. These data indicate that tannins may be
used to improve the chemical fixation or pretreatment step used with tissue-derived
cardiovascular implants, thus increasing the longevity of these devices. In addition, using
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an animal model to induce abdominal aortic aneurysm formation, we were able to show
that elastin stabilization (via tannin treatment) may be effective in inhibiting aneurysm
formation and progression. The potential use of tannins as a novel therapy for abdominal
aortic aneurysms is significant, as the only current treatment for this potentially fatal
pathology is surgical repair (bypass with a stent graft) or outright surgical replacement,
options which possess substantial drawbacks.
Future studies are needed to better evaluate the long-term efficacy and binding
interactions between tannins and tissue. Additionally, the in vivo efficacy of tanninmediated elastin stabilization for both bioprosthetic heart valves and abdominal aortic
aneurysms should be tested in large animal models, such as sheep and/or pigs.

If

successful, this concept of elastin stabilization could have significant clinical implications
by improving the longevity of tissue-derived cardiovascular devices, and by
revolutionizing the management and treatment of abdominal aortic aneurysm patients.
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CHAPTER 1
INTRODUCTION
Elastin is an extracellular matrix protein which provides numerous connective
tissues with resilience or elasticity. In general, it is well understood that elastin is fairly
stable against proteolysis, as accounted for by its high insolubility and extremely low
metabolic turnover (with a half-life on the order of decades).1 Despite this perception,
there are distinct cases where elastin degradation and/or an imbalance of elastindegrading enzymes have been observed, namely within (1) tissue-derived cardiovascular
devices, such as bioprosthetic heart valves, and (2) the development and progression of
aortic aneurysms, a disease associated with progressive connective tissue degeneration of
the arterial wall.
Cardiovascular biomaterials derived from glutaraldehyde fixed animal tissues are
often used to surgically replace diseased or damaged human heart valves. Although these
devices improve the lives of hundreds of thousands of patients annually, they often fail
due to issues of tissue degeneration and calcification.2 Elastin and collagen are the two
major extracellular matrix components found within tissue-derived cardiovascular
biomaterials. While it is recognized that collagen fibers are adequately stabilized or
crosslinked by glutaraldehyde fixation, elastin is apparently not protected from
degeneration once implanted. This is likely due to the vulnerability of glutaraldehyde
treated elastin towards the action of matrix-degrading enzymes, as elastin lacks the amine
groups necessary for reaction with glutaraldehyde. Therefore, in regards to bioprosthetic
heart valves, the objective of this work is to develop a safe and effective procedure that
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stabilizes elastin in such as way as to render these bioprostheses more resistant to
biological degeneration. The expectation is that this approach will extend the durability
of tissue-derived cardiovascular biomaterials beyond their present limits, as the average
bioprosthetic heart valve currently lasts just 10 years.2,3
Abdominal aortic aneurysms are cardiovascular pathologies associated with
impaired aortic wall integrity, subsequently leading to an abnormal ballooning of a
segment of the artery. In general, aneurysm patients are asymptomatic, which can be
detrimental as aneurysm progression can lead to further dilatation of the artery and
eventual fatal rupture. Abdominal aortic aneurysms, which are apparently increasing in
frequency among the population, have been cited as one of the top ten causes of death
among older males.4 In fact, studies have indicated that as many as 5% of men over age
50 have such an aneurysm.5

The dilatation observed within aneurysmal tissues is

associated with deterioration of the arterial architecture. This degeneration of the aortic
wall is due to elastin degradation, one of the definining characteristics of an abdominal
aortic aneurysm. As such, it is logical to assume that the progression of this disease
could be greatly reduced by local delivery of pharmacological agents capable of
stabilizing elastin.

Such a technology could significantly increase the longevity of

aneurysm patients and substantially delay (or potentially eliminate) the requirement for
surgical interventions. The idea of elastin stabilization may present a treatment option for
patients with small or early-stage aneurysms, a group which represents the largest
percentage of patients with a known aneurysm.6 As aneurysm therapies stand now, the
only option for these patients is an imaging surveillance program; once the aorta reaches
a critical diameter, surgical repair or replacement is performed. Such an approach is
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risky, however, as 10% of aneurysm ruptures occur before reaching this critical
diameter.6
For these applications, we propose to investigate tannins as novel agents that
stabilize elastin. Tannins are naturally derived plant polyphenols, which are known to
specifically bind to hydrophobic regions in proline-rich proteins such as elastin and
collagen.7

Tannins, specifically tannic acid, are also commonly used in electron

microscopy, sometimes in combination with glutaraldehyde, for ultrastructural
demonstration of elastin fibers, suggesting that tannins bind to elastin.8,9
The work presented in the following chapters is outlined in Figure 1.1. To briefly
summarize, the motivation of this project stems from the fact that although there is no
known elastin stabilizing technology, elastin is susceptible to enzymatic degradation in
some distinct pathological cases.

Treatment with tannins can circumvent this

vulnerability to elastolysis, as we demonstrated that these polyphenolic compounds bind
to and stabilize pure elastin against the action of degradative enzymes. This idea of
elastin stabilization was extended to investigate its feasibility and efficacy within our
proposed applications, as a pretreatment for tissue-derived cardiovascular devices and as
a therapy for inhibiting aneurysm development. Studies on the structural requirements
and safety of tannin-elastin interactions revealed that tannic acid derivatives, specifically
pentagalloyl glucose, may be the ideal elastin stabilizing agent.

4

Figure 1.1 A schematic highlighting the primary studies performed for this project.
(TA = tannic acid, PGG = pentagalloyl glucose)
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CHAPTER 2
LITERATURE REVIEW

2.1 Heart Valve Prostheses
Heart valves, consisting of two or three opening leaflets or cusps (depending on
the location of the valve), control the one-way flow of blood through the four chambers
of the heart. The right and left sides of the heart each consist of two chambers and two
valves (Figure 2.1). On the right side, the tricuspid valve regulates blood flow between
the right atrium (the upper chamber) and the right ventricle (the lower chamber). The
pulmonary valve is an outgoing valve that allows for flow from the right ventricle to the
pulmonary arteries, which carry blood to the lungs to acquire oxygen. Oxygen-rich blood
is then returned to the heart to the left atrium. Similar to the tricuspid valve on the right
side, the mitral valve controls flow between the left atrium and left ventricle. Both the
tricuspid and mitral valves, classified as atrioventricular, possess a support system which
anchors the cusps into the base of their respective ventricles. The primary structural
entity of this support system is the chordae tendineae, a series of cord-like tendons which
actively help to prevent backflow into the atria during ventricular contraction. Once in
the left ventricle, blood flow is pumped through and regulated by the aortic valve out to
the aorta, allowing the distribution of oxygen-rich blood throughout the body. After
being circulated, blood returns to the right atrium via the vena cava, thus completing the
cycle.
The mitral and aortic valves are under a larger amount of stress due to higher
pressure in the left side of the heart, and thus require a more frequent need for
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replacement among these valves. This is particularly true for the aortic valve, which will
be the primary focus of this section on replacement or prosthethic heart valves.

Figure 2.1 Cross-section of the heart, including all four valves.1

2.1.1 Anatomy and Function of the Aortic Valve
The aortic valve facilitates the one-way flow of blood that is pumped from the
heart to the rest of the body. The human aortic valve consists of three leaflets which open
and close passively due to pressure differentials between the left ventricle and the aorta.
Structurally, the leaflets of these valves are primarily composed of collagen, elastin, and
glycosaminoglycans (GAGs).

These components are distributed in an anisotropic

pattern, comprising a structure with three layers: the fibrosa, spongiosa, and ventricularis
(Figure 2.2).2-4 This three-layered composite structure makes cuspal tissue extremely soft

8
and pliable when unloaded yet strong enough to bear loads when closed. The fibrosa
layer is located at the outflow surface (the aortic side of the cusp tissue) and composed
predominantly of collagen fibers aligned in the circumferential direction, parallel to the
unattached, free edge of the cusp. These collagen fibers contain macroscopic crimps that
give rise to corrugations on the outflow surface of the valve when it is open during
systole. The corrugations disappear during diastole as the cusps straighten, allowing
elongation of the layer with minimal stress.3

Figure 2.2 Cross-section of aortic valve cusp.5

The ventricularis layer exists at the inflow surface of the valve and is composed
primarily of elastin. These fibers are arranged in the radial direction, providing the tissue
with a great deal of extensibility. This permits the expansion of the cusp during diastolic
closing of the valve. Similarly, elastin recoils during the systolic phase, causing a slight
reduction in size during valve opening.6
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The shear stresses and compressive forces acting on the cuspal tissue during
flexion are managed by the action of the centrally located spongiosa layer.7 This layer
consists largely of GAGs and loosely arranged collagen fibers. The hydrophilic GAGs,
due to the absorption of water, form a gel within this center layer, which works to
minimize the shear stress which results from the opposing movement of the cusp’s two
outer layers during flexion. The spongiosa layer is also responsible for the absorption of
compressive forces acting upon the valve under diastolic conditions.
Functionally, the three anisotropic layers of the valve structure are crucial to the
durability and function of the valve.

It should be noted, however, that the outer

endothelial cell layer of this structure is also crucial to its interaction with the blood.2,8
The layer of endothelial cells covering the surfaces of the native valve allow for a
minimal amount of damage to blood components, as well as guard against the infiltration
of undesirable biological molecules such as cholesterol and lipids.

2.1.2 The Need for Aortic Valve Replacement
Diseased heart valves are generally classified as either stenotic or regurgitant.
Valvular stenosis is due to a loss of mobility of one or more valve cusps, resulting in the
partial or complete blockage of the valve orifice, causing increased resistance to blood
flow through the valve.

In contrast, valvular regurgitation (or insufficiency) is the

inability of the valve cusps to fully close, potentially resulting in undesirable backflow of
blood.

Both conditions can result in a reduced amount of blood being distributed

throughout the body and/or an increased workload on the heart itself. The most common
pathology observed in diseased heart valves is age-related (or degenerative) calcification
(Figure 2.3), resulting in valvular stenosis.9 Other conditions responsible for valvular
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disease include rheumatic fever and bacterial infection, which may induce tissue
inflammation and fibrosis, potentially producing stiff valve tissue that may become
stenotic. Marfan syndrome, a genetic connective tissue disorder, can lead to aortic
insufficiency even within younger patients.10 In addition, a number of congenital defects
that hinder normal valve formation may lead to valvular stenosis or insufficiency.

Figure 2.3 Outflow surface of normal (A) and calcified (B) aortic valves in their closed
positions. Mineral deposits on the cuspal tissue are denoted by arrows.9

To date, there is no prevalent drug therapy for diseased heart valves. Therefore,
in these cases of valvular damage or disease, surgical intervention in the form of valve
repair or valve replacement is required. The most common repair technique involves
minimally invasive valvuloplasty performed on stenotic valves. A balloon catheter is
deployed upon the diseased valve to assist in mechanically shifting the valve cusps,
potentially breaking apart areas of heavy calcification. Although potentially beneficial,
valvuloplasty patients are presented with risk of embolism (due to release of debris) or
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valvular insufficiency (due to mechanically-induced trauma to the cusp) as a result of the
procedure.11 Other methods of valve repair involve “patching” a torn or physically
damaged leaflet with a segment of autologous or xenogenic tissue such as
pericardium.12,13
Although such options for valve repair exist, the current therapy of choice for
treating diseased heart valves is clearly surgical replacement using heart valve prostheses.
It is estimated that approximately 275,000 valve replacement surgeries are performed
worldwide each year.14

This accounts for approximately 15% of all adult cardiac

surgeries.15 These replacements, which have been widely used for decades, are typically
categorized as mechanical valves or valves made from biological tissues, commonly
referred to as bioprosthetic heart valves (BHVs). Briefly, mechanical valves are known
for their biological inertness and longevity, but present the risk of thromboembolism to
the recipient; therefore, chronic anticoagulation therapies are typically required for
recipients of these valves. On the other hand, tissue-derived valves do not usually entail
long-term administration of anticoagulant medication, however they are susceptible to
degeneration and calcification, thus limiting their durability.

2.1.3 Options for Heart Valve Replacement
2.1.3.1 Mechanical Heart Valves
The evolution of mechanical heart valves has seen three generations of designs:
the caged ball, the tilting disc (or leaflet), and the tilting bileaflet designs.
The era of commercially available mechanical valves began with the
implementation of the Starr-Edwards caged-ball design in the early 1960s. (It should be
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noted that the Hufnagel descending aortic ball valve was the first design to be used in the
1950s, however its application as a “commercially available” device may be disputed
with only about 200 patients receiving this style of valve.16,17 The design, a methacrylate
ball and tube secured with nylon rings, resulted in a high rate of thromboemboli, but
displayed excellent wear resistance and paved the way for more successful devices with
similar concepts.) The Starr-Edwards valve originally implemented a methacrylate cage
housing a silicon rubber ball which served as the mobile occluding element of the valve.
The modern version of the Starr-Edwards valve (Edwards Lifesciences; Irvine, CA)
consists of a heat-cured silicon occluder and a cage covered with Teflon fabric. Although
various modifications such as these have been made, the original idea behind the design
is still in use. In fact, it is approximated that 80,000 Starr-Edwards valves have been
implanted as aortic valve replacements, with an even greater population receiving them
as mitral valve substitutes.17
While these devices were relatively successful in the clinical setting, their
susceptibility to thromboembolism and wear drove the search for a more suitable
mechanical valve design. As such, the tilting disc valves made their debut with the
Bjork-Shiley flat-disc valve in 1969. As the name suggests, the tilting disc valves consist
of a single disc which acts as the occluder, with an outer “cage” or struts serving to retain
the occluder. This tilting disc valve experienced great success for nearly two decades,
accounting for more than 150,000 aortic valve replacements in that time span.17 The
most common tilting disc valves currently in use implement a pyrolytic carbon disc
retained by titanium struts, such as the Medtronic Hall valve (Figure 2.4A; Medtronic;
Minneapolis, MN).18
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Figure 2.4 Examples of contemporary mechanical heart valves. (A) Medtronic Hall
tilting disc design, (B) Sorin Bicarbon tilting bileaflet design.

The use of tilting disc valves naturally led to the next generation of mechanical
prostheses, the tilting bileaflet design.

The Gott-Daggett bileaflet valve was first

introduced in 1963, but was taken off the market shortly after due to suboptimal flow
characteristics. However, this led to the implementation of the most widely implanted
prosthetic valve to date, the St. Jude Medical bileaflet valve (St. Jude Medical Inc.;
Minneapolis, MN).

Since its inception in the late 1970s until 2003, approximately

800,000 of these valves have been used to replace diseased aortic valves.17 Its fluid
profile, along with the implementation of pyrolytic carbon-coated leaflets and struts,
resulted in enhanced hemodynamics and biocompatibility. Various valve manufacturers
have joined in the crusade for the ultimate bileaflet mechanical valve, resulting in a
number of commercially available bileaflet designs. One recent development in these
designs is the employment of “floating hinges”, which allow the surgeon to properly
orient the leaflets in the most favorable position for fluid flow, as implemented in the
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Bicarbon valve (Figure 2.4B) by Sorin Biomedica (Saluggia, Italy) and the Edwards
MIRA valve by Edwards Lifesciences (Irvine, CA).18
2.1.3.2 Tissue-Derived Heart Valves
As with many biological materials used in the medical device industry, tissuederived valves can be broken down into three categories based on their origin: autografts,
homografts (allografts), and xenografts. As one might expect, the designs behaving most
similarly to the native valve are the pulmonary autograft and the human allograft valves.
The pulmonary autograft replacement, referred to as the Ross procedure and first
performed in the late 1960s, entails the transplantation of the patient’s own pulmonary
valve into the aortic valve position.19 The pulmonary valve is then replaced with a
cryopreserved pulmonary valve from a cadaver (homograft). Since the replacement for
the aortic valve is autologous, it results in improved hemodynamics and creates the
potential for the replacement tissue to become a living, growing (and thus dynamic)
tissue, making it an attractive valve substitute for younger patients. Along with its ability
to potentially remodel, the autografts typically do not require long-term anti-coagulation
and provide solid durability. Drawbacks of these autografts include the lack of suitable
pulmonary valves for all patients, with potential complications arising from differences in
size and geometry between the native pulmonary and aortic valves.20 In addition, with
two valves being excised, the Ross procedure is not suitable for all patients due to the
severity of the procedure. Along these lines, the Ross procedure is considered the most
technically demanding valve replacement technique for surgeons.21
Because of these complications, surgeons often opt to perform valve replacement
surgery in younger patients using a cryopreserved cadaveric human aortic or pulmonary
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valve known as an allograft or homograft. Because this type of replacement valve is
obtained through a tissue donor, there is no need for a double valve replacement as in the
case of the Ross procedure. In addition, aortic allografts present significant geometrical,
hemodynamic, and structural advantages over the use of a pulmonary valve in the aortic
position.21 However, in spite of these advantages, the possible immunologic response to
donor tissue and the limited, if any, donor-cell viability following tissue procurement,
preservation, and subsequent implantation are thought to decrease the long term
durability of these valves, especially in pediatric patients.20-22 These deficiencies, along
with the insufficient supply in both numbers and sizes of allograft valves often
necessitate the use of mechanical valves with anticoagulation therapy in young patients.20
Xenograft valves, also called bioprosthetic heart valves, fabricated from
chemically pretreated porcine aortic valves or bovine pericardia have been in use since
the late 1960s.2,18

Chemical pretreatment, often referred to as fixation, of these

xenografts is required in order to make the prosthetic devices resistant to enzymatic
attack upon implantation and to reduce immunity of the xenogenic tissue. Ongoing
improvements of these bioprosthetic heart valves (BHVs) have focused on fixation at
different pressures, as well as pretreatments to help mitigate the propensity of the
xenograft tissue to calcify, a major problem which will be discussed in greater detail later
in the text. First generation BHVs were fixed at high pressure with glutaraldehyde, but
with no anti-calcification treatments. Glutaraldehyde is a highly reactive water soluble
dialdehyde that has been widely used as a tissue fixative for xenografts due to its ability
to crosslink extracellular matrix proteins (specifically collagen), sterilize tissue, and
reduce tissue antigenicity. Many modern designs of BHVs utilize very low (or zero)
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pressure fixation with glutaraldehyde and/or include other chemical treatments that are
intended to prevent or reduce calcification. While glutaraldehyde has been used for
decades as a BHV fixative, it certainly has its drawbacks which will be addressed later in
the text; however, a clear-cut superior alternative has yet to be found.
Historically, the majority of BHVs that have been clinically utilized are stented
valves; that is, they consist of chemically fixed tissue cusps (collected from porcine aortic
valves or produced from bovine pericardia) mounted onto either a metal or plastic stent
with three posts (struts) and surrounded by a sewing ring at the base. In contrast, a
number of contemporary BHV designs are “stentless”, consisting of the porcine aortic
valve dissected with a portion of the aortic wall intact. The absence of a synthetic
support structure (i.e., a stent) in these designs is thought to allow for more natural
hemodynamics and a larger orifice area, allowing larger valves to be implanted in a given
root. Examples of both stented and stentless designs are shown in Figure 2.5. Potential
complications of stentless BHVs are derived from the fact that a greater amount of
xenogenic tissue is exposed after implantation. For instance, the portion of aortic wall
which accompanies these devices has been shown to be highly susceptible to calcific
degeneration when implanted without the proper anti-calcification measures.23,24

In

addition, stentless valves are more difficult to implant, which results in longer surgery
times; therefore, care must be taken in deciding which patients are suitable for such a
procedure. It should be noted that since stentless valves consist of a significant portion of
aorta, elastin is a component of great concern within these devices.
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Figure 2.5 Examples of stented (A) and stentless (B) BHV designs.25

2.1.4 Goals of Heart Valve Prosthesis Design
The goal of prosthetic heart valve design is to provide a durable substitute for one
or more natural heart valves that are no longer optimally functional. As previously
described by others2 and originally presented by Harken et al26, the ideal heart valve
replacement should follow the “Ten Commandments of Satisfactory Prosthetic Heart
Valves” as adapted and outlined in Table 2.1. Heart valve substitutes should be generally
biocompatible (nonthrombogenic, resistant to infection, and chemically inert); durable;
easy to implant; non-obtrusive (allowing full opening and closure); and noise free to the
patient. With the exception of a “noisy” replacement valve, the absence of one or more
of these properties may lead to potential device failure. As such, to truly understand the
requirements of an exceptional heart valve substitute, it is appropriate to investigate the
mechanisms by which current prosthetic valves fail. Since our primary focus in regards
to heart valve replacements is ultimately a treatment targeted at elastin stabilization, the
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remainder of this literature review will predominantly focus on tissue-derived
bioprosthetic heart valves.

Table 2.1 The Ten Commandments of Satisfactory Prosthetic Heart Valves
Nonthrombogenic
Chemically inert (and nonhemolytic)
Offer little to resistance to flow
Prompt closure
Complete closure
Durable
Practical and relatively easy to implant
Capable of permanent implantation
Proper healing at the implant interface
Noise-free to the patient

2.1.5 Mechanisms of Bioprosthetic Heart Valve Failure
Glutaraldehyde treated bioprosthetic heart valves (BHVs) comprise more than
half of all valve replacements, and this percentage appears to be increasing in favor of
these tissue-derived devices.27 While these BHVs improve the lives of thousands of
patients each year, their suboptimal performance is difficult to ignore. In fact, it has been
estimated that about half of all implanted valve bioprostheses fail (that is, result in death
or require re-operation) within 10 years.2,28 This loss of function can be the result of
several problems, including infection, prosthesis-related thromboembolism, nonstructural dysfunction, and structural deterioration or degradation.
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2.1.5.1 Valvular Endocarditis
Infective endocarditis is a serious problem in which the majority of cases are fatal,
necessitating a great deal of precaution concerning sterility.29 Endocarditis occurs at least
two to three times more often during prosthetic valve replacement than with other open
heart surgeries.

This high risk of infection is primarily due to the insertion of an

intracardiac foreign body and the numerous opportunities for infection during surgery
and postoperatively. The most common mechanism for failure of infected prosthetic
valves is dehiscence (loss of implant attachment due to rupture at the suture line).
Although these cases are somewhat rare, patients with early-onset valvular endocarditis
unfortunately experience an extremely high rate of mortality, estimated as high as 80%.30
2.1.5.2 Prosthesis-Related Thromboembolism
When speaking of thromboembolism risk in patients receiving replacement heart
valves, the focus automatically shifts to mechanical heart valves, and rightfully so. Due
to a combination of unnatural hemodynamics and material-blood interactions, mechanical
heart valves have the increased risk of cause thrombosis formations upon implantation.16
The natural cusps of tissue-derived valves provide a flow profile more similar to that of
the native valve, making thromboembolism in these cases an uncommon event. Although
rare, the possibility of thrombosis in patients receiving BHVs does exist, particularly in
the first few months after implantation. Just as the mechanical valves go through an
initial adaptation period just after implantation when thromboembolism risk is at its peak,
stented tissue-derived valves experience this same precarious interval. For this reason,
short-term administration (usually up to 3 months post-surgery) of anticoagulant
medication is often still prescribed for these patients. Among BHV recipients, it appears
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that those receiving stented BHVs are at a slightly higher risk for thrombosis in
comparison to patients receiving stentless BHVs.31
2.1.5.3 Non-Structural Dysfunction
Non-structural dysfunction includes problems such as tissue (pannus) overgrowth,
paravalvular leakage, hemolysis, and any other host tissue responses that might be
detrimental to the function of the implant. Unlike many of the other forms of BHV
failure, these show little specificity for the implant type, occurring at approximately the
same rate in both tissue-derived and mechanical prostheses.32 This is particularly true for
pannus overgrowth, which is the overgrowth of the tissue around the sewing ring of the
implanted valve during implant integration.

A potentially serious problem, pannus

overgrowth often compromises the ability of prosthetic valve cusps to open and close
properly.
Non-structural dysfunction can also derive itself from the interaction between the
surface of the replacement valve and blood. As such, replacement valve designs must
account for the risk of hemolysis, the destruction of red blood cells on the foreign
surfaces of valves caused by the vulnerability of these blood cells to mechanical shearing.
This can ultimately lead to a depleted capability of the blood to transport oxygen to and
from the body’s tissues. Similar to the risk of thromboembolism, tissue-derived valves
fare much better than mechanical valves in this respect, primarily due to the ability of the
more natural cusps to open completely, thus creating less hemodynamic disturbance in
the blood flow.
Leakage around the outside of the valve (at the interface between the replacement
valve and native tissue) may also have serious consequences. Referred to as paravalvular
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leakage, this malady defeats the purpose an operational heart valve by simply allowing
blood to flow around a closed prosthesis, resulting in undesirable blood backflow.
Fortunately, paravalvular leakage is extremely rare unless the valve recipient is inflicted
with valvular endocarditis.18
2.1.5.4 Structural Dysfunction
The most common form of failure for tissue-derived valves is structural
dysfunction, a mechanism of failure often separated into two categories: calcific and
noncalcific.32 Noncalcific structural dysfunction includes all forms of mechanical and
material degradation not involving cuspal mineralization. Calcific failure, as the name
implies, involves the calcification of the tissue cusps due to the deposition of calcium
phosphate crystals.33,34 This process of crystal of formation shares similarities with bone
formation and results in tissue hardening and the subsequent loss of valve mechanical
properties, ultimately causing tissue degeneration and failure.
Noncalcific Structural Dysfunction
There is considerable evidence that degradation of the extracellular matrix
components (independent of calcification) may lead to mechanical issues and ultimately
be responsible for the failure of bioprosthetic heart valves. The constant cyclic burden of
high pressure differentials across heart valves makes them extremely vulnerable to
mechanical failure, or noncalcific structural dysfunction. This is commonly manifested
through tears or perforations at highly stressed regions such as the cuspal commissures
and points of maximal flexion. Implanted valve tissue has been shown to undergo a 50%
reduction in mechanical strength after only four years of implantation.35 The alteration in
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the behavior of collagen fibers during valve flexion as well as the loss of the valve’s
ability to remodel its extracellular matrix can result in abnormal cuspal flexion. Longterm fatigue has been shown to damage the microstructure of extracellular collagen
fibrils, thus making them more prone to failure by contributing to the reduction in
bending strength of the valve tissue.7 From a biochemical standpoint, increased levels of
matrix-degrading enzymes such as matrix metalloproteinases (MMPs), which will be
discussed in greater detail later in the text (Section 2.2.1.3), have been observed in
clinically explanted bioprosthetic valves.7,36
The reduction in the amount of glycosaminoglycan (GAG) molecules is also
thought to be involved in this process, altering the natural strain-absorbing cuspal
configuration.7,37 The loss of these GAG molecules might also be responsible for the
presence of interlayer shearing, resulting in delamination, fracture, and loss of collagen
fibers from the functioning valve.
Elastin fibers, which provide tissue with resilience and serve to dampen the abrupt
loading and unloading cycles experienced by valve leaflets, are also interconnected with
the collagen fibers within these tissues. While it is unclear if their degradation leads
directly to noncalcific structural dysfunction, the mechanical role of elastin in heart
valves has been widely investigated and reported.5,38-40 This role will be discussed in
greater detail later in the text (Section 2.3.1).
Calcific Structural Dysfunction
Calcification can occur independently or in conjunction with mechanicallyinduced abrasions or tears (noncalcific dysfunction). The majority of implanted BHVs
undergo some degree of calcification, with the following three phases: nucleation,
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deposition, and accumulation leading to structural failure. The mechanisms that lead to
this type of valvular dysfunction are incompletely understood.34 Several factors influence
the likelihood of deposition, which can be divided into three categories: host factors,
implant-related factors, and mechanical stress-related factors.
The most significant and most frequently recognized host factor associated with
the promotion of implant calcification is recipient age. Calcification occurs in only 10%
of BHV patients aged 65 and over within ten years of implantation. This is in extreme
contrast to young patients (<35 years of age), of whom nearly all require reoperation and
replacement within five years of implantation, most often due to calcification.2 The
contribution of age toward the rate of calcification is thought to be the result of
comparatively high levels of osteocalcin (a bone-associated protein linked to tissue
mineralization) as well as enhanced parathyroid hormone and vitamin D metabolism in
the younger population.41
Implant-related factors affecting calcification include glutaraldehyde pretreatment
as well as the integrity of certain tissue components such as collagen, proteoglycans,
elastin, and phospholipids.23,24,41-43 The relationship between glutaraldehyde crosslinking
of BHVs and in vivo calcification is the most widely discussed implant-related factor,
with several theories attempting to explain the correlation between the two. The first, and
most widely accepted of these, is through the devitalization of the interstitial cells of
valve tissue.33,44

This action results in the loss of the cell’s ability to sustain the

energetically expensive action of the membrane calcium pumps that maintain low
intracellular calcium concentrations.

The outcome is an influx of calcium into the

phosphate-rich cell body, resulting in the nucleation of hydroxyapatite, the primary
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structural element of calcium-phosphate crystals. It is apparent, however, that this is
likely not the only mechanism through which glutaraldehyde affects implant
calcification. The crosslinking of acellular collagenous biomaterials has also resulted in a
calcified matrix, revealing that the amount of calcification may be proportional to the
level of crosslinking.45 Additionally, it is theorized that the binding of the amine groups
of lysyl side chains within the collagen molecule by glutaraldehyde might result in a net
negative charge among collagen’s amino acids, exposing negatively charged carboxyl
groups for binding to positive calcium ions. Furthermore, residual free aldehydes (those
aldehyde groups which are loosely bound or unreacted) have been implicated as a major
mechanism for the promotion of calcification.46,47
The exact role of extracellular matrix components in calcification is still unclear,
although several theories exist for their involvement. Studies have shown that collagen
fibers may potentially act as sites for crystal nucleation in undersaturated solutions of
calcium and phosphate, thereby serving as a catalyst for the formation of
hydroxyapatite.33

The likelihood of collagen’s involvement in the initial phase of

calcification could be small, but it may participate in the accumulation and enlargement
of the hydroxyapatite formation. Proteoglycans are thought to play in a role in the
prevention of the hydroxyapatite nucleation process via multiple mechanisms, including
serving as a protector of collagen molecules. The staggered nature of collagen molecules
creates a series of empty gaps, which are occupied by proteoglycans. Seemingly, by
filling these holes, proteoglycans interfere with hydroxyapatite nucleation and protect the
collagen from calcification.33,34 In addition, the glycosaminoglycan components of these
molecules may serve to chelate calcium, thereby preventing binding with extracellular
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phosphate in the nucleation of hydroxyapatite crystals.7

The link between

glycosaminoglycan loss and calcification is noteworthy since glutaraldehyde has no
apparent stabilizing effect on these molecules.48
Similar to the lack of reactivity with glycosaminoglycans, glutaraldehyde fixation
also has an extremely limited effect on elastin.49 Elastin, a structural protein responsible
for tissue recoil, is abundant in the aortic wall (making it an extremely vital component of
stentless BHVs), and although present in small amounts, works as a functional
component of aortic valve cusps.39 It has been shown that elastin may be susceptible to
deterioration in BHVs, which likely leads to subsequent initiation and proliferation of
calcium deposition.24,50,51 While the exact mechanisms of elastin-oriented calcification
are not fully understood, it is hypothesized that elastin’s vulnerability to this pathology
begins with the degradation of its own protective coating.34 This degradation renders
particular areas of the elastin molecule susceptible to calcium binding, thus leading to
hydroxyapatite formation. Furthermore, it appears that elastin degradation can actively
stimulate the manifestation of osteogenic proteins and genes, which ultimately leads to
increased propensity to calcification.52,53
Phospholipids have also been implicated in calcification, however, their role is
unclear but suspected to be electrostatic in nature.

This is supported by evidence

suggesting that implants devoid of lipids contain much lower amounts of calcium and are
therefore less likely to undergo calcification.44,54
It is also believed that mechanical stress acts as a catalyst for the formation of
calcific deposits within implanted BHVs. Hydroxyapatite deposition most often occurs
in areas under the highest levels of stress and/or flexure such as the cuspal
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commissures.55 As with many issues involving cardiovascular implant calcification, the
exact correlation between mechanical stress and tissue mineralization is not completely
understood. Studies have shown that implants in the mitral position are more likely to
calcify than those in the aortic position, presumably due to the higher stresses incurred by
the mitral valve when closed, thus linking mechanical forces and mineralization.56,57
Higher mechanical stresses have also been theorized to contribute to the increased rate of
calcification in younger patients.58

This apparent synergism between calcific and

noncalcific structural dysfunction underlines the importance of maintaining the structural
integrity of the tissue components within replacement heart valves.

For instance,

degradation of elastin could lead to both calcific and noncalcific mechanisms of failure.

2.1.6 Limiting Structural Dysfunction in Bioprosthetic Heart Valves
In addition to reducing tissue antigenicity, chemical pretreatments of BHV tissue
primarily exist to perform one of the following preventive functions: (1) resist enzymatic
and chemical degradation, or (2) serve as an anti-calcification therapy. In other words,
their purpose is to limit noncalcific and/or calcific structural dysfunction, respectively.
2.1.6.1 Glutaraldehyde Fixation
As early as 1967, researchers discovered that collagenous biomaterials could be
stabilized by reaction with aldehydes. Initial investigations into tissue fixation focused
on two common fixatives, glutaraldehyde and formaldehyde. Experiments suggested that
although formaldehyde was successful as a tissue fixative, it did not result in the same
resistance to degradation as glutaraldehyde.59

Formaldehyde has only one active

aldehyde group in its chemical structure, while glutaraldehyde is a dialdehyde. The
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difunctionality of glutaraldehyde makes it capable of forming extremely stable crosslinks
between lysine groups of protein molecules, thereby increasing the tissue’s resistance to
degradation.
Glutaraldehyde crosslinking is successful in making certain components of the
tissue, namely collagen, resistant to enzymatic and chemical degradation by the
formation of stable crosslinks within and between the molecules of the extracellular
matrix. Moreover, these crosslinks reduce tissue antigenicity, thereby limiting implant
rejection. Glutaraldehyde is also capable of killing both bacteria and spores, making it a
successful sterilizing agent.59
The

fixation

reactions

involving

glutaraldehyde

are

dependent

upon

concentration, temperature, pH, and the composition of the glutaraldehyde solution (i.e.
the amount of monomer and polymer components).59,60 The functional groups taking part
in this reaction are the amines of peptide lysyl residues and the two aldehydes of
glutaraldehyde. Many forms of this reaction are possible, some of which may contribute
to the unusual long-term stability of the crosslinks formed. The proposed crosslinking
structures of glutaraldehyde can be both short and long, allowing crosslinks to form both
intramolecularly (within individual collagen fibers), as well as intermolecularly (between
adjacent proteins molecules), resulting in the stabilization of the implant tissue.
While glutaraldehyde treated BHVs provide a valve substitute that is sterile, nonantigenic, and fairly resistant to collagen-specific degradation, this pretreatment is
certainly not without fault, as indicated by their limited durability. Structural changes
undergone within and between collagen fibers impose a variety of alterations in the
mechanical properties and flexural behavior of the replacement tissue.

Additional

28
drawbacks of glutaraldehyde fixation include incomplete fixation of certain extracellular
matrix (ECM) components (other than collagen) and cell lysis, which results in the
exposure of intracellular components to the extracellular environment.
The altered mechanical properties of BHVs due to glutaraldehyde crosslinking are
frequently implicated in the susceptibility of these implants to failure.3,61-67 Bioprosthetic
valves are subjected to three types of stress: tensile, compressive, and shear. These all act
in a cyclic manner, loading and unloading the tissue as the heart beats nearly 30-40
million times per year.

For this reason, the mechanical properties and the fatigue

resistance of this tissue are extremely important factors to consider in design. Despite
these considerations, glutaraldehyde fixation has been shown to cause an increase in
tissue stiffness, possibly resulting in abnormal flexure patterns during valve function.3,64
Another major shortcoming of glutaraldehyde fixation is its inability to stabilize
non-collagenous components of the ECM. Many of the molecules making up the ECM
lack the amine functionalities necessary for crosslinking with aldehydes, most notably
elastin and glycosaminoglycans (GAGs), leaving them susceptible to enzymatic
degradation.49,68,69
In regards to elastin, this vulnerability is significant considering it is one of the
major ECM components of the aortic segment of stentless BHVs and the ventricularis
layer of the valvular cusp structure. Elastin degeneration could lead to loss of elastic
recoil and deterioration of mechanical properties,40,70 potentially resulting in clinical
failure of implanted cardiovascular prostheses.

The inability of glutaraldehyde to

stabilize elastin is also significant with respect to calcification, as elastolysis and the
presence of elastin-degrading enzymes, specifically matrix metalloproteinases (MMPs),
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have been linked to calcium deposition.71 In regards to GAGs, the hydrophilicity of these
molecules contributes greatly to the shear behavior of valve tissue, an action occurring
primarily in the spongiosa layer. Failed glutaraldehyde treated BHVs have been shown
to have a decreased amount of GAG molecules, furthering their implication in valve
failure.7,37 These facts suggest that elastin and GAG degeneration in glutaraldehyde
treated BHVs may be important clinically.
Natural heart valves are certainly dynamic structures, a quality which is lost by
“locking” the tissue into place by glutaraldehyde fixation. Through the formation of
extremely stable crosslinks within the extracellular matrix, the ability of structural
collagen fibers to deform in response to applied forces is diminished.72,73 Under normal
circumstances, the fibers making up the ECM are constantly rearranging within the
surrounding ground substance in order to optimize the valve’s mechanical properties for
the current phase of the cardiac cycle. The loss of this ability further contributes to the
suboptimal mechanical properties of glutaraldehyde treated bioprosthetic tissue.
Similarly, glutaraldehyde pretreatment also leads to a loss of cell viability within
the BHV tissue. The interstitial cells existing within all three layers of the heart valve
structure serve a key role in its function by maintaining the mechanical integrity of the
tissue as it undergoes constant fatigue. These cells work to continually replenish the
ECM in response to the dynamic loads and environment. The loss of this cellular
capability is largely responsible for the gradual degradation of glutaraldehyde crosslinked
bioprosthetic heart valves.

Endothelial cells also play an important function in the

prevention of valve related complications, but are adversely affected by glutaraldehyde
fixation. These cells serve as a blood interface throughout the cardiovascular system
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preventing the initiation of the coagulation cascade. By causing the denuding of this
endothelial layer in cuspal tissue, glutaraldehyde is responsible for potential
thromboembolic events which may result from the contact of blood with subendothelial
components.
2.1.6.2 Anti-Calcification Pretreatments and Alternative Fixatives
In addition to glutaraldehyde’s effect on the viability of different cells and
biostability of ECM components, the fixative has also been implicated as a direct
contributor to the pathogenesis of calcification. This is thought to occur secondary to
many of the problems previously discussed, such as cell death. For instance, free residual
aldehydes (which are toxic) following fixation are thought to be promoters of calcium
deposition.46,47 As a result, many BHVs now incorporate anti-calcification pretreatments,
some which work in conjunction with glutaraldehyde and others which have been
proposed as replacements to glutaraldehyde (that is, tissue fixatives which are less likely
to calcify than glutaraldehyde).
As mentioned, residual aldehydes and “free” glutaraldehyde (that which is not
fully bound) are believed to be linked to calcification. Therefore, one strategy to mitigate
calcification is to neutralize these free aldehyde groups with compounds that have
reactive amines, thus “capping off” or quenching these aldehydes. The most notable of
these neutralizing agents are common amino acids such as glutamine, homocysteic acid,46
and lysine.74,75 Other anti-calcification agents used in conjunction with glutaraldehyde
include amino-oleic acid76 and amino-biphosphonates.77 While it is suspected that both
of these compounds work as aldehyde neutralizing agents, other mechanisms may also
play a role. For instance, it has been hypothesized that amino-oleic acid may work to
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limit the diffusion of calcium ions into valve-related tissue.78

Similarly, amino-

bisphosphonates, which are widely used in orthopedic research as well, are known to
disrupt crystal formation, thus hindering the production of hydroxyapatite. Aluminum
chloride, ethanol, and detergents are also among the growing class of anti-calcification
treatments that are used in combination with glutaraldehyde. Rather than working to
“neutralize” glutaraldehyde, as in the case of some of the aforementioned amino acid
treatments, these agents are active toward other components of the tissue such as elastin
and phospholipids. The use of aluminum chloride is particularly noteworthy for the
aortic portion of stentless BHVs, as this compound apparently binds to elastin and in
doing so, delays the onset of elastin-oriented calcification.79-81 In addition to aluminum,
other trivalent metal ions, namely ferric chloride, have also exhibited promising anticalcific properties.80,82 Ethanol is often used to treat BHV cusps for its ability to extract
cell lipids, which are a major proponent of calcification.

In addition, this ethanol

pretreatment has been shown to have an effect on the conformation of collagen fibers,
which is believed to be beneficial towards calcification prevention.44
A number of anti-calcification therapies have been used without glutaraldehyde
fixation and have shown to successfully inhibit or delay tissue mineralization, however
none are in clinical use to date. The term “anti-calcification therapy” may be misleading,
as the primary purpose of the majority of these compounds is not necessarily to prevent
calcification. Rather, they are meant to be alternative crosslinking agents and since they
do not implement glutaraldehyde, they also result in reduced propensity to calcify. The
most popular of these alternative fixatives includes the use of carbodiimides83 as well as
fixations triggered by the oxidation of a light-sensitive dye (PhotoFix®, Carbomedics;
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Austin, TX).84

In regards to carbodiimides, 1-ethyl-3-(3-dimethyl aminopropyl)-

carbodiimide (EDC) is used in conjunction with n-hydroxysuccinimide (NHS), which
acts as an enhancer to the reaction. By coupling the amine and carboxyl groups within
the tissue, this treatment creates amide bonds or bridges between proteins, thus
crosslinking the tissue.83,85 Photo-oxidation fixation relies on the use of a photoactive
dye, whose activation leads to the formation of a catalyst. This catalyst aids in the
conversion of amino acids within the tissue, subsequently allowing for crosslink
formation with nearby amino acids.86,87 These BHV pretreatments, along with a number
of others including epoxies,88 diisocyanates,89 acyl azide,90 and genipin91 have resulted in
reduced calcification and cytotoxicity (in comparison to glutaraldehyde treated tissue) in
animal models.

Although these alternatives appear somewhat promising, questions

remain as to their ability to crosslink collagen to the same degree as glutaraldehyde. As
such, glutaraldehyde-fixed devices are still the conventional choice for commercially
available BHVs, often used in conjunction with one or more of the aforementioned
anticalcification treatments.

2.2 Abdominal Aortic Aneurysms

2.2.1 Definition and Pathological Characteristics
Aneurysms are vascular pathologies associated with impaired integrity of the
blood vessel wall, subsequently leading to an abnormal ballooning of a segment of the
artery (Figure 2.6). They occur most commonly in the aorta (thoracic aneurysm if in the
chest, abdominal aneurysm if in the abdomen) or in the blood vessels in the brain
(cerebral aneurysm).
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Abdominal aortic aneurysms (AAAs), which are the most common, typically
occur in the infrarenal abdominal aorta; that is, the portion of aorta between the renal
artery branches and the iliac bifurcation. In general, AAA patients are asymptomatic,
which can be detrimental as aneurysm progression can lead to further dilatation of the
artery and eventual fatal rupture. AAAs, which are apparently increasing in frequency
among the population, have been cited as one of the top ten causes of death among older
males.92 In fact, studies have indicated that as many as 5% of men over the age of 50
have an AAA.93

Figure 2.6 Schematic depicting a normal and aneurysmal abdominal aorta.94

While smoking is the most common risk factor for AAAs, strong correlations
have also been observed for genetic predisposition, hypertension, age, atherosclerosis,
and sex.95 For instance, those patients with a family history of AAAs have an increased
risk of about 30% and are apparently more likely to experience aneurysm rupture.96
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Furthermore, even though men are 10 times more likely to have an AAA, women are
about 3 times more likely for that AAA to rupture.97,98
Although aneurysms were once believed to be caused solely by a late
degenerative phase of atherosclerosis, their pathogenesis is now considered to be more
multifactorial.92

The risk factors listed above, such as genetic predisposition,

hypertension, immunologic factors, hemodynamic factors, and defects of arterial
components can also play a role in aneurysm development. However, it should be noted
that atherosclerosis can still signficantly contribute to this “multifactorial” theory behind
aneurysm formation. For instance, atherosclerotic lipid and calcium deposits within the
arterial wall can elicit an inflammatory response, thus stimulating secretion of elastolytic
enzymes. These subsequently induce and maintain progressive destruction and
weakening of aortic structural proteins, which eventually results in aneurysmal dilatation.
As such, AAA development is typically characterized by aortic dilatation, an overall
degeneration of the arterial architecture, the presence of matrix-degrading enzymes, and
inflammatory infiltration.
2.2.1.1 Aortic Dilatation
Normal infrarenal aortic diameters are about 1.7 cm in men over the age of 50.
Conventionally, any aorta 3 cm in diameter or larger is considered aneurysmal.
According to the American Academy of Family Physicians, an aneurysm is a “permanent
focal dilatation of an artery to 1.5 times its normal diameter”.99 As this statement
implies, aortic dilatation is the primary characteristic by which aneurysms are defined.
As a result, aortic diameter is the sole means of diagnosing and monitoring AAAs. The
observed dilatation is associated with changes in aortic wall mechanical properties,100
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which can be further attributed to other characteristics of AAA formation, namely loss of
extracellular matrix components such as elastin and collagen.
2.2.1.2 Degeneration of Extracellular Matrix Components
The mechanical properties exhibited by the aortic wall rely on the extracellular
matrix components, elastin and collagen. Therefore, the loss of structural integrity of the
aneurysmal aortic wall is primarily explained by degeneration (and remodelling in
general) of these matrix components.101,102
It is well understood that elastin, which provides resilience or elastic
distensibility, absorbs the majority of normal load experienced by the abdominal aorta
under physiological conditions. At the same time, aortic collagen functions as a “safety
net”, assisting in bearing a portion of the load during periods of heightened aortic
distension and high pressures.103 In a healthy aorta, these two proteins work in concert to
provide a three-dimensional network which simultaneously endows the aorta with
distensibility and strength.
Accelerated elastin degradation has been established as a primary trait of AAA
and is thought to be essential in the formation and progression (expansion) of these
pathologies.104,105 It has been estimated that there is a 75% loss of medial elastin content
in explanted human aneurysmal aortas as compared to normal aortic tissue.105 Studies
have also shown that the diseased tissue from AAA patients exhibit elastic lamellae
disruption or fragmentation and increased levels of elastase activity.105-107 This lack of
elastin within the aneurysmal aorta contributes to its inability to maintain its original size
and shape, resulting in the typical “balloon” associated with aneurysms.
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On the other hand, loss of collagen has been linked to aneurysm rupture.104 In
regards to collagen, the term “loss” may be misleading since it has been found that the
collagen content within aneurysms actually increases as the aneurysm grows.108 This
increase in collagen is likely a compensatory response due to loss of elastin and collagen,
increased mechanical load on the existing collagen fibers, and an overall increase in
tissue remodelling.

The increased cyclic load has been shown to induce collagen

synthesis by nearby vascular smooth muscle cells.109 In addition to medial smooth
muscle cells, collagen is also laid down by adventitial fibroblasts. These compensatory
mechanisms do well in keeping the diseased aorta functional as long as possible;
however, they obviously have a threshold. The ultimate strength of the diseased aorta
relies on collagen; as such, it is reasonable to assume that rupture occurs when collagen
degradation (mediated by matrix-degrading enzymes) exceeds this compensatory
collagen production.
2.2.1.3 Matrix Metalloproteinase Activity
Various enzymes are believed to play in a role in the development and
progression of AAAs. Included in this group are cathepsins,110 serine proteases,111 and
plasminogen activators.112 Cathepsins and serine proteases are capable of some of the
proteolytic activity similar to that which is described and observed within aneurysmal
tissue. Plasminogen activators assist in transforming plasminogen to plasmin, a general
protease that is capable of activating matrix metalloproteinases (MMPs). While these
different enzymes play a role in the aforementioned proteolysis associated with
aneurysms, MMPs are apparently the group of enzymes most closely related to arterial
wall weakening and AAA development.113
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MMPs are a family of enzymes that play an important role in extensive tissue
remodelling, specifically by degrading extracellular matrix components such as elastin
and collagen. MMPs are characterized from other proteases by their requirement for zinc
binding to their active site. They are secreted in latent form and because of their potential
proteolytic (and thus destructive) nature, MMP activation is deeply regulated on multiple
levels: intracellular gene transcription, extracellular activation of the latent enzyme, and
inhibition by endogenous tissue inhibitors of metallproteinases (TIMPs).108 In general,
MMPs consist of three domains: (1) the propeptide domain, including the cysteine switch
which is important in maintaining latent form, (2) the catalytic domain, which possesses
the zinc binding site, and (3) the C-terminal domain, which is the varying portion across
different MMPs. TIMPs inhibit MMPs by irreversibly binding to the active form of the
protease in a 1:1 molar ratio. Consequently, the overall proteolytic environment is
determined by the relative amounts or ratios of MMPs and TIMPs.
While MMPs are prevalent in pathological disorders, they are also important in
normal physiological processes such as angiogenesis, bone remodelling, embryogenesis,
and many others. Some of the cardiovascular diseases in which elevated levels of MMPs
are observed include intimal hyperplasia, atherosclerosis, heart valve disease, and aortic
aneurysms.108,114
Specific to aneurysms, the most widely investigated MMPs are those capable of
elastolytic activity: MMP-2 (72 kDa gelatinase), MMP-9 (92 kDa gelatinase), and MMP12 (macrophage metalloelastase). The role of such enzymes has been validated by
experimental results as well as studies on explanted human AAAs. It is believed that
MMP-2 plays a significant role in initial aneurysm formation, as it has been found in high
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concentrations within small or early-stage aneurysms in experimental animal models and
human tissue.115 This trend of elevated MMP-2, which is commonly secreted by smooth
muscle cells and fibroblasts, has been observed in the form of increased enzyme
activity107 and increased mRNA expression.116
The other gelatinase, MMP-9, has also been found to contribute to AAA
development. MMP-9, which is capable of degrading elastin (but to a somewhat lesser
degree than MMP-2)117, is exhibited in human aneurysmal tissue at levels 10 times
greater than normal aorta. This same study revealed that the predominant source of
MMP-9 overexpression was localized to macrophages.118

MMP-9 is of utmost

importance as it is the most abundant elastolytic enzyme found within aneurysmal tissues
and possesses strong collagenolytic capabilities as well.119
The roles of MMP-2 and MMP-9 on aneurysm formation have been further
authenticated with the implementation of knockout mice models. MMP-2 and MMP-9
knockout mice were extremely resistant to experimental aneurysm formation, displaying
virtually no increasee in aortic diameter (less than 10%) in both cases.120 This study
revealed that the absence of either gelatinase offered protection toward the tissue’s
matrix, thus preventing aneurysm formation. As a result, an interaction between these
two MMPs is apparently required to properly elicit aneurysm formation; in other words,
the enzymes work in concert within this pathology.
In regards to MMPs, one of the primary catalysts for aneurysm formation is
apparently an imbalance between MMPs and their inhibitors, TIMPs. Expression of
MMP-2, MMP-9, TIMP-1, and TIMP-2 mRNA was elevated in human aneurysmal aorta
versus normal aorta.121 The key to this study, however, was the large increase in the ratio
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between MMPs and inhibitors, suggesting an imbalance that favors proteolytic
degradation. Similar results, also on human cadaveric tissues, have been published
confirming an extreme increase in the MMP-2 to TIMP-2 ratio (for protein) for
aneurysmal aorta.122 In general, all TIMPs possess the ability to inhibit multiple different
MMPs, however, it appears that TIMP-1 possesses an affinity to inhibit MMP-9 while
TIMP-2 is important in regulating MMP-2 activity.108 Mice deficient in the gene for
TIMP-1 exhibited an increased susceptibility to AAA formation, indicative of the
protective effects of these endogenous MMP inhibitors.123
Aside from MMP-2 and MMP-9, other MMPs have been investigated for their
part in aneurysm formation and development, such as MMP-1, MMP-8, MMP-12, and
MMP-13. MMP-1 is an interstitial collagenase that is increased in human aneurysms and
in addition to possessing the ability to directly digest collagen, can also cleave latent
MMP-9 into its active form.124 MMP-8, a relatively powerful neutrophil collagenase, is
elevated within human AAA tissue.125

This enzyme has been connected to

atherosclerosis and, more recently, shown to be in abundance along with MMP-9 at the
site of aneurysm rupture.126 MMP-12 knockout mice displayed somewhat improved
resistance to aneurysm formation in an experimental model.127 It is important to note,
however, that the effect of MMP-12, a macrophage metalloelastase, knockout was not
nearly as significant as compared to MMP-2 and MMP-9 knockout studies.120,127 MMP13, also referred to as collagenase-3, is also overactive in aneurysmal aorta.128 This
collagenase is localized to smooth muscle cells (SMCs) and is adept in activating other
latent MMPs. The origins and substrates for these MMPs is summarized in Table 2.2.
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Table 2.2 Matrix Metalloproteinases (MMPs) Associated with Aneurysm Formation115
Enzyme

Alternate name

Primary substrate(s)

Source/origin

MMP-1

Collagenase-1

Collagen (type I, III)

Inflammatory

MMP-2

72 kDa gelatinase A

Collagen (type IV), elastin

SMCs, fibroblasts

MMP-8

Neutrophil
collagenase

Collagen (type I, III)

Neutrophils

MMP-9

92 kDa gelatinase B

Elastin, collagen

Macrophages, SMCs

MMP-12

Macrophage elastase

Elastin

Macrophages

MMP-13

Collagenase-3

Collagen (type IV)

SMCs

2.2.1.4 Inflammation
A notorious attribute of abdominal aortic aneurysms is the consistent presence of
an inflammatory infiltrate.

This inflammation is characterized by the presence of

macrophages and lymphocytes.104,107 One study on human AAA specimens revealed that
approximately 80% of aneurysms had major inflammatory infiltrates.129 The use of
powerful immunosuppressants has also been shown to at least partially prevent
experimental aneurysm formation in rodents.130
Although the exact source of this inflammation is unclear (and likely varies from
patient to patient), potential causes include an autoimmune response131 or an infection
due to chlamydia pneumoniae.132 The intense inflammatory reaction is more likely
induced by products of matrix degradation, specifically elastin peptides. These peptides
apparently serve as a chemotactic agent for infiltrating macrophages through interactions
with the 67 kDa elastin laminin receptor.133 Vascular smooth cells exposed to elastin
peptides in vitro exhibited an increased expression for this receptor as well as an increase
in MMPs.134
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Inflammatory cells are a common source for many of the aforementioned MMPs
implicated in aneurysm formation, most notably MMP-9. As such, it is likely that these
cells release a cascade of pro-inflammatory cytokines that results in the activation of
MMPs and other proteolytic enzymes.115 Such cytokines have been found to be elevated
in aneurysm patients, including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor
(TNF)-α.119 With this in mind, it is reasonable to assume that there is likely a complex
interaction between matrix degradation, the production of matrix-degrading enzymes, and
the recruitment of inflammatory cells.
2.2.1.5 Summary
Abdominal aortic aneurysms are clearly complex pathologies that cannot be
explained by one particular phenomenon. Instead, they are likely due to a multifactorial
process characterized by enzymatic degradation and inflammation. Figure 2.7 shows a
hypothesized path for aneurysm formation. While this is one viable path, it is important
to note that the chronology of these events may vary significantly from case to case.
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Figure 2.7 Hypothesis for mechanisms of abdominal aortic aneurysm formation.

For the set of circumstances shown in Figure 2.7, initial matrix degradation (due
to aging, angiogenesis, protease/inhibitor imbalance, or atherosclerosis) may result in the
release of elastin peptides.

These peptides will elicit an intensified inflammatory

response. This elevated inflammation likely causes the release of more MMPs, such as
MMP-9 which has been primarily localized to macrophages. Elevated MMPs cause even
more matrix degradation, and the subsequent release of more degradation products. This
triggers the intertwined ongoing cascade of MMP production, matrix degradation, and
inflammation, eventually leading to enough tissue degeneration to allow for aneurysmal
dilatation.

43
2.2.2 Diagnosis and Screening
The majority of abdominal aortic aneurysm patients are asymptomatic. As a
result, aneurysms are most often discovered incidentally via imaging processes such as
ultrasonography, computed tomography (CT) scans, magnetic resonance imaging (MRI)
scans, and chest X-rays. It should be noted that in cases of very large AAAs, physical
palpation of the patient’s abdomen can reveal the presence of arterial dilatation.
However, this detection method is severely limited in its accuracy, particularly with
obese patients135 and those patients with early stage (3.0 to 3.9 cm) aneurysms.136
However, late stage aneurysms (greater than 5.0 cm) are palpable 76% of the time.136
As stated earlier, aortic diameter is the primary means of diagnosing and
monitoring aneurysm formation and progression. Aortic diameters that are 3 cm or larger
are considered aneurysmal and merit further observation. Frequency of surveillance is
dependent on the size of the aneurysm, as outlined in Table 2.3.

Screening and

monitoring are most often performed by abdominal ultrasound, which is relatively
inexpensive, non-invasive, and does not require contrast media. CT imaging is more
expensive and requires intravenous contrast agents, but its image provides more insight
and accuracy in regards to the size and three-dimensional shape of the aneurysm. Figure
2.8 shows an example of a 3D CT scan of an AAA in a human.
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Table 2.3 Recommended Surveillance for Abdominal Aortic Aneurysm Patients99
Diameter of aneurysm

Frequency of follow-up observation

Less than 3 cm

No further testing

3 to 4 cm

Every 12 months

4 to 4.5 cm

Every 6 months

Greater than 4.5 cm

Referral to vascular specialist

Figure 2.8 Three dimensional CT scan of an abdominal aortic aneurysm.99

Unfortunately, ruptured aneurysms are associated with an extremely high
mortality rate.

This, along with the fact that the majority of AAA patients are

asymptomatic, has led to the possibility of routine screening for asymptomatic adults. In
a “consensus statement” made by a number of American vascular specialists in 2004,
they recommended that the following groups be screened for AAAs even if
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asymptomatic: all men 60 to 85 years of age, all women 60 to 85 years of age with
cardiovascular risk factors, and both men and women over 50 years of age with a family
history of AAA.137 Recently, this suggestion came to partial fruition in the United States,
as the SAAAVE Act was passed into legislation.138 This law provides for aneurysm
screening as a Medicare benefit for high-risk males (those with a family history of AAAs
and those who smoke). The significance of this new legislation is profound in that it will
allow many more aneurysms to be detected and at an earlier stage. The need for such a
screening program has been justified with similar clinical studies. For instance, the
Multicenter Aneurysm Screening Study Group in the United Kingdom utilized a very
large sample size of asymptomatic men (approximately 67,000) and found that
approximately 5% of those subjects had an abdominal aortic aneurysm.93 Furthermore,
the screening decreased aneurysm-related mortality by 50% in comparison to a control
group of patients who were not screened.

2.2.3 Current Options for Treatment or Repair
Currently, the primary methods of AAA treatment are surgical repair of the
diseased aorta in order to prevent rupture.

For this reason, elective surgery is not

suggested until the risk of rupture exceeds the risk of operative mortality. Through
various trial studies, it has been established that an aortic diameter of 5.5 cm should serve
as the threshold of AAA surgical repair. In one study, moderate aneurysms (4 to 5.5 cm)
were electively repaired, but with minimal benefits.

Mortality was not improved

improved in these patients as compared to those that underwent normal imaging
surveillance without surgery.139 In a different study, the UK Small Aneurysm Trial
reaffirmed that the benefits of elective surgery performed on small or moderate diameter
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aneuryms (less than 5.5 cm) did not outweigh the surgical risks.140 Once the aortic
diameter surpasses 5.5 cm, however, risk of rupture rises from 1% to 10%; thus, the 5.5
cm threshold.119 This limit has not been validated for females with AAAs, which is
noteworthy since it has been observed that the risk of rupture within women is greater
and is more likely to occur at a smaller diameter than men.104
In the cases where surgical repair is required and performed, two options exist:
open and endovascular repair.

Open aneurysm repair (Figure 2.9) is the more

conventional therapy in which the diseased or aneurysmal portion of the aortic wall is
dissected away and replaced with an artificial mesh vascular graft.99 This method, which
is well established, requires little to no radiologic follow-up after repair. Due to the
severity of this open procedure, however, it is limited in that it is not appropriate for
many older patients and those presented with other pre-existing cardiovascular issues.
When used in an “elective” situation, this procedure yields an operative mortality of 4%
to 6%.95

Figure 2.9 Schematic of open surgical aneurysm repair.141
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More recently, endovascular repair of abdominal aortic aneurysms has been
gaining in popularity. Like many less invasive technologies, this procedure involves
gaining access to the lumen of the abdominal aorta through small incisions in the femoral
vessels. With the help of a guide wire, endovascular stent grafts are then implanted
percutaneously at the site of aneurysm as shown in Figure 2.10.

These devices,

consisting of a cloth graft with a stent “exoskeleton”, are deployed across the diseased
portion of aorta, thus creating a bypass for blood flow through the prosthetic lumen of the
stent graft.99 While this method of repair is less invasive and thus more suitable for those
patients who cannot handle major vascular surgery, these devices are unfortunately
anatomically appropriate for only 30% to 60% of aortic aneurysms.95 The endografts
also require close postoperative monitoring as CT scans are typically suggested at 1, 6,
and 12 months after repair, and annually after that. One of the primary reasons for this
precautionary approach is the risk of endoleaks (and the subsequent potential for graft
migration) for these devices, occurring in 10% to 20% of cases.142 Endoleaks allow the
flow of blood into the aneurysm sac, resulting in increased risk for aneurysm expansion
and/or rupture. Although this less invasive technology is promising, its complications
and lack of long-term data make its overall application as an aneurysm treatment
suboptimal.
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Figure 2.10 Schematic of endovascular stent graft repair.141

2.2.4 Animal Models
Most samples of human aneurysms come from patients who have reached the late
stage threshold (5.5 cm or greater), and subsequently had their diseased aorta removed
and replaced with a graft. Additionally, aneurysmal tissues are often collected from
cadavers whose mortality is associated with aneurysm rupture.

From a research

standpoint, these tissues provide little insight into the pathogenesis of abdominal aortic
aneurysms since they are collected at such a late stage. Subsequently, little information
can be gained on potential pathways for inhibiting aneurysm formation and/or
progression from these samples. This underlines the importance of reproducible animal
models for aortic aneurysms, which can allow for examination and potential inhibitory
treatments of early-stage pathogenic processes.
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2.2.4.1 Genetically Engineered Mice
Due to their relative low cost and the ability to manipulate specific genes,
genetically engineered mice have become widely used subjects for aneurysm animal
models. Certain mutations have been found to make mice naturally predisposed to AAA
formation. For instance, blotchy mice have a genetic mutation which ultimately results in
reduced levels of lysyl oxidase, an enzyme which facilitates the natural crosslinking of
elastin and collagen fibers. As a result of these extracellular matrix defects, these mice
have a predisposition to form AAAs which are histologically characterized by elastin
fragmentation and disrupted smooth muscle layers.143,144 Aneurysms found in these
animals are typically in the thoracic rather than abdominal region.
Mice deficient in low density lipoprotein (LDL) receptors and apoliprotein E
(apoE), a protein responsible for lipoprotein transport, are also prone to aneurysm
formation.145,146 These genetic defects lead to hyperlipidemia and are often used with
special diets to produce hypercholesterolemia as well. These models were originally
used for atherosclerosis research, but have more recently been used as an aneurysm
model as well. Aneurysms within these altered mice will occur naturally, but are most
often found in the suprarenal abdominal aorta, while human aneurysms are typically in
the infrarenal region.
2.2.4.2 Angiotensin II Induced Aneurysms
Systemic delivery of angiotensin II to hyperlipidemic (LDL receptor or apoE
deficient) mice results in aneurysm formation147,148 The delivery of angiotensin II is
typically regulated by osmotic minipumps. Although its mechanisms of action are not
necessarily clear, recent research suggests that accumulation of macrophages in the aortic
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media may act as the primary causal event.149 This attraction of macrophages, mediated
by increased cytokine activity,150 results in elastin degradation likely due to increased
protease recruitment.

Interestingly, this rodent model shows preference towards

aneurysm formation in males over females, similar to the trend observed in human
AAAs.151
Downsides of this model include the location of aneurysm formation, as it
consistently forms only in the suprarenal region. In addition, dilatations within the
angiotensin II model appear to be associated with very large thrombus formation rather
than the luminal dilatation and wall thinning observed in human aneurysms.148
2.2.4.3 Chemical Injury Aneurysm Models
Elastase Perfusion
It has been established that elastin degradation is one the primary characteristics
of aneurysm development. As such, the use of elastase to induce AAAs in animals has
been widely used since its introduction in 1990.152 While primarily used on rats, it has
also been attempted on larger animals such as dogs.153 Within this model, the abdominal
aorta is clamped off near the renal arteries and near the iliac bifurcation, thus isolating an
infrarenal segment of aorta.

Using a small catheter, this segment is perfused with

pancreatic elastase, typically for 2 hours at a rate of approximately 1 mL/hour in rats.154
Over the course of a few days, the aorta is characterized by inflammatory infiltrates
(dominated by macrophages and T cell lymphocytes) and increased protease
activity.155,156

In addition, disruption of the elastic lamellae is seen immediately

following infusion with elastase.143

This abrupt elastin degradation, along with
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perfusion-induced mechanical forces, causes an instantaneous change in diameter in the
range of a 30% to 70% increase.157-159 While this model results in reproducible aortic
dilatation associated with AAA formation, one may argue this immediate diameter
change is not truly representative of the somewhat slow progression of human AAA
development.
Elastin peptides, the products of elastin degradation, also induced aneurysm
formation in rats when infused through the infrarenal aorta in the same fashion, which
lends insight into the mechanisms of the elastase perfusion model.160 The use of elastase
periadventitially (directly applied to the outside of the artery rather than through luminal
perfusion) to provoke aneurysm formation in rats has also been met with moderate
success.161 However, it also appears to cause significant immediate dilatation and its
ability to form “true” aneurysms has been debated.162
Calcium Chloride
The calcium chloride (CaCl2) model is based on the perivascular or periadventitial
application of a high concentration calcium chloride solution for 15 minutes, a method
originally used to induce aneurysms in rabbit carotid arteries.163 More recently, this
model has been used on abdominal aorta of rabbits,164 mice,165 and rats.166 The CaCl2based chemical injury model has also been adapted to rat abdominal aorta to study
mechanisms of vascular calcification.167
This model, which has been utilized in rats for our aneurysm experiments, was
chosen for its ability to progressively elicit elastin degradation, inflammation, elastinoriented calcification, elevated MMP levels, and arterial dilatation, which are all
characteristics of human AAA development and progression. Using this model on mice,
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studies have shown that MMP-deficient mice exhibited a decreased susceptibility to
calcium chloride-induced AAA formation120; therefore, asserting that the perivascular
CaCl2 model relies heavily on MMP activity to induce AAA formation. In addition, the
aforementioned model allows for easy periadventitial application of potential AAA
therapies.

Ultimately, this perivascular model was beneficial over other aneurysm

models for its ability to mimic the morphologic aspects of human AAA progression
without the major mechanical damage apparently induced by the elastase perfusion
model. For instance, using calcium chloride, mice did not exhibit an immediate increase
in aortic diameter after one week; however, significant increases were observed after two
weeks with progressive expansion continuing in following weeks.165

This slower

progression of aneurysm development closely imitates the morphology of human AAA
development.

2.2.5 Pharmacological Strategies
For the many patients who have a small or early stage aneurysm, there is
unfortunately no current option or therapy (other than imaging surveillance). In these
cases, the aortic diameter is periodically monitored until it reaches a critical threshold
(typically 5.5 cm), at which point surgical repair or replacement is performed as
described above. This “wait and see” approach is not without risk, however, as 10% of
the abdominal aortic aneurysms that rupture do so at diameters less than 5 cm.119
Therefore, alternative pharmacological treatments targeted at limiting aortic expansion
may be helpful in reducing incidence of rupture and circumventing the need for surgical
repair.
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2.2.5.1 Beta Blockers
Beta blockers, or beta-adrenergic antagonists, are conventionally used for
hypertension, but have also proven to be effective in limiting the rate of aortic expansion
in aneurysmal patients.168 Propanolol, the most noteworthy beta blocker, was originally
shown to reduce aneurysm-related deaths in a turkey model from 44% in control animals
to just 1%.169 These agents are known to lower blood pressure, which would logically
benefit the aneurysmal aortic wall from a mechanical viewpoint. However, it has also
been shown to stimulate lysyl oxidase activity, thus theoretically enhancing the natural
crosslinks of collagen and elastin.170,171 Although initially promising, three randomized
human trials of propanolol administered to small AAA patients revealed that this drug did
not inhibit aneurysm expansion in comparison to patients receiving a placebo.
Furthermore, the drop-out rates of subjects within these studies were overwhelmingly
high (between 40% and 70%) due to symptoms of impaired pulmonary function and an
overall reduction in quality of life.172,173
2.2.5.2 Anti-Angiotensin II Agents
Angiotensin-converting enzyme (ACE) inhibitors block the conversion of
angiotensin I to angiotensin II, which is a major vasoconstrictor. For this reason, ACE
inhibitors, like beta blockers, are used for the treatment of hypertension. In addition to
improving high blood pressure, ACE inhibitors apparently demonstrate some degree of
MMP inhibition by likely interacting with the zinc binding site, as well as having a
significant effect on connective tissue remodeling following vascular wall injury.174,175
Furthermore, humans taking ACE inhibitors for hypertension exhibit increases in markers
for collagen III production, which may be a sign of a strengthened aortic wall.176 These
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beneficial effects carried over to the rat elastase perfusion model, where ACE inhibitors
were able to inhibit experimental aneurysm formation.177 The effect of ACE inhibitors
on human aneurysms has not yet been verified by randomized trials.
2.2.5.3 Anti-Inflammatory Agents
Since inflammation is one of the primary traits of aneurysmal tissues, and has
even been suggested as the possible root cause of these pathologies, it is logical to
assume anti-inflammatory agents may be useful in treating AAAs. The reduction in
inflammation provided by corticosteroids correlated into improved elastin preservation,
thus resulting in improved resistance to aneurysm formation.130 While the use of these
particular anti-inflammatory agents would not be appropriate due to their effect on
immunosuppression and wound healing, these studies opened the door for the potential
use of related anti-inflammatory agents as an aneurysm therapy.
In a small case study with human patients, the use of non-steroidal antiinflammatory drugs decreased the rate of aneurysm growth (1.5 mm/year vs. 3.2 mm/year
in controls).178 The anti-inflammatory drug used was indomethacin, which apparently
limits prostaglandin-E2, whose synthesis has been linked to aortic aneurysm growth.179
Unfortunately, a number of anti-inflammatory agents have been taken off the market due
to risk factors.

Indomethacin, which may elicit gastrointestinal side effects, could

potentially face a similar fate.119
2.2.5.4 Matrix Metalloproteinase Inhibitors
Doxycycline, a member of the tetracycline family has been studied extensively for
its ability to inhibit MMPs and, therefore, as a potential pharmacological treatment for
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aneurysms. Doxycycline is effective toward MMPs on multiple levels: (1) it suppresses
MMP mRNA synthesis,180 (2) it inhibits extracellular activation of the proenzyme,119 and
(3) through non-specific direct inhibition, it can block the zinc binding sites along the
MMP’s catalytic domain.181 In addition to MMP inhibition, tetracyclines also possess
antibacterial properties.
In the initial aneurysm animal study by Petrinec et al (utilizing the elastase
perfusion model in rats), doxycycline improved susceptibility to aortic dilatation while
preserving the elastin.157 As expected, MMP activities were downregulated in those rats
receiving doxycycline treatment. These results were confirmed in the murine angiotensin
II aneurysm model as well.182
In humans, studies have shown that the doses and serum levels of doxycycline
that are required to inhibit MMP activity are tolerable.183 Furthermore, significant levels
of the drug were found in the aortic wall of patients given an intravenous bolus of
doxycycline.184 It was concluded that the levels found in these tissues was enough to
inhibit MMP-9 activity. A small preliminary trial by Thompson et al revealed that an
oral dose of doxycycline (twice a day for seven days) significantly reduced MMP-2 and
MMP-9 expression in aortic wall, thus opening the door for a larger ramdomized
study.185 In the only reported human randomized trial to date, doxycycline apparently
reduced aortic expansion rates (1.5 mm/year vs. 3 mm/year in controls), however, there
was no statistical significance over the 18 month follow-up period.186
MMP and protease inhibitors hold great promise as an AAA therapy. However,
caution should be taken in regards to their efficacy and safety.

The “biological

redundancy” of the different MMPs may allow for other members of the MMP family to
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compensate when one is being inhibited. In addition, these enzymes are essential for
many normal physiological processes such as wound healing, angiogenesis, and
embryonic development; therefore, their systemic inhibition could be perilous. This
possibility has recently been foreshadowed by the prevalence of musculoskeletal side
effects in patients undergoing systemic MMP inhibitor therapy.187

2.3 Elastin

2.3.1 Structural Features and Function
Elastin is a crucial insoluble extracellular matrix component of many tissues,
including blood vessels, skin, lung, and ligamentum nuchae. Of particular interest to our
research is the elastin found in arterial tissue and in the ventricularis layer (that layer of
the valve leaflet closest to the heart) of valve cusp tissue. Depending on its location and
size, elastin can constitute greater than 50% of an artery’s dry weight.188
The monomeric unit of elastin, tropoelastin, is a soluble ~70 kDa protein
synthesized by fibroblasts and smooth muscle cells. Tropoelastin is crosslinked with
desmosine and isodesmosine by the action of lysyl oxidase to form mature elastic fibers,
which are oriented in vascular tissue to form concentric rings of elastic lamellae through
the medial layer as shown in Figure 2.11. Embedded between these lamellae are layers
of smooth muscle cells. The protein structure of elastin is rich in proline and glycine,
however is not glycosylated and consists of very little free lysine. Mature elastin, which
is insoluble and primarily hydrophobic in nature, is unusual in that it experiences very
little metabolic turnover, as evidenced by its nearly 70-year biological half-life.101 The
inability of elastin to revitalize itself is significant since this means elastin degradation
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(such as that observed in tissue-derived cardiovascular devices and abdominal aortic
aneurysms) is not likely to be accompanied by new elastin synthesis. Therefore, an
elastin stabilizing agent for these cases would be extremely beneficial.

Figure 2.11 Distribution of elastic lamellae through a cross-section of arterial wall.189

Based on present knowledge of elastin, we believe that an elastin-stabilizing agent
(specifically tannins, which are introduced and described below in Section 2.4) may be
able to bind to potential enzyme cleavage sites on the elastin molecule. A schematic
depicting the main features of the elastin molecule is shown in Figure 2.12.

The

secondary structure of tropoelastin is characterized by an alternance of β-sheets, which
are hydrophobic areas susceptible to elastases, and α-helical crosslinking domains that
offer resistance to proteases.190

Most elastin-degrading enzymes, such as MMPs,

neutrophil elastase, and pancreatic elastase preferentially act on hydrophobic areas in the
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elastin structure.191,192 As such, elastin stabilization should be targeted toward these areas
along the elastin molecule.

Figure 2.12 Structural features of elastin showing the repetitive alternance (square
brackets) of β-hydrophobic domains and α-crosslinking areas.

Developmentally, elastin is essential to arterial morphogenesis, as mutations or
deficiencies in the elastin gene have resulted in supravalvular aortic stenosis and other
arterial occlusive diseases.188,193 This may be related to the fact that vascular elastin
plays a role in regulating the proliferation, differentiation, and migration of smooth
muscle cells.194

In regards to its function, elastin is generally known more for its

mechanical contribution. In many biological tissues, including blood vessels, elastin
bears mechanical loads at low strains until that load reaches a threshold, at which point
the stiffer collagen fibers assume the duty. As its name implies, elastin provides the
tissue with elasticity or resilience. In arteries, the concentric elastin layers allow the
tissue to stretch repetitively under the hemodynamic forces of blood flow without plastic
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deformation. Because of elastin, the tissue is able to recoil back to its original shape,
size, and configuration (Figure 2.13). This compliance is particularly important in the
aorta, where the vessel’s recoil is the driving force behind blood flow into other
branching vessels, such as the coronary arteries.

Figure 2.13 Depiction of elastin recoil.

Similarly, elastin fibers within heart valve leaflets serve to dampen the abrupt
loading and unloading cycles experienced by these tissues. Studies have shown that
elastin in both human and porcine cusps is like a “sponge”, creating an intertwining
framework in which tubular collagen bundles pass through.38 As described above, elastin
is able to withstand very large deformations, particularly in comparison to collagen.
Cusp tissue, whose extracellular structure is dominated by collagen, undergoes a
significant amount of deformation. Therefore, it is reasonable to assume that elastin
plays a major role in the biomechanics of this tissue despite being overshadowed, in
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regards to overall content, by collagen. For instance, it has been shown that this elastic
fiber network absorbs tissue forces, thus allowing for slower valve closure.39 It has been
theorized that this three-dimensional network of elastin and collagen works by allowing
elastin to bear the tension during the initial phases of loading while collagen fibers begin
to straighten. The less-extensible collagen fibers begin taking on a more significant load
once they straighten.

The most significant function of elastin takes place during

unloading, in which elastin serves to return the collagen bundles back to their original
(undeformed) state.5,38 This has been the observed case within native aortic valve cusps,
so its exact correlation to cusps within fixed BHVs is somewhat less clear. However, it
makes sense that any damage to elastin within these BHV tissues may be damaging to the
implant. Collagen would have to bear abrupt loads in conditions it was not necessarily
meant to withstand, potentially leading to material/implant fatigue.40
In addition to its mechanical contribution, the significance of elastin degradation
is described in greater details below.

2.3.2 Elastin Degradation
Due to its insolubility, natural desmosine and isodesmosine crosslinks, and
extremely long biological half-life, elastin is generally perceived to be resistant to
degradation. However, there are a specific set of enzymes, matrix metalloproteinases
(MMP-2, MMP-9, and MMP-12), which are capable of degrading elastin. The activity of
these enzymes is a clinical reality, as we have already discussed their presence within
diseased native heart valves, explanted bioprosthetic heart valves, and abdominal aortic
aneurysms. Elastin degeneration has also been implicated in other vascular pathologies,
such as atherosclerosis and coronary restenosis.194
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Elastin degradation results in the release of soluble elastin peptides.

These

peptides are not simply passive by-products of the degradation process; rather, it has been
demonstrated that they are active in protease production, chemotaxis, cellular
proliferation, and various other biological activities.195 The release of elastin peptides
can result in even more matrix degradation, as it has been shown that interactions
between these peptides and smooth muscle cells increase expression of the elastin
laminin receptor (ELR). This binding with ELR, a 67 kDa receptor found on a number of
cell types, subsequently results in the promotion of greater MMP synthesis both at the
mRNA and protein levels.134 Numerous studies have confirmed this correlation between
upregulated MMP activity and the presence of elastin peptides.196-198

The use of

luminally-perfused elastin peptides as an aneurysm animal model, which elicits elevated
MMP levels and matrix degradation at the site of perfusion, also solidifies the biological
power of these peptides.160
In addition to MMP activity, elastin peptides have been shown to have varying
effects on a broad range of cell types, including smooth muscle cells,194 fibroblasts,199
endothelial cells,200 macrophages,201 neutrophils,201 lymphocytes,202 and leukocytes.203
Of particular importance to many vascular diseases is the activation of vascular smooth
muscle cells into a proliferative and migratory phenotype. This activation, which again is
mediated by interactions between elastin peptides and ELR, is associated with an abrupt
increase in intracellular calcium and has been implicated as a primary contributor to
neointimal occlusion.204

The extreme bioactivity of elastin peptides underlines the

clinical significance of elastin degradation and the subsequent need to protect elastin
from degeneration.
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2.4 Tannins

2.4.1 Chemical Structure and Properties
Based on their known properties, we propose to investigate tannins as novel
agents that stabilize elastin from degradation.

Tannins are naturally derived plant

polyphenols typically divided into the following categories: condensed tannins, complex
tannins, and hydrolysable tannins.

Hydrolysable tannins are further classified into

gallotannins, which are esters of gallic acid, and ellagitannins, which are esters of
hexahydroxydiphenoic acid.

For our application, we have focused on the use of

gallotannins, particularly tannic acid (TA) and pentagalloyl glucose (PGG).

Such

gallotannins are known to specifically bind to hydrophobic regions in proline-rich
proteins such as elastin and collagen and form a shell of multiple hydrogen bonds with
surrounding proteins.205,206 Tannins, particularly TA, are also commonly used in electron
microscopy, sometimes in combination with glutaraldehyde, for ultrastructural
demonstration of elastin fibers, suggesting that tannins possess an affinity for
elastin.207,208 Other advantages of tannins include the ability to partially inhibit enzyme
activity, provide antibacterial and anti-inflammatory effects, and effectively reduce
protein antigenicity.209
The chemical structure of tannic acid, displayed in Figure 2.14, is characterized
by a D-glucose molecule esterified at all five hydroxyl moieties by gallic acid (3, 4, 5trihydroxybenzoic acid), yielding a pentagalloyl glucose “core”. This core molecule is
further derivatized to produce five “tails” of gallic acid residues extending from the
original glucose. The exact chemical structure of TA is somewhat ill-defined as each one
of these tails may consist of anywhere between 2 and 10 galloyl residues.209

The
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structures depicted in Figure 2.14 show variations of deca-galloyl glucose, a common
representation of TA.

Figure 2.14 Composition and structure of tannic acid.

Another member of the gallotannin family of particular interest for our
application is pentagalloyl glucose (PGG). PGG, shown as an isolated chemical structure
in Figure 2.15 but also highlighted by the grey circle in Figure 2.14, is essentially the
core of tannic acid. This relative of TA has a well-defined chemical structure, consisting
of just one gallic acid residue bound to each hydroxyl moiety of the central glucose
molecule, in contrast to the tails of multiple gallic acids found in TA.
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Figure 2.15 Chemical structure of pentagalloyl glucose (PGG).

2.4.2 Previous Medical Applications
Decades ago (first reported in 1925), tannic acid was used as a standard topical
treatment of burns due to its ability to reduce inflammation and bind to tissues,
consequently fixing burn toxins into the wound area and preventing their further
distribution throughout the patient’s body.210 This practice was relatively short-lived,
however, due to issues of hepatotoxicity. More recent literature has questioned the
negative effects of TA, however, since (1) the observed hepatotoxicity was independent
of TA dosage, and (2) a high incidence of liver damage is seen even in those burn
patients never treated with tannic acid.211 It is believed that the majority of the inferior
results for this application were likely due to inadequate preparations (poor purity) of TA
and/or the chemical instability of TA.
While the topic of TA and hepatotoxicity has been and still is heavily debated, a
significant amount of research has recently been dedicated to assessing the validity of
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these issues and the use of potential alternatives, such as TA “mimics”

212,213

and high

purity TA.211 The proposed mimics are synthetic dendrimers consisting of a varying
number of galloyl moieties. These dendrimers were shown to have activities similar to
TA but with improved chemical stability.212 Likewise, the use of high purity TA resulted
in improved chemical stability and thus decreased hepatotoxicity;211 however, it should
be noted that these results contradict previously reported studies.214 The correlation
between the chemical structure of tannic acid, its instability, and potential toxicity will be
clarified later in Chapter 6.
Studies have also shown that TA may be used as a (partial) collagen crosslinking
agent, as exhibited by increased denaturation temperature of tannin-crosslinked dermal
collagen.215 These results are consistent with studies showing stabilization of collagen
with catechin, a plant-derived polyphenol unrelated to the gallotannin family.216 It is
important to point out, however, that while the degree of collagen crosslinking was
improved as compared to untreated collagen in these cases, it did not come near to
matching the properties of glutaraldehyde, a common collagen crosslinker.
The pharmacological properties of tannins have been investigated for their
anticarcinogenic, antimutagenic, antiviral, and antimicrobial capabilities.217 Indirectly,
many tannin-containing food and drinks, such as green tea and red wine, have also been
associated with these properties. For instance, the inverse correlation between green tea
consumption and frequency of (gastric) cancer has been widely investigated and
documented.218 This same relationship was exhibited for any diet rich in vegetables and
fruits, which contain an abundance of polyphenolic tannins. In specific tumor studies on
animals, TA and other green tea polyphenols inhibited skin tumors in mice, a trend which
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was observed in different cases of tumor induction.219,220 Even oral administration of
green tea polyphenols in very low doses inhibited formation of colonic tumors in rats.221
This beneficial effect of TA and/or green tea polyphenols has been demonstrated
extensively in a number of animal models and tissues.217 Although the exact mechanism
of action is not clear, it is hypothesized that these anticarcinogenic and antimutagenic
properties are likely related to the antioxidative traits of tannins, thus protecting cells
from oxidative damage.
Tannins have also been shown to inhibit growth of a number of filamentous fungi,
yeasts, and bacteria, therefore exhibiting antimicrobial properties. This includes the
ability to at least partially inactivate viruses such as strains of influenza and herpes, with
inhibitory effects towards human immunodeficiency virus (HIV) as well.221 The capacity
of tannins to inhibit the growth of microorganisms such as these is likely due to their
ability to form complexes with numerous substrates, such as enzymes and metal ions. In
both cases, this may result in inactivation of these substrates, which are required for
microbe survival.
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CHAPTER 3
PROJECT RATIONALE

3.1 Hypothesis
Due to its insolubility and low metabolic turnover, elastin is generally perceived
to be stable and resistant to proteolysis. However, there are pathological cases where
degradation of elastin is observed, such as within tissue-derived cardiovascular devices
(bioprosthetic heart valves) and abdominal aortic aneurysms.
Glutaraldehyde, the conventional pretreatment for bioprosthetic heart valves,
essentially does not react with elastin, thus leaving this pivotal extracellular matrix
component vulnerable to enzymatic attack once implanted. Therefore, a pretreatment for
these devices targeted at stabilizing elastin (analogous to the use of glutaraldehyde as
collagen stabilizing fixative) may be beneficial in extending the overall longevity of these
devices. This is important as we believe the indifference towards elastin could contribute
to their less-than-ideal performance.
Elastin degradation is a primary hallmark of abdominal aortic aneurysm formation
and progression. Elastin and the general architecture of the aorta degrades in these cases,
resulting in progressive expansion associated with aneurysmal tissues. As such, it is
logical to assume that by stabilizing the elastin within these diseased arteries, that we
may be able to halt or limit the development of this potentially fatal pathology.
For both of these applications, we hypothesize to stabilize elastin using tannins, a
class of naturally derived plant polyphenols known to interact with elastin.
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3.2 Specific Aims
Aim 1: Identify polyphenolic tannins as potential elastin-stabilizing agents.
Elastin, which is vulnerable to enzymatic degeneration, may be stabilized with
polyphenolic tannins. Time-dependent binding studies between pure elastin and tannins
were completed, as well as subsequent studies on tannin-treated pure elastin and its
ability to resist in vitro enzymatic digestion.
Aim 2: Evaluate the feasibility of tannic acid as an elastin-stabilizing agent
for tissue-derived cardiovascular implants, such as bioprosthetic heart valves.
Tannic acid treatment of aortic wall may be beneficial in rendering the tissue resistant to
enzymatic degradation and calcification, which could extend the clinical durability of
these tissue-derived devices. The properties of tannin-treated aortic wall were evaluated
and compared with tissue treated with glutaraldehyde, a common tissue pretreatment for
bioprosthetic heart valves.
Aim 3: Assess the toxicity of tannic acid treated tissues and investigate
potential (less toxic) alternatives. Tannic acid, which was once used as a burn wound
treatment, may elicit toxic effects.1,2 As a result, toxicity of tannic acid treated tissues
was evaluated and compared to tannin derivatives such as pentagalloyl glucose, which is
essentially the core structure of tannic acid.

Due to improved chemical stability,

pentagalloyl glucose may be a more viable option as an elastin stabilizing agent.
Aim 4: Investigate polyphenolic tannins as therapeutic agents for abdominal
aortic aneurysms.

The formation or progression of aortic aneurysms, a disease

associated with elastin degeneration, may be inhibited with site-specific treatment of
elastin stabilizing agents. Using an animal model to induce aortic aneurysm formation,
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site-specific tannin treatment was applied perivascularly and evaluated for its ability to
hinder aneurysm formation and progression (separately) by monitoring changes in aortic
diameter and elastin integrity.

3.3 Clinical Significance

3.3.1 Elastin Stabilization in Bioprosthetic Heart Valves
To date, there is no prevalent drug therapy for diseased heart valves; therefore,
surgical replacement is the primary option. It is estimated that approximately 275,000
valve replacement surgeries are performed annually, with tissue-derived bioprosthetic
heart valves constituting about half of these.3,4 These devices are typically made from
porcine aortic valve tissue or bovine pericardium. In order to make these xenogenic
tissue devices more resistant to enzymatic degradation, they are pretreated prior to being
implanted into a human. Glutaraldehyde, the most common pretreatment or fixative used
for this purpose, stabilizes collagen within these valves.

Collagen is the prevalent

component of valve cusps and possesses a large amount of lysine, meaning many amine
groups are available for binding with glutaraldehyde. While glutaraldehyde demonstrates
an excellent capacity to bind with and crosslink collagen, it has virtually no stabilizing
effect on elastin. This is likely due to elastin’s lack of amine groups necessary for
reaction with glutaraldehyde. In addition to glutaraldehyde, there is no pretreatment or
fixative available which claims to bind to elastin.
This indifference towards elastin could be detrimental since elastin degradation
(and the resulting products, elastin peptides) can lead to calcification, altered mechanical
properties, intensified inflammation, and stimulation of protease production.5-7 The issue
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of elastin degradation is especially noteworthy for stentless bioprosthetic heart valves,
which include a portion of the elastin-rich aortic wall. For all bioprosthetic heart valves
(stented and stentless), elastin is also present within the cusps. Elastin degradation may
contribute to the suboptimal performance of these devices, as it has been estimated that
about half fail within 10 years of implantation.8,9 The development of a pretreatment
targeted specifically at stabilizing elastin, just as glutaraldehyde is used to crosslink
collagen, may beneficial in extending the clinical durability of bioprosthetic heart valves.

3.3.2 Elastin Stabilization as a Treatment for Abdominal Aortic Aneurysms
Patients with small or early stage aneurysms (aorta less than 5 cm in diameter)
comprise the largest percentage of all AAA patients.10 This number is likely to increase
dramatically with the advent of “blanket” screening of asymptomatic subjects. In these
cases of small AAAs, no treatment exists (other than imaging surveillance) until the
aortic diameter reaches the 5.5 cm threshold, thus requiring surgery. This “wait and see”
approach is not without risk, however, as 10% of the abdominal aortic aneurysms that
rupture do so at diameters less than 5 cm.10 Therefore, alternative pharmacological
treatments targeted at limiting aortic expansion may be helpful in reducing incidence of
rupture and circumventing the need for surgical repair.
As a result, the long-term goal of this project is to slow the evolution of
degenerative processes associated with abdominal aortic aneurysms.

The unique

properties of polyphenolic tannins may allow for the development of a novel site-specific
strategy based on stabilizing elastin against enzymatic degradation. If successful, this
technology could offer more effective therapies for treating aortic aneurysms, either (1)
in conjunction with endovascular stent grafts, or (2) as a stand-alone treatment, including
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for aneurysms at the early and moderate stages for which there is no current option other
than medical surveillance.
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CHAPTER 4
TANNINS AS ELASTIN STABILIZING AGENTS

4.1 Introduction
Elastin is an extracellular matrix protein which endows tissue with resilience or
the ability to recoil repetitively. In addition to tissue mechanics, preserving elastin is also
important since the by-products of elastin degradation have been associated with
undesirable effects, such as tissue calcification and recruitment of inflammatory cells and
proteases. Despite this, virtually no effort has been made to stabilize elastin against the
action of proteolytic enzymes. We propose to do this with tannins, a class of naturally
derived plant polyphenols. Tannins were chosen for their ability to bind to proline-rich
proteins such as elastin.1 Furthermore, they are often used in electron microscopy as an
elastin-specific mordanting agent, indicating that an interaction between elastin and
tannins exists.2
In the studies presented in this chapter, we provide evidence that tannic acid, a
polyphenolic tannin, binds to pure elastin in a time-dependent pattern and this binding
increases the resistance of elastin to enzymatic degradation. Throughout these studies,
tannin treated elastin is compared to that treated with glutaraldehyde. Glutaraldehyde is a
common tissue treatment used for its ability to stabilize and crosslink collagen. As
shown here, however, glutaraldehyde does not protect pure elastin from enzymatic
degradation.
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4.2 Methods

4.2.1 Materials
Porcine hearts were obtained from local USDA approved slaughterhouses. Ultra
pure type VII collagenase, tannic acid, trinitrobenzenesulfonic acid, and other chemicals
were of highest purity available and obtained from Sigma (St. Louis, MO). Elastin
purified from bovine neck ligament, ultra pure pancreatic elastase, and elastin-orcein
were from Elastin Products Company Inc. (Owensville, MO).

Glutaraldehyde was

obtained from Polysciences Inc. (Warrington, PA).

4.2.2 Elastin-Orcein Study
Pilot experiments utilized commercially available bovine neck insoluble elastic
fibers labeled with orcein (elastin-orcein), which is routinely used as a substrate for
pancreatic elastase.

Glutaraldehyde (Glut) fixed elastin substrate was prepared by

treating elastin-orcein with 0.6% Glut in 50 mM Hepes buffered saline, pH 7.4, overnight
at room temperature. Following treatment, samples were centrifuged at 5000 rpm for 15
minutes, followed by washing with ddH2O, dialyzing against ddH2O, and finally
suspending the Glut-treated elastin substrate in elastase buffer (100 mM Tris buffer, pH
8.0, 1 mM CaCl2, 0.02% NaN3) at a final concentration of 20 mg/ml. Similarly, elastinorcein substrate was treated with 0.3% tannic acid (TA) in Hepes buffer, rinsed, dialyzed
and resuspended as above. As a control, elastin-orcein was incubated overnight in 50
mM Hepes buffered saline (without Glut or TA), washed, dialyzed and resuspended at a
final concentration of 20 mg/ml.

Elastase assays were performed by separately

incubating untreated, Glut-treated, and TA-treated elastin substrates (n=3) with pure
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pancreatic elastase (0.1 Units/mL in elastase buffer) at 37oC for 96 hours. Following
elastase digestion, samples were centrifuged at 12,000 rpm and the amount of digested
elastin was assayed by measuring the supernatant OD at 570 nm (maximal absorption
wavelength of orcein).

The release of orcein dye in solution allowed for direct

quantification of elastin degradation. As background controls, corresponding substrates
incubated in buffer without elastase were used. Values are expressed as % degradation,
using untreated elastin-orcein (completely degraded after 96 hours) as a positive (100%)
control. All samples were assayed in triplicates.

4.2.3 Preparation and Characterization of Pure Aortic Elastin
Ascending porcine aorta was collected fresh at the slaughterhouse and transported
to the laboratory on ice. After cleaning fat and adherent tissues, aorta was cut into 2 mm
x 4 mm strips and thoroughly rinsed in cold saline. Aortic elastin was purified by a
sequence of extractions that included sodium hydroxide (NaOH) treatment3 and
collagenase digestion4 with slight modifications. Aortic strips were suspended in 100
mM NaOH (60 strips in 100 ml) and incubated for 14 hours at 37oC on a shaker at 180
rpm. This step extracts all cellular material, non-collagenous components, and some of
the collagen, leaving elastin intact. The strips were rinsed thoroughly in ddH2O and then
incubated on a shaker at 180 rpm for 16 hours at 37oC with collagenase (0.5 Units / mg
wet tissue) in 50 mM Tris buffer, 10 mM CaCl2, pH 8.0. The collagenase preparation
was pre-adsorbed with elastin fibers to remove residual elastolytic activities.5 This final
digestion step completely removes residual collagen, leaving behind pure aortic elastin.
Elastin strips were rinsed thoroughly in ddH2O and stored frozen at -80oC.
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4.2.4 Purity Analysis of Aortic Elastin
The porcine elastin preparation (and standard bovine neck elastin for comparison)
were subjected to N-terminal amine group analysis6 and hexosamine assay.7 In addition,
sodium dodecyl sulfate extracts prepared from elastin were subjected to polyacrylamide
gel electrophoresis and silver staining for detection of contaminating proteins.8 For
histological studies, paraffin embedded samples were sectioned and stained with Movat’s
pentachrome.

4.2.5 Optimization of Elastase Digestion
In order to develop a screening method for elastin stabilization, we developed and
optimized an in vitro assay that investigates resistance to porcine pancreatic elastase.
This test is analogous to the widely used assay for resistance to collagenase, which is
utilized as a barometer for collagen crosslinking or stabilization.
4.2.5.1 Elastase Concentration
Strips of lyophilized pure aortic elastin (~10 mg/strip) were suspended in 1 ml of
0, 1, 5, 10 or 20 Units/mL of elastase solutions prepared in 100 mM Tris buffer, 1 mM
CaCl2, 0.02% NaN3 pH 7.8, and incubated at 37oC for 20 hours with shaking at 600 rpm.
Samples were centrifuged for 10 minutes at 10,000 rpm (4oC), rinsed in ddH2O,
lyophilized, weighed, and percentage of elastin degradation calculated from dry weights
before and after exposure to elastase.
4.2.5.2 Elastase Digestion Time
Lyophilized pure aortic elastin strips were incubated with 20 Units/mL of elastase
in buffer (as above; 100 mM Tris, 1 mM CaCl2, 0.02% NaN3, pH 7.8) for 0, 2, 6, 24 or 48
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hours at 37oC with shaking at 600 rpm. Samples were rinsed, lyophilized, weighed and
percentage of elastin degradation was calculated based on dry weights before and after
elastase as described above.

4.2.6 Tannic Acid Binding with Pure Aortic Elastin
Pure aortic elastin strips (2 mm x 4 mm) were suspended in 1.5 mL of an 8 mg%
tannic acid (TA) solution prepared in 50 mM Na2HPO4 buffered saline, pH 5.5. A
second group consisted of pure aortic elastin suspended in a solution containing 8 mg%
TA and 16 mg% glutaraldehyde (TA+Glut) in same buffer. As controls, TA solution and
the mixture of TA and Glut were incubated without exposure to samples of elastin.
Samples were incubated at room temperature and at defined time intervals (0, 20, 40, 60,
120, 360 minutes and 24 hours). Following each respective time interval, samples were
retrieved and analyzed for tannin content in solution according to the Folin-Denis method
for total phenols, as originally described by Rosenblatt9 and modified by Mole.10 For this
phenol quantification assay, samples were mixed with a tungstate-phosphomolybdate
reagent, followed by addition of a saturated sodium carbonate solution and ddH2O. After
10 minutes at room temperature, OD at 760 nm was measured in a microplate
spectrophotometer. Standard curves were constructed with TA in the range of 0 to 8mg%
and with TA (0 to 8mg%) in mixtures with Glut (16 mg%). Glut interference with the
TA color reaction was minimal (no statistical differences found for all data points).
Finally, the elastin strips were rinsed in ddH2O and lyophilized. The amount of TA
bound to pure aortic elastin was calculated from the differences between initial TA
concentration in solution and concentration of TA in solution after incubation with elastin
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strips. Results were expressed as μg of TA bound by 1 mg dry elastin. All samples were
assayed in triplicates.

4.2.7 Effect of Tannic Acid pH on Elastin Stabilization
Strips of pure aortic elastin were treated with solutions of 0.3% tannic acid for 4
days at room temperature. The effect of solution acidity on elastin stabilization was
investigated at pH 5.5 and pH 7.4. For pH 5.5, TA was dissolved in 50 mM Na2HPO4
buffered saline. For pH 7.4, TA solution was in 50 mM Hepes buffered saline. As
controls, buffer solutions (with no TA) were made for each pH using either Na2HPO4 for
pH 5.5 or Hepes for pH 7.4. After incubating the pure elastin in one of these four groups,
samples were rinsed (3 times, 1 hour each in ddH2O) and the elastase digestion assay was
performed with 20 Units/mL of elastase dissolved in 100 mM Tris buffer, 1 mM CaCl2,
0.02% NaN3, pH 7.8 at 37oC for 48 hours with shaking at 600 rpm. Dry weights before
and after enzyme digestion were used to calculate percent digestion or mass loss.

4.2.8 Effect of Tannic Acid Concentration on Elastin Stabilization
Lyophilized pure aortic elastin strips were suspended in 0, 0.003, 0.03, 0.3 and
0.8% tannic acid solutions in 50 mM Na2HPO4 buffered saline, pH 5.5, at room
temperature. A second series of elastin strips were incubated in 0.6% Glut solutions
containing 0, 0.003, 0.03, 0.3 and 0.8% TA in same buffer. After 48 hours, samples were
rinsed in ddH2O, lyophilized, and weighed.

The treated elastin samples were then

incubated with 20 Units/mL of elastase dissolved in 100 mM Tris buffer, 1 mM CaCl2,
0.02% NaN3, pH 7.8 at 37oC for 48 hours with shaking at 600 rpm. Samples were rinsed,
lyophilized, weighed, and percentage of elastin degradation calculated from weights
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before and after exposure to elastase. The “used” elastase solutions were recovered after
incubation with treated elastin and routinely assayed for elastase activity using elastinorcein as a substrate to rule out potential inhibitory effects of TA that may have leached
from elastin samples.11

4.2.9 Kinetics of Tannic Acid-Mediated Elastin Stabilization
Lyophilized pure aortic elastin strips were treated with 0.3% tannic acid in 50 mM
Na2HPO4 buffered saline, pH 5.5, at room temperature. A second series of elastin strips
were incubated in a mixture of 0.6% Glut and 0.3% TA in this same buffer. Samples
were incubated for 1, 2, 4, and 7 days at room temperature. At designated time intervals,
samples were rinsed in ddH2O, lyophilized, and weighed. Samples were then incubated
with 20 Units/mL of elastase dissolved in 100 mM Tris buffer, 1 mM CaCl2, 0.02% NaN3
pH 7.8 at 37oC for 48 hours with shaking at 600 rpm. Samples were rinsed, lyophilized,
weighed and percentage of elastin degradation was calculated from weights before and
after exposure to elastase. The elastase solution recovered after incubation with treated
elastin was assayed for elastase activity with elastin-orcein as described above.

4.2.10 Data Analysis
Results are expressed as means ± standard error of the mean (SEM) with n=6 for
each experimental group, unless otherwise noted. Statistical analyses of the data were
performed using the Student’s t-test and probability values (p) for significance were
calculated, with p<0.05 considered significant.
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4.3 Results

4.3.1 Elastin-Orcein Study
In a pilot experiment, we tested the ability of Glut and separately TA to stabilize
elastin-orcein against the action of elastase (Figure 4.1). Orcein dye, which is originally
bound to the elastin, is released into solution upon cleavage of elastin; therefore,
spectrophotometric measurement of the dye in solution can be directly correlated to
elastin degradation. As expected, untreated elastin was completely degraded after 96
hours (~100% degradation). Glut-treated elastin-orcein was also almost degraded in its
entirety (93.7%). These values for Glut were not statistically different from those of
native elastin (p>0.10) indicating that Glut does not effectively stabilize elastin, meaning
this treatment leaves elastin extremely vulnerable to enzymatic degradation. In contrast,
only about 35% of TA-treated elastin-orcein (p<0.05) was degraded by elastase,
indicating that a significant portion of elastin was protected from enzymatic activity by
treatment with TA. These data indicate that TA has an excellent potential as an elastinstabilizing agent.
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Figure 4.1 Tannic acid (TA) mediated stabilization of elastin-orcein against the action of
elastase. Note the complete degradation of Glut-treated elastin-orcein and protection by
TA (p<0.05 for Glut vs. TA).

4.3.2 Purity of Porcine Aortic Elastin
Selection of proper elastin purification methods is important because preparations
may differ in purity and integrity and thus may compromise binding, stabilization, and
digestion results.8 For our studies, we selected a sequence of extraction steps that result
in intact, highly purified elastin. The method does not involve excessive heating and thus
may conserve the natural configuration of elastin. The porcine aortic elastin preparation
contained 10.12 ± 1.6 moles of amines per mole of elastin, indicating that the preparation
procedure induced minimal degree of random peptide cleavage. These values were not
statistically different from those of the historical standard of bovine neck ligament elastin
(data not shown).

Hexosamine levels were also minimal (0.25% of total weight),

indicating relative absence of glycosaminoglycans or matrix glycoproteins in the aortic
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elastin preparation. In addition, aortic elastin contained undetectable protein impurities,
as evidenced by electrophoretic analysis of extracts followed by silver staining (data not
shown). Histological analysis with Movat’s pentachrome stain confirmed the absence of
cell remnants and collagen fibers in the aortic elastin preparation (Figure 4.2). The fact
that the untreated aortic elastin preparation was completely digested by elastase (see
results below in section 4.3.3) was also an excellent indication that the preparation was
pure.12

Figure 4.2 Histology of fresh porcine aorta (A) and the pure aortic elastin preparation
used in this study (B). Note the absence of smooth muscle cells (red), collagen (yellow),
and ground matrix (blue) in the purified elastin. Original magnification, 100x.

4.3.3 Stabilization of Porcine Aortic Elastin
To harness the potential of tannins as elastin stabilizing agents, we investigated
the optimal conditions required for TA-mediated stabilization of elastin purified from
porcine aorta. This was tested using an elastase digestion assay which we developed. To
optimize this assay, we first investigated the appropriate concentration of elastase (Figure
4.3) and time (Figure 4.4) required for complete degradation of pure aortic elastin. The
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results show that a minimum of 10 units of porcine pancreatic elastase per mL are
required for 24 hours in order to get complete degradation of ~10 mg dry pure aortic
elastin. To ensure complete degradative capabilities were reached, we selected to use 20
Units/mL of elastase for 48 hours for further studies.
In order to determine the kinetics of TA binding to elastin, we incubated elastin
strips with TA and separately with mixtures of TA and Glut (TA+Glut) and assayed the
concentration of TA in solution for up to 24 hours (Figure 4.5). The TA concentration
for this binding study was selected so that it fits within the linear portion of the FolinDenis assay standard curve. For TA and Glut mixtures, we used a ratio of 1:2 (TA:Glut),
as this is a standard ratio used in tissue processing for electron microscopy.13 Levels of
TA in control solutions incubated without elastin remained constant throughout the study,
indicating that the solutions were stable. However, within 1 hour of incubation with
elastin, the amount of TA in solution decreased by ~50%, decreasing to 10% after 6
hours, and to less than 3.5% of initial TA at 24 hours, clearly indicative of TA binding to
elastin. TA binding values were also normalized to dry weight of elastin strips and are
depicted in Figure 4.5. The resulting kinetics show a rapid binding within the first 6
hours, leveling off afterwards at ~3 mg of TA per mg dry elastin. Interestingly, the
binding rate of TA from the mixtures of TA and Glut was higher than that of TA alone up
to 6 hours of incubation (Figure 4.6; p<0.05 for all time points between 20 minutes and 6
hours), thus suggesting that Glut may facilitate or accelerate the binding of tannins to
elastin.
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Figure 4.3 The minimum elastase concentration needed to obtain complete digestion
(>99% mass loss) of untreated pure aortic elastin is 10 Units/mL.

Figure 4.4 The minimum time of elastase incubation needed for complete digestion
(>99% mass loss) of untreated pure aortic elastin is 24 hours.

101

Figure 4.5 Kinetics of tannin-elastin interactions. Tannic acid (TA) concentration in
solution (µg TA/mL) decreases in the presence of aortic elastin (EL) as to compared to
controls without added elastin (CTRL).

Figure 4.6 Cumulative binding of tannic acid (TA) to pure aortic elastin (µg TA per mg
dry elastin). ●---● indicates statistically different values (all data points up to 6 hours)
for TA vs. TA+Glut (p<0.05).
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Tannic acid treatment was performed at pH 5.5 and pH 7.4 to determine the more
suitable condition for elastin stabilization. Elastase digestion results revealed that TA at
pH 5.5 was significantly improved over that at pH 7.4 (p<0.05; Figure 4.7). These
experiments also revealed that TA is not stable in solution (long-term) at pH greater than
6. This instability was associated with the appearance of a brown precipitate, which was
apparently ineffective as an elastin-stabilizing agent. Since TA stability was significantly
improved at pH 5.5 over a long period of time, we chose this pH for present studies.

Figure 4.7 Digestion of pure aortic elastin after varying the pH of tannic acid (TA)
solutions revealed that elastin stabilization was more effective at pH 5.5.
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To determine the optimal TA concentration for elastin stabilization, pure aortic
elastin was exposed to increasing TA concentrations and tested for resistance to elastase
(Figure 4.8). Control elastin preparations, including Glut-treated elastin, were completely
degraded. Treatment with 0.003% TA did not apparently stabilize elastin and 0.03% TA
offered minimal stabilization (p>0.05). Meanwhile, concentrations of 0.3% TA and
higher reduced the susceptibility towards elastase by ~50%. Statistical analysis showed
that digestion values for elastin treated with 0.8% TA were not different from those of
0.3% TA-stabilized elastin (p>0.10). Mixtures of increasing TA concentrations prepared
in 0.6% Glut were more effective than TA alone (p<0.05 for 0.3% TA), suggesting that
Glut enhances TA-mediated stabilization of elastin. For further stabilization studies, we
selected to use concentrations of 0.3% TA and 0.3% TA in 0.6% Glut.

Figure 4.8 Digestion of pure aortic elastin treated with varying concentrations of tannic
acid (TA) with and without glutaraldehyde (Glut). The combination (TA+Glut) was
slightly more effective in stabilizing elastin than TA alone (p<0.05).
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The time needed for TA treatment to stabilize pure elastin was investigated for
TA alone as well as mixtures of TA and Glut (Figure 4.9). All elastin samples treated in
Glut were completely digested by elastase, irrespective of the length of Glut treatment.
Stabilization of elastin by TA, as well as by TA and Glut increased with time, reaching a
relatively constant value after 4 days (Figure 4.9).

These results indicate that

stabilization of pure elastin may occur within 4 days of treatment with TA or mixtures of
TA and Glut.

Figure 4.9 Treatment time of tannic acid (TA) needed to obtain elastin stabilization.
Note that glutaraldehyde (Glut) treated elastin was vulnerable to digestion in all cases.

Gravimetric digestion data were further confirmed by histology with Movat’s
pentachrome stain. As seen in Figures 4.10A and 4.10B, the following general trends
across all studies were validated visually: Glut treatment leaves elastin fibers susceptible
to enzymatic degradation, while tannin treatment alleviates this vulnerability. In fact,
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analysis of elastase digested, Glut-treated elastin was not possible due to complete
(~100%) degradation. We therefore selected to expose Glut-treated elastin to elastase for
just 1.5 hours, an interval which we found to yield about 50% digestion and mass loss
(Figure 4.4).

Partially degraded Glut-fixed elastin exhibited extensive fraying and

massive loss of fibers (Figure 4.10A). Elastase treatment of TA+Glut stabilized elastin
revealed excellent preservation of aortic structure, without massive loss of elastin
integrity (Figure 4.10B), as seen in the similarity to pure elastin which was never exposed
to enzyme (Figure 4.2B).

Figure 4.10 Glutaraldehyde fixed aortic elastin exposed to elastase shows clear signs of
fiber degradation after 1.5 hours of incubation (A), while elastin stabilized with a mixture
of tannic acid and glutaraldehyde exhibits nearly complete resistance to elastase
degradation for up to 48 hours (B).
Movat’s pentachrome stain, original magnification, 100x.

4.4 Discussion
The long-term aim of this project is to develop a method for elastin stabilization
which may be applied to improve tissue-derived cardiovascular devices (such as
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bioprosthetic heart valves) and/or treat abdominal aortic aneurysms. Due to the complex
composition of the cardiovascular and vascular tissues associated with these applications,
it was considered imperative to undertake a fundamental study using pure elastin as a
model for elastin-containing tissues. For this purpose we purified elastin from porcine
aorta using established procedures and developed an accelerated degradation assay using
pancreatic elastase. Optimal conditions for complete enzymatic digestion of pure aortic
elastin were found to be 48 hours of incubation with 20 units of pancreatic elastase at
37oC with vigorous shaking (Figures 4.3 and 4.4). These conditions constituted a reliable
in vitro model of elastin degeneration. Since the degree of elastin degradation in vivo is
not fully known, this model could be considered an accelerated screening system that
allows for evaluation of elastin stabilization strategies.
The lack of basic knowledge regarding the use of tannic acid (TA) for elastin
stabilization also prompted us to investigate the stability of TA solutions and optimal
conditions required for interactions between TA and elastin, such as pH of TA solutions
(Figure 4.7), TA concentration (Figure 4.8), and time of TA treatment (Figure 4.9).
The first finding of our studies was that treatment of elastin with glutaraldehyde
(Glut) had practically no effect on its susceptibility to elastase. This was shown initially
in a pilot experiment using orcein-labeled bovine neck elastin, a traditional elastase
substrate (Figure 4.1) and in subsequent experiments using aortic elastin (Figures 4.8,
4.9, and 4.10).

Elastin stabilization by Glut could not be improved by increasing

incubation time for up to 7 days (Figure 4.9) or by altering the pH of the Glut solution
(data not shown). It was previously shown that extremely low levels of radioactive Glut
incorporated into elastin in vitro at pH 7.4, providing evidence that Glut does not
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effectively react with elastin.14 This lack of stabilization by Glut may be explained by the
fact that elastin contains an extremely low number of reactive amine groups suitable for
reaction with Glut.15 Glut was used in these studies not only as a kind of negative
control, but also because Glut is widely used in the preparation of commercially available
tissue-derived cardiovascular devices.

Therefore, we have demonstrated that these

preparations are ineffective toward the elastin within these tissues.
By comparison with Glut, treatment of elastin-orcein (Figure 4.1) and pure aortic
elastin (Figures 4.7, 4.8, 4.9, and 4.10) with TA was efficient in preventing elastasemediated degradation, indicating that TA has excellent potential as a stabilizing agent.
Binding studies clearly showed that TA binds to pure elastin in a time-dependent pattern
(Figures 4.5 and 4.6). A calculated 3 μg of TA were found to bind to 1 mg of dry elastin
within 24 hours, which yielded a calculated value of ~1 mole of TA bound per mole of
elastin (considering the molecular weight of elastin as 70 kDa and that of TA as 1.8 kDa
for a decagalloyl derivative) under current experimental conditions. Interestingly, when
TA was used in mixture with Glut, the kinetics of TA binding to elastin were enhanced
within the first 6 hours of incubation (Figures 4.5 and 4.6), suggesting that a beneficial
interaction between TA and Glut may occur during treatment of elastin. From studies
presented in Figures 4.8 and 4.9, it also appeared that the use of TA in combination with
Glut might be beneficial for elastin stabilization. While this compatibility between TA
and Glut may be important for the development of a tissue pretreatment for
cardiovascular devices, it is important to note that TA, even when used alone, also
provided a significant level of stabilization in all cases as compared to untreated and
Glut-treated elastin.
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The mechanisms of TA-mediated elastin stabilization against the action of
elastase are not known. One potential explanation could be that TA that may have
leached from treated elastin samples is working by inhibiting elastase activity. As a
result, we tested elastase solutions (recovered after incubation with treated elastin) using
an elastin-orcein assay and showed no change in activity as compared to fresh elastase
solutions (data not shown), ruling out this possibility.
Based on present knowledge of elastin composition, we speculate that TA protects
elastin by binding to potential elastase cleavage sites on the elastin molecule.

A

schematic depicting the main features of the elastin molecule was previously shown in
Figure 2.12. The secondary structure of tropoelastin is characterized by an alternance of
β−sheets, hydrophobic areas susceptible to elastases, and α-helical, crosslinking
domains.16

Most elastolytic enzymes, such as matrix metalloproteinases, neutrophil

elastase, and pancreatic elastase preferentially act on hydrophobic areas in the elastin
structure.17,18 Therefore, it is tempting to speculate that TA, which has a known affinity
for hydrophobic regions,1 stabilizes elastin by binding to these (hydrophobic) potential
elastase cleavage sites, thus preventing enzyme-substrate interactions. This hypothetical
relationship between TA and elastin is schematically illustrated in Figure 4.11. The
bonds between TA and elastin are shown as hydrogen bonds, since it is known that TA
interacts with proteins by creating a vast “shell” of hydrogen bonds.19
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Figure 4.11 Hypothetical interactions between TA and elastin. Elastin is composed of
alternating hydrophilic crosslinking regions (1) and hydrophobic domains (2). The
naturally derived desmosine crosslinks (3) connect mainly hydrophilic regions of the
elastin molecule. Hydrophobic areas are susceptible to elastase cleavage and are also the
potential target of TA stabilization. The hydrophobic “core” of the TA molecule (circular
structure), likely incorporates itself into hydrophobic areas (4), while the hydroxyl
moieties of TA establish multiple hydrogen bonds (dashed lines) with neighboring elastin
molecules (5), resulting in improved elastin stabilization.

4.5 Conclusions
Glutaraldehyde (Glut) treatment is entirely ineffective in protecting elastin from
enzymatic degradation, but treatments with tannins such as tannic acid (TA) can
circumvent this vulnerability. TA binds to vascular elastin and this binding significantly
increases its resistance to enzymatic degradation. As a result, TA may hold great promise
for (1) improving the long-term performance of cardiovascular implants such as
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bioprosthetic heart valves, and (2) developing a therapy for limiting the progression of
abdominal aortic aneurysms based on elastin stabilization.
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CHAPTER 5
ELASTIN STABILIZATION IN BIOPROSTHETIC HEART VALVES

5.1 Introduction
Chemically preserved biological tissues have been used in the form of
bioprosthetic heart valves (BHVs) for several decades.

The intended result of this

preservation or fixation is to reduce the xenogenic tissue’s antigenicity and to form
crosslinks within the extracellular matrix, resulting in a biomaterial that is more resistant
to enzymatic degradation.

Glutaraldehyde (Glut) has been widely used as a tissue

fixative for BHVs due to its ability to crosslink matrix molecules, sterilize tissue, and
reduce tissue antigenicity.

Thousands of Glut-fixed BHVs are used for surgical

replacement of diseased human valves annually, yet over half of these treated BHVs fail
within 10 years of implantation due to tissue degeneration and calcification.1,2
While Glut fixation is generally perceived to adequately crosslink the collagen
component of BHVs, it is unable to stabilize other important constituents of the ECM,
particularly elastin. The elastin molecule is known to contain very few free amine groups
required for crosslinking with Glut, which leaves it highly susceptible to enzymatic
degradation. This vulnerability is significant considering elastin is one of the major ECM
components of the aortic segment of stentless BHVs and the ventricularis layer of the
valvular cusp structure. Elastin degeneration could lead to loss of elastic recoil and
deterioration of mechanical properties, potentially resulting in clinical failure of
implanted cardiovascular prostheses.3,4 It has also been shown that pure elastin, even in
the absence of Glut fixation, is susceptible to degradation and calcification after
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implantation in animal models.5,6 These facts suggest that elastin degeneration in BHVs
and tissue-derived cardiovascular implants may be important in the clinical setting and
that there is a need for a fixation procedure that specifically enhances the stability of
elastin towards enzymatic degradation.
We propose to do this with tannins, a class of naturally occurring plant
polyphenols known to interact with proteins. As presented in the previous chapter, Glut
did not adequately stabilize pure elastin, whereas tannins (specifically tannic acid, TA)
bound to pure aortic elastin in a time-dependent pattern which resulted in improved
resistance to elastase. In addition, when TA was used in mixture with Glut, the kinetics
of TA binding to elastin were enhanced, which translated into improved elastin
stabilization. In the studies presented here, this work has been extended to evaluate the
feasibility and applicability of TA as a pretreatment or fixative for bioprosthetic heart
valves. To do so, we investigated the efficacy of TA to stabilize elastin within porcine
aortic wall. We demonstrate that TA does not impair the ability of Glut to adequately
crosslink aortic collagen and that by protecting elastin from enzymatic attack, TA may
also inhibit calcification of Glut-treated aorta.
In addition, we evaluated the efficacy of tannin treatment when used in
conjunction with metals, specifically aluminum chloride and ferric chloride. Aluminum
and iron, which are suspected to bind to elastin, have been previously investigated as
anti-calcification pretreatments for BHVs.7,8 Furthermore, tannins have a strong binding
affinity for metal ions such as these,9 so the effects of the two agents together (tannins
and anti-calcification metal ions) were examined as a potential BHV pretreatment.
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5.2 Methods

5.2.1 Materials
Tannic acid, type I bacterial collagenase (277 U/mg), azo dye-impregnated
collagen, aluminum chloride, ferric chloride, and other chemicals were of highest purity
available and obtained from Sigma (St. Louis, MO). Glutaraldehyde (EM grade, 8%
solution) was acquired from Polysciences, Inc. (Warrington, PA). High purity porcine
pancreatic elastase (135 U/mg) and elastin-orcein were obtained from Elastin Products
Company, Inc. (Owensville, MO).

5.2.2 Tissue Preparation and Fixation Procedures
Ascending porcine aorta (supravalvular segments, approximately 3 cm in height)
was collected fresh at local USDA-approved slaughterhouses and transported to the
laboratory on ice in saline (9 g NaCl per liter). All tissues were harvested from healthy
male pigs, six to eight months of age, and weighing approximately 200 pounds. Aorta
was cleaned of fat and extraneous tissue, rinsed exhaustively in cold physiological saline,
and cut into 4 mm x 4 mm squares. Dumbbell shapes (40 mm long, 10 mm wide at each
end, 5 mm wide in center) were also cut for mechanical testing.
For the majority of studies, samples were treated by one of two methodologies:
(a) glutaraldehyde (Glut) fixation, or (b) Glut treatment followed by tannic acid
(Glut/TA). For Glut treatment, aortic samples were fixed with 0.6% glutaraldehyde in 50
mM Hepes buffered saline, pH 7.4, overnight at room temperature, followed by 0.2%
glutaraldehyde in same buffer for 7 days at room temperature, as described previously.10
Glut/TA treatment consisted of the fixation steps outlined in the Glut protocol, followed
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by TA treatment (0.3% tannic acid in 0.6% glutaraldehyde in 50 mM Na2HPO4 buffered
saline, pH 5.5 for 4 days at room temperature). For each treatment, 50 mL of fixative or
solution were used for every 6 aortic samples (4 mm x 4 mm). As controls, fresh
untreated samples were also used in all experiments except in the case of subdermal
implantation.

5.2.3 Tannin Binding to Porcine Aortic Wall
Tannic acid (TA) was first investigated for its ability to bind to porcine aortic wall
using a phenol-specific histological stain.

Porcine tissue was left untreated (fresh),

treated with glutaraldehyde alone (Glut), or treated with Glut/TA.

Samples were

sectioned (6 µm) and then stained with 10% ferric chloride (FeCl3) in methanol and
counterstained with 1% light green. The ferric chloride in this case stains phenols, such
as tannins, black.

5.2.4 Elastin Stabilization of Porcine Aortic Wall
Resistance to elastase was evaluated using the enzyme digestion assay previously
optimized by our group for pure aortic elastin. Samples of porcine aorta were either left
untreated (fresh) or fixed with one of the two aforementioned treatments (Glut or
Glut/TA, n=6 per group), rinsed 3 times (1 hour each) in 100 mL ddH2O at room
temperature, and lyophilized to record dry weight. Each sample (~15 to 25 mg dry
weight) was incubated with 1.0 mL of elastase (20 U/mL) dissolved in 100 mM Tris
buffer, 1 mM CaCl2, 0.02% NaN3, pH 7.8, for 48 hours at 37oC with orbital shaking at
650 rpm. Samples were then centrifuged (10000 rpm, 10 minutes, 4oC) and supernatants
retained for enzyme assay (see below). Tissue samples were individually rinsed 3 times
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in 1 mL ddH2O, centrifuged (as above), lyophilized to obtain dry weight after elastase,
and the percent of digested tissue was calculated.

To evaluate the possible direct

inhibitory effects of Glut and/or TA (leaching from the fixed tissues) on elastase activity,
the enzyme solutions retrieved after elastase treatments were checked for activity using
an elastin-orcein assay.11
Elastin stabilization after elastase treatment was also verified by histology. Tissue
samples randomly retrieved from each group were placed in Karnovsky’s fixative (2.5%
glutaraldehyde, 2% formaldehyde in 0.1 M cacodylic acid buffer, pH 7.4), dehydrated
through graded alcohols, and embedded in paraffin. Sections (5 μm) were stained with
Verhoeff van Giesson’s procedure (elastin fibers stain black while collagen fibers stain
red or pink) to assess the integrity of aortic elastin fibers.

5.2.5 Collagen Crosslinking Studies
The thermal denaturation temperatures (Td), common indicators of collagen
crosslinking density,12 were measured in samples from each treatment group (n=3) using
a differential scanning calorimeter (DSC) (Perkin-Elmer DSC 7; Boston, MA). The
treated aortic wall samples (approximately 2 mm x 2 mm) were sealed in aluminum pans,
heated at a rate of 10oC/min from 20oC to 110oC, and Td determined as the temperature
measured at the endothermic peak.

This observed endothermic peak occurs at the

temperature where collagen fibers unravel or denature, resulting in a measurable release
of energy.

Therefore, a higher denaturation temperature correlates into improved

collagen crosslinking.
As an additional test of collagen crosslinking, samples were tested for resistance
to collagenase. Samples of porcine aortic wall were either left untreated (fresh) or fixed
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with Glut or Glut/TA as outlined above (n=6), rinsed 3 times (1 hour each) in 100 mL
ddH2O, and lyophilized to record dry weight. Samples (~15 to 25 mg dry weight) were
immersed in 1.2 mL of type I collagenase (150 U/mL) dissolved in 50 mM Tris buffer, 10
mM CaCl2, pH 7.4, and incubated at 37oC with orbital shaking at 650 rpm for 24 hours.
Following this exposure to collagenase, samples were centrifuged (10000 rpm, 10
minutes, 4oC), individually rinsed 3 times in 1 mL ddH2O, lyophilized to obtain dry
weight after collagenase, and the percent of digested tissue was calculated. The “used”
collagenase solutions were salvaged in order to test for enzyme activity using an azoic
dye-impregnated collagen assay,13 similar to the elastin-orcein assay used to check for
elastase activity.

5.2.6 Mechanical Testing
Porcine aorta was cut into dumbbell shapes in the circumferential direction of the
aorta and either left untreated (fresh) or fixed by the Glut or Glut/TA methodologies as
described above. Stress-strain analysis was performed on each group (n=3) at a constant
uniaxial velocity of 0.2 mm/sec using a 10-pound load cell on a Vitrodyne V1000
material testing apparatus (Liveco, Inc.; Burlington, VT). Results are displayed as stressstrain curves in the range of 0 to approximately 80% elongation or strain.

5.2.7 Rat Subdermal Implantation
Male juvenile Sprague-Dawley rats (25-35 days old, weighing ~50 g, Harlan
Laboratories; Indianapolis, IN) were sedated with acepromazine (0.5 mg/kg, Ayerst
Laboratories; Rouses Point, NJ) and maintained on 2% isoflurane throughout surgery. A
small incision was made on the backs of the rats and three subdermal pouches were
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created. Glut and Glut/TA-treated samples of aortic wall (4 mm x 4 mm) were implanted
into the subdermal pouches (30 implants per group). The rats were euthanized by CO2
asphyxiation at 7 and 21 days and capsule-free samples were retrieved for calcium
analysis, histology, and elastase digestion. The animal protocol was approved by the
Animal Research Committee at Clemson University and NIH guidelines for the care and
use of laboratory animals (NIH publication #85-23 Rev. 1985) were observed throughout
the experiment.
For calcium analysis, explants (n=10 per group per time point) were rinsed in
saline, cut approximately in half, and lyophilized to obtain dry weight (10 to 15 mg each).
The samples were then individually hydrolyzed in 6 N hydrochloric acid (HCl) at 95oC
for approximately 8 hours. Following hydrolysis, they were dried under a continuous
stream of nitrogen gas (~45 minutes) and subsequently reconstituted in 1.0 mL of 0.01 N
HCl. These tissue hydrolysates were diluted in the range of 20-fold to 50-fold in an
atomic absorption matrix (0.5% lanthanum oxide in 0.3 N HCl) and assayed for calcium
content using atomic absorption spectrophotometry.14
Using these same tissue hydrolysates, desmosine content within Glut and
Glut/TA-treated 21 day explants was examined using radioimmunoassay by our
collaborator Dr. Barry Starcher.15 Desmosine, an amino acid unique to elastin, may be
used to express elastin content. As controls, tissue hydrolysates from non-implanted Glut
and Glut/TA-treated aorta were used to calculate percent of desmosine lost due to the in
vivo model.
The other half of the explants (n=10), which were not acid hydrolyzed, were
lyophilized and used for elastase digestion. Details of this in vitro enzyme digestion were
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performed as described above (20 Units/mL porcine pancreatic elastase, 48 hours, 37oC,
600 rpm) and dry weights recorded in order to calculate percent mass loss. For histology
studies, explanted samples were placed in Karnovsky’s fixative and paraffin embedded
sections (5 μm) were stained using Alizarin red for calcium deposits and hematoxylin and
eosin for general morphology.

5.2.8 Long-Term Stability of Tannic Acid Treatment
An in vitro system was implemented to test the propensity of TA to leach out
from the treated tissue and to evaluate the effect of this leaching on resistance to elastase.
Aortic wall samples (n=6) treated with one of the fixation procedures (Glut or Glut/TA)
were rinsed 3 times (1 hour each) in 100 mL ddH2O, then shaken reciprocally at 120 rpm
in phosphate buffered saline (PBS) with 0.02% NaN3, pH 7.4 for 14 days at 37oC (50 mL
per 6 tissue samples). After subjecting tissues to this system, samples were rinsed,
lyophilized to record dry weight, and subjected to the elastase digestion assay as
described above. For comparative purposes and as a possible indicator of elastin stability
in vivo, Glut and Glut/TA-treated aortic samples were implanted subdermally in juvenile
rats for 7 and 21 days (as described above) and explants analyzed for resistance to
elastase. This would allow us to not only test for stability of TA interactions in vivo, but
to also assess the accuracy and validity of our in vitro leaching model.

5.2.9 Effect of Metals on Tannic Acid Treatment
Samples of porcine aortic wall were treated with aluminum chloride, ferric
chloride, or one of these metals in combination with glutaraldehyde and/or tannic acid, as
outlined in Table 5.1. Once treatments were complete, samples were rinsed in ddH2O (3
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rinses, 1 hour each), lyophilized to record dry weight, and exposed to the elastase
digestion assay as described above (n=6). Since metals such as aluminum and iron are
expected to bind very strongly with polyphenolic tannins, we investigated the long-term
stability of TA binding with tissue in the presence of these metal ions. Once treated with
one of the aforementioned methodologies, samples were exposed to the prolonged in
vitro model with vigorous shaking as described above in Section 5.2.8. The treated
samples of aortic wall were shaken reciprocally at 120 rpm in phosphate buffered saline
(PBS), 0.02% NaN3, pH 7.4 for 14 days at 37oC (50 ml per 6 tissue samples). After 14
days, these samples were subjected to the elastase digestion assay (n=6) to investigate the
potential effects of instability or reversibility of metal-tannin-tissue interactions. As an
alternative model for investigating stability of the interactions with tissue, aluminumtreated samples were also implanted in a rat subdermal implant model (see below) and
exposed to elastase digestion following explantation at 7 and 21 days. The resulting
values for resistance to enzyme were subsequently compared to those exposed to the 14
day in vitro leaching system.
Since aluminum chloride has been widely proposed as an anti-calcification
treatment for the aortic portion of bioprosthetic heart valves, samples treated with
aluminum (G/Al) or aluminum and tannic acid (Glut/Al/TA) were also utilized in the rat
subdermal model to investigate in vivo tissue calcification. Capsule-free explants were
retrieved at 7 and 21 days (n=10 per time point), hydrolyzed in 6 N hydrochloric acid
(HCl), dried under nitrogen, reconstituted in 1.0 mL of 0.01 N HCl, and analyzed for
calcium content using atomic absorption spectrophotometry as described above.
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Table 5.1 Descriptions of tissue treatment groups.
Group Name

Description

Glut

0.6% glutaraldehyde (1 day) followed by 0.2% glutaraldehyde (7
days), in 50 mM Hepes buffered saline, pH 7.4

Glut/TA

Glut (as listed above) followed by 0.3% tannic acid (4 days) in 50
mM Na2HPO4 buffered saline containing 0.6% glutaraldehyde, pH
5.5

Al

0.1 M aluminum chloride in ddH2O (4 hours)

Glut/Al

Glut cycle followed by 0.1 M aluminum chloride (4 hours)

Glut/Al/TA

Glut cycle followed by aluminum chloride, then 0.3% tannic acid (4
days) in 50 mM Na2HPO4 buffered saline containing 0.6%
glutaraldehyde, pH 5.5

Fe

0.1 M ferric chloride in ddH2O (4 hours)

Glut/Fe

Glut cycle followed by 0.1 M ferric chloride (4 hours)

Glut/Fe/TA

Glut cycle followed by aluminum chloride, then 0.3% tannic acid (4
days) in 50 mM Na2HPO4 buffered saline containing 0.6%
glutaraldehyde, pH 5.5

5.2.10 Data Analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.
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5.3 Results

5.3.1 Effect of Tannic Acid on Porcine Aortic Wall
The ability of tannic acid (TA) to bind to intact porcine aortic wall was
investigated using a histology stain specific for phenols. This technique allows us to see
if/where TA is incorporating itself into the tissue following fixation, as indicated by a
distinct black stain. Expectedly, fresh tissue (data not shown) and glutaraldehyde treated
tissue resulted in virtually no black staining (Figure 5.1A). Meanwhile, a large amount of
TA apparently incorporated itself into the tissue, as suggested by the large amount of
black seen in Figure 5.1B. The majority of the (black) stain is seen along the elastin
fibers, providing evidence that tannins primarily bind to the elastin within aortic wall.

Figure 5.1 Phenol-specific stain shows incorporation of tannins into Glut/TA-treated
porcine aortic wall (B) as compared to glutaraldehyde-treated tissue (A). Phenols such as
TA stain black as denoted by arrow in (B). Original magnification, 200x.

Resistance to elastase digestion was tested using fresh aortic samples and aorta
treated with Glut or with the sequential treatment of Glut followed by TA (Figure 5.2).
While Glut-treated aorta was evidently less susceptible to elastase degradation than fresh
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aorta (p<0.05), the conventional Glut treatment still left the tissue extremely vulnerable
(greater than 60% mass loss). Treatment with Glut/TA dramatically increased resistance
of aorta to elastase, yielding values 15 times lower than those of Glut alone (p<0.05).
The quantitative elastase digestion values were also confirmed by histology (Figure 5.3).
Almost no aortic elastin fibers were preserved after elastase treatment of the Glut-fixed
aorta (Figure 5.3B), while the majority of elastin fibers remained intact for the Glut/TA
group after enzyme digestion (Figure 5.3D), indicating excellent elastin preservation by
Glut/TA.

All enzyme solutions retrieved after elastase treatment of tissue samples

displayed similar activities using an elastin-orcein assay (data not shown) suggesting that
Glut and/or TA that may have leached from the fixed tissues had no direct inhibitory
effects on elastase activity.

Figure 5.2 Efficacy of tannic acid as elastin-stabilizing agent for porcine aortic wall.
Aorta treated with glutaraldehyde and tannic acid (Glut/TA) was significantly more
resistant to elastase-mediated degradation than Glut alone (p<0.05).
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Figure 5.3 Histology of aortic samples before and after elastase. Glut treated aorta
before (A) and after elastase (B); Glut/TA-treated aorta before (C) and after elastase (D).
Elastin fibers remained primarily intact within the Glut/TA-treated tissue (D). VVG stain,
original magnification, 200x. Elastin fibers (stained black) are indicated by white arrows.

In order to evaluate the potential inhibitory effects of TA on Glut fixation of
aortic collagen, the thermal denaturation temperature (Td) and resistance to collagenase of
treated aortic samples was analyzed. As anticipated, aorta fixed with Glut had a marked
increase in Td as compared to that of fresh aorta (p<0.05, Table 5.2). Treatment of aorta
with Glut/TA yielded slightly higher Td values but these were not statistically different
that those of Glut-fixed aorta (p>0.10).
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Table 5.2 Denaturation temperatures of treated porcine aortic wall samples.

Treatment Group

Thermal Denaturation
Temperature (Td)

Fresh

68.37 ± 0.67oC

Glut

90.43 ± 0.27oC

Glut/TA

92.92 ± 0.93oC

As expected, resistance to collagenase digestion showed that Glut treatment had a
stabilizing effect on aortic collagen in comparison to fresh aorta (p<0.05, Figure 5.4).
Treatment with the Glut/TA sequence appeared to significantly improve the stability of
aortic collagen as compared to Glut alone (p<0.05), as indicated by the virtually complete
preservation of tissue mass after collagenase (undetectable mass loss).

All enzyme

solutions retrieved after collagenase treatments displayed similar activities using an
azocollagen assay (data not shown), suggesting that Glut and/or TA that may have
leached from the fixed tissues had no direct inhibitory effects on the activity of the
collagenase enzyme. These results indicate that TA does not impede, and may even
assist in, the collagen crosslinking ability of Glut.
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Figure 5.4 Resistance to collagenase revealed that glutaraldehyde (Glut) maintained its
ability to crosslink collagen even in the presence of tannins (Glut/TA). In fact, mass loss
values for Glut/TA-treated aorta were essentially zero, suggesting that TA may even
enhance the ability of Glut to protect collagen from enzymatic degradation.

Stress-strain analysis was performed on samples from each group (n=3) and
representative plots are shown in Figure 5.5. Expectedly, as indicated by the greater
slope of the stress-strain curves, Glut fixation reduced distensibility and stiffened aorta.
Treatment with Glut/TA apparently produced a stiffer material than both fresh and Gluttreated aorta, clearly indicating that TA interacts with elastin fibers within the aortic
tissue.
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Figure 5.5 Mechanical properties of porcine aorta treated with glutaraldehyde (Glut) and
a combination of Glut and tannic acid (Glut/TA). As compared to untreated aorta
(Fresh), all stabilization treatments reduced distensibility of aortic tissue.

The propensity of tannic acid to inhibit calcification of Glut-fixed aortic wall was
studied in a well-established rat subdermal model. The calcium analysis performed on
subdermal explants from two different time points is shown in Figure 5.6. For both 7 and
21 day time points, the calcium content was approximately three times lower for Glut/TA
in comparison with Glut alone (p<0.05). Explants were examined by histology with
Alizarin red staining to confirm the presence of calcium deposits and study their
distribution (Figure 5.7).

The abundance of calcium deposits in the Glut samples

(Figures 5.7A and 5.7B) and the lower numbers of deposits within Glut/TA explants
(Figures 5.7C and 5.7D) validates the values obtained by calcium analysis (Figure 5.6).
Hematoxylin and eosin staining did not reveal significant differences in tissue structure or
host response between the two groups (data not shown). The weight gain in the rats

128
implanted with Glut/TA treated aorta as compared to Glut samples did not differ
significantly indicating that TA treatment did not adversely influence rat growth (data not
shown). Overall, these results indicate that tissue stabilization by TA may partially
inhibit calcification of Glut-fixed aortic wall.

Figure 5.6 Calcification of treated aorta in the rat subdermal implant model. For both
time points, treatment with tannic acid (Glut/TA) yielded approximately three times less
calcium than glutaraldehyde (Glut) alone (p<0.05).
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Figure 5.7 Calcium deposition in subdermally implanted aorta. Representative sections
(lumen is at right) of glutaraldehyde-treated aorta explanted at 7 days (A) and 21 days
(B). Glut/TA treatment of aorta yielded few detectable calcification deposits after 7 days
(C) and only moderate amounts within 21 days of implantation (D). Alizarin red stain,
calcium deposits (red) indicated by arrows, original magnification, 100x.

Samples explanted from the rat subdermal implant model at 21 days were also
assayed for desmosine content. Desmosine is an amino acid specific to elastin and can
therefore be used to express relative elastin content. After 21 days, Glut-treated aorta lost
more than 35% of its original pre-implant desmosine, confirming the presence of in vivo
elastin degradation (Figure 5.8). Meanwhile, Glut/TA-treated tissue lost about half as
much desmosine as compared to Glut (Figure 5.8, p<0.05). These values endorse the
conclusions drawn from our in vitro elastase digestion studies. As such, we can conclude
that TA treatment significantly protects elastin from in vivo degradation.
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Figure 5.8 Percent of desmosine lost in aortic wall implants after 21 days in the rat
subdermal model. Loss of desmosine can be correlated to elastin loss or degradation,
suggesting that tannins (Glut/TA) provide a significant amount of elastin stabilization in
vivo (p<0.05).

The reversibility of tannic acid binding to aortic tissue was investigated using an
accelerated in vitro system and an in vivo animal model (designed to stimulate “leaching”
of unbound or reversibly bound TA). Once exposed to these models, samples were
subjected to the elastase digestion assay (Figure 5.9). After 14 days of continuous and
vigorous shaking in PBS, elastase digestion results revealed that the Glut/TA-treated
group became somewhat more vulnerable to enzyme treatment (Figure 5.9) than those
samples not exposed to prolonged shaking (unimplanted controls in Figure 5.9; p<0.05).
This partial loss of elastin stabilizing capabilities is an indication that a small fraction of
the tissue-bound TA may have been loosely attached to the aortic extracellular matrix
components. It is also important to note that even with the aggressive shaking, the
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Glut/TA group still exhibited a 3-fold stronger resistance to elastase than aorta treated
with Glut alone (p<0.05), suggesting that a substantial amount of TA remains tightly
bound within the tissue.
For comparative purposes, we also studied the in vivo stability of interactions
between tannic acid and porcine aorta. This was done by implanting treated tissues
subdermally into juvenile rats for 7 and 21 days, the same model used to investigate in
vivo calcification. Following completion of these time points, explants were subjected to
the elastase digestion assay (Figure 5.9). For both 7 day and 21 day explants, the
resistance to elastase of the Glut/TA group was significantly different from nonimplanted controls, yet still improved over that of Glut alone (p<0.05). It is apparent that
any leaching of TA from the Glut/TA treated aorta may have reached a plateau within 7
days of implantation, as indicated by the small change in elastase resistance from 7 to 21
days. These results indicate that a significant portion of TA is strongly bound within
porcine aorta; however, partial reversibility or instability of these interactions may be a
concern, as this was observed both in vitro and in vivo.
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Figure 5.9 In vitro and in vivo reversibility of tissue stabilization. For the in vitro
model, samples were treated and aggressively shaken to stimulate TA to leach from the
tissue and then tested for resistance to elastase. Glut and Glut/TA tissues were also
implanted subdermally for 7 and 21 days in juvenile rats and explanted samples tested for
resistance to elastase. Both in vitro and in vivo models revealed that a portion of the
incorporated TA may be reversibly bound. As compared to controls, the tannin-treated
groups consistently exhibited improved resistance to enzyme (p<0.05).

5.3.2 Effect of Metals and Tannic Acid on Porcine Aortic Wall
Tannins, with their ability to stabilize elastin against enzymatic degradation, and
metals (such as aluminum and iron), with their ability to inhibit calcification, were
investigated to see if an improved bioprosthetic heart valve pretreatment could be
developed by combining these technologies. Samples of porcine aortic wall were treated
with Glut, TA, aluminum chloride, and/or ferric chloride (Table 5.1). In vitro elastase
results (Figure 5.10) revealed that aluminum, which is believed to bind to elastin fibers,
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did not protect elastin whether used alone (Al) or in conjunction with glutaraldehyde
(Glut/Al; p>0.10 versus Glut alone). The implementation of Al within the glutaraldehyde
and tannic acid fixation procedure (Glut/Al/TA) slightly improved the tissue’s resistance
to elastase, although this difference was not significant (p>0.10 versus Glut/TA; Figure
5.10). In all cases, extremely similar results were reflected in experiments involving
ferric chloride in place of aluminum chloride (Figure 5.11). For instance, the iron
treatment had little to no effect on resistance to elastase when used alone or with Glut
(Fe, Glut/Fe), and slightly improved resistance when used in combination with Glut and
TA, although not to a significant level (Glut/Fe/TA; Figure 5.11). Together, these results
suggest that: (1) aluminum and iron, despite inhibiting elastin-oriented calcification, do
not protect elastin from enzymatic degradation, and (2) aluminum and iron do not hinder
the elastin stabilizing capabilities of tannins when used in a stepwise treatment procedure.

Figure 5.10 Resistance to elastase revealed that aluminum (Al) had no effect on elastin
stabilization (p>0.10 for Glut vs. Glut/Al). Similarly, the addition of Al to tannin
treatment (Glut/Al/TA) did not significantly change elastin stabilization properties.
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Figure 5.11 Similar to the results obtained for aluminum, ferric chloride treatment
resulted in very minimal effects on resistance to elastase (p>0.05 for Glut vs. Glut/Fe,
Glut/TA vs. Glut/Fe/TA).

Despite the apparent inefficacy of these metal ions in regards to elastin
stabilization, we also examined their effect on the long-term tissue binding between
tannins and tissues. Metal ions, which bind very strongly to tannins, may be beneficial in
reducing some of the reversibility issues of TA-tissue interactions displayed in Figure
5.9. To investigate this, we exposed tissue to the same in vitro (14 days of continuous,
vigorous shaking at 37oC in PBS) and in vivo models (7 and 21 day subdermal implants
in juvenile rats). Note that ferric chloride-treated aortic wall was only exposed to the in
vitro system, as this tissue was not implanted. Results from the in vitro model showed
that aluminum or iron treatment significantly curtailed the amount of TA leaching from
the tissue, as evidenced by its retention of elastin stabilizing qualities after 14 days
(p<0.05 for Glut/TA vs. Glut/Al/TA or Glut/Fe/TA). In fact, both of these metal iron
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treatments resulted in virtually no changes in resistance to elastase after undergoing the
accelerated 14 day in vitro model: from 6.0% digestion immediately after fixation to
7.4% for aluminum, and from 5.1% to 6.3% for iron (p>0.10, Figure 5.12). Although
promising, these results apparently may be an indication of the in vitro model’s
limitations. When exposed to an in vivo model, the elastin stabilizing properties of the
Glut/Al/TA group were very similar to those from tissue without aluminum (Glut/TA;
p<0.05). That is, they also exhibited a partial reversibility in their interactions with the
tissue. As was the case with Glut/TA treated tissue, this reversibility for aluminum
treated samples appeared to level off, as 7 and 21 day data were similar (p>0.10).

Figure 5.12 The use of aluminum (Glut/Al/TA) or iron (Glut/Fe/TA) appeared to delay
or hinder TA leaching from the tissue, as evidenced by minimal changes in digestion
after 14 days in the in vitro model. However, implant studies revealed that these metal
ions were ineffective in limiting this partial reversibility in vivo. (# denotes that no
implant studies were performed for Glut/Fe/TA.)
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The effect of aluminum on tissue calcification was investigated through the
juvenile rat subdermal implant model. Aluminum with glutaraldehyde, a commercially
utilized fixation and anti-calcification procedure, yielded less calcification than Glut (as
expected) and Glut/TA treated aorta at both time points (Figure 5.13). In comparison to
Glut/TA, however, this data was statistically significant only at the 21 day time point
(p<0.05). Interestingly, tissue treated with both aluminum and tannic acid (Glut/Al/TA)
exhibited significantly higher calcium deposition than both Glut/Al and Glut/TA at both
time points (p<0.05, Figure 5.13). Therefore, it appears that the combination of the two
treatments may negate their efficacy in regards to limiting or hindering tissue
mineralization.

Figure 5.13 Aluminum, which is known to limit tissue mineralization, did not hinder the
propensity of aortic wall to calcify in the presence of glutaraldehyde and tannic acid
(Glut/TA vs. Glut/Al/TA).
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5.4 Discussion
One of the long-term objectives of this work is to create an elastin stabilization
procedure for cardiovascular implants, namely bioprosthetic heart valves. In preliminary
experiments presented in Chapter 4, we showed that tannic acid (TA) binds to pure aortic
elastin and, in doing so, increases its resistance to enzymatic degradation. We also
demonstrated that the binding kinetics and efficacy of TA solutions are enhanced in the
presence of glutaraldehyde (Glut) at pH 5.5. In the studies presented here, we chose this
Glut/TA mixture for studies on efficacy of TA-mediated elastin stabilization in porcine
aorta. The ability to crosslink aortic collagen and effects on mechanical properties were
also studied. In addition, an in vivo model was used to investigate the effect of TA
stabilization on calcification. We evaluated the reversibility of interactions between TA
and aortic elastin using in vitro and in vivo models. Finally, we tested the efficacy of
tannin treatment of aortic wall when used in conjunction with with anti-calcific metal
ions.
Conventional fixation methodologies for cardiovascular implants, such as Glut1
and others,16-18 have typically focused on collagen crosslinking.

These fixation

techniques, most notably Glut, have proven to be efficient in crosslinking the collagen
component, as suggested by their improvements in resistance to collagenase and
increased thermal denaturation temperatures.19 However, to our knowledge no claim has
been made pertaining to their ability to stabilize elastin. Elastin’s exceptionally low
number of reactive amine groups in comparison to collagen make elastin a poor target for
fixation by Glut.

This ineffectiveness has been confirmed earlier by the minimal

incorporation of radioactive Glut into purified elastin in vitro.5
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It was already exhibited that pure aortic elastin treated with Glut is not protected
from elastase-mediated degradation. In present studies, we demonstrate that this same
vulnerability to enzymatic degradation is present within Glut-treated aortic wall (Figure
5.2). Even prolonged treatment with Glut (up to 8 weeks), yielded tissue that was still
significantly susceptible to elastase digestion (data not shown). This lack of stabilization
by Glut is noteworthy since elastin is the most prevalent extracellular matrix protein
within aortic wall.20 Although it is not as abundant within the valve leaflets, elastin is
also present within the cusp structure and crucial to their mechanical properties.4
Therefore, it would be advantageous to develop a method for improved elastin
stabilization in cardiovascular implants.
The process by which elastin degradation occurs within cardiovascular implants is
not fully understood, although it is tempting to speculate that elastin-degrading enzymes
play a dominant role in this degeneration. Studies indicate that there is a relationship
between enzymatic degradation of elastin and the presence of matrix metalloproteinases
(MMPs), a class of enzymes responsible for extracellular matrix remodeling.21,22
Consequently, elastase treatment was used as an in vitro model of elastin degradation by
MMPs. The use of high purity pancreatic elastase is analogous to the widely accepted
method of utilizing collagenase to study the collagen crosslinking ability of a fixative.
Just as resistance to collagenase digestion is used as an indicator of collagen fixation,
elastin stabilization can be analyzed by investigating resistance to elastase digestion.
Using a histology stain specific for tannins, we saw visual confirmation that
tannic acid apparently bound to porcine aortic wall, with a specific concentration of
tannins accumulated on or around the elastin fibers (Figure 5.1). By using the elastase
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digestion assay, we saw that this binding correlated into extremely efficient protection of
aortic elastin (and the aorta in general) from enzymatic degeneration. This was verified
gravimetrically (Figure 5.2) and by histology (Figure 5.3). As mentioned in the previous
chapter and portrayed in Figure 4.10, it is our hypothesis that tannins, which have a
known affinity for hydrophobic regions,23 stabilize elastin by binding to potential elastase
cleavage sites, which are also hydrophobic in nature.
The compatibility between Glut and TA was addressed by investigating thermal
denaturation temperatures and resistance to collagenase of treated porcine aorta. The
addition of TA as a fixation step had virtually no effect on the thermal denaturation
temperature of Glut-fixed aorta indicating that TA does not hinder Glut fixation of
collagen in the aorta (Table 5.2). As the same time, TA did make the Glut-treated
samples significantly more resistant to collagenase, producing a biomaterial which was
virtually un-degradable by collagenase (Figure 5.4). These results suggest that TA,
besides binding to elastin, may also bind to Glut-fixed collagen and render it more
resistant to enzymatic attack. It was therefore apparent that TA does not hinder Glut
fixation of aortic collagen, nor does Glut impede TA stabilization of elastin. Moreover,
TA improves the ability of Glut-fixed aortic tissue to resist both elastase and collagenase.
The mechanisms of these synergistic effects of Glut and TA on tissues are not
known, but they may be due to: a) binding to different sites (Glut binds to amine groups,
while TA has high affinity for hydrophobic domains in matrix proteins) or b) chemical
interactions between Glut and TA that may yield a new unknown reaction product that
acts as a superior elastin and collagen fixative. Although the exact nature of this product
is unknown, the reaction of Glut with TA may form acetals, which could enhance the
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crosslinking ability of Glut.24 This synergy and chemical compatibility between the two
fixatives is important in that it may enable the implementation of TA into current Glut
fixation procedures for bioprosthetic heart valves.
By definition, the application of any effective tissue fixative will yield mechanical
properties different from those of fresh aorta and also could be used to approximate
efficacy of fixation.25 By interacting with the aortic matrix components, TA treatment
produces a material which is less distensible than Glut-fixed aorta (Figure 5.5). These
results clearly indicate that TA interacts strongly with elastin and possibly with collagen
components of aortic tissues. The functional implications of these changes in mechanical
properties require further investigation using accelerated fatigue testing and intracirculatory implants in large animals.
Calcification of cardiovascular implants is one of the most crucial problems
associated with the failure of bioprosthetic heart valves. Although the exact mechanisms
of implant calcification are not fully understood, the link between calcification and the
integrity of elastin fibers has been under great investigation.6,14,26

Elastin-oriented

calcification has been associated with increased activities of elastin-degrading MMPs;
furthermore, site-specific delivery of MMP inhibitors significantly reduced elastinmediated calcification,27 suggesting a strong correlation between elastolysis and calcium
deposition. Therefore, by protecting elastin from enzymatic degradation, it is reasonable
to speculate that elastin-oriented calcification may also be inhibited. This hypothesis was
partially confirmed by our results, which clearly documented the ability of TA (which
effectively prevents elastin degradation) to significantly reduce the propensity of Glutfixed aorta to calcify in vivo (Figures 5.6 and 5.7). While no particular claim is being
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made for tannins as an anti-calcification treatment, it is important to note the apparent
correlation between elastin stabilization by TA and inhibition of calcification.
Using samples from this same model, it was discovered that glutaraldehyde
treated aorta lost approximately 35% of its desmosine, or elastin (Figure 5.8). Although
it has been expected that Glut treatment leaves elastin vulnerable to enzymatic
degradation, this finding is significant since in vivo loss of elastin within treated
bioprosthetic heart valve tissue has not previously been shown quantitatively (to our
knowledge). These results further solidify the need for an elastin stabilizing technology
for these tissues, especially considering samples were implanted for just 21 days in a noncirculatory model.

As hypothesized, the addition of tannins to the Glut fixation

procedure, as in the case of Glut/TA, significantly reduced the amount of in vivo elastin
degradation. Not only does this provide more evidence for the efficacy of tannins as
elastin stabilizing agents, but it also validates many of our in vitro studies, such as tannin
binding and resistance to elastase, as we have demonstrated elastin stabilization is a
potential reality in vivo as well.
As an additional test of tannic acid efficacy and safety, the long-term stability of
TA binding to aortic tissue was investigated by prolonged shaking in vitro in PBS for 14
days and by implantation in the rat subdermal model for up to 21 days (Figure 5.9). After
being subjected to these “accelerated degeneration” systems, samples were tested for
resistance to elastase. While the conditions of the in vitro shaking model are meant to
imitate physiological conditions (pH 7.4, 37oC, PBS), the difference in elastase digestion
results between this group and the rat subdermal explants was statistically significant
(p<0.05), suggesting that additional unknown biological factors may have played a role
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within the implant model. In the case of both model systems, TA-treated tissue became
significantly more vulnerable to elastase as compared to tissue immediately exposed to
enzyme. However, resistance to elastase apparently reached a plateau after 7 days in vivo
indicating that only a portion of the TA was susceptible to leaching, possibly only those
TA molecules which were not tightly bound or in excess. However, it is notable that TA
treatment yielded a biomaterial that was significantly more resistant to elastase digestion
than Glut-treated aorta in all cases (Figure 5.9).

These two models have evident

limitations, and definitive answers regarding the long-term stability of TA require more
extended studies in fatigue testers and circulatory implants. The potential causes and
effects of this partial reversibility will be investigated in greater detail in Chapter 6.
The use of aluminum and iron, metal ions which have been shown to resist aortic
calcification when used as a tissue pretreatment, were tested for their effect on tannin
fixation. We hypothesized that the use of tannins and metal ions together may be useful
since: (1) tannins bind very strongly with such metal ions creating a very stable metaltannin complex,28 and (2) the anti-calcific metal ions are believed to interact directly with
elastin.6 Therefore, it is reasonable to assume that this complex may serve as a more
stable “bridge” linking tannic acid to elastin, thus limiting the partial reversibility
between tannins and tissue. This seemed to be the case using our long-term in vitro
model for binding reversibility, as we observed that the aluminum and iron (with TA)
treated tissues exhibited virtually no changes in susceptibility to enzymatic degradation
after being vigorously shaken for 14 days (Figure 5.12). As already mentioned, this same
model caused Glut/TA treated tissue to be approximately twice as susceptible to
enzymatic degradation after 14 days of shaking. This effect, however, did not carry over
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to in vivo studies, as resistance to elastase was similar for Glut/Al/TA explants in
comparison to Glut/TA explants (Figure 5.12). Likewise, in vivo tissue calcification of
Glut/TA samples was not improved (and was actually made worse) by adding the
aluminum treatment step. This incompatibility between tannins and aluminum may be
attributable to (1) competitive binding between the two agents, and (2) an ineffective
complex resulting from tannin-aluminum interactions. In other words, when tannins bind
to aluminum, they may be blocking or “capping off” the aluminum ions, thus partially
preventing their ability to inhibit calcification as they normally would. Such a conclusion
is purely speculation, however, especially considering the anti-calcification mechanisms
of aluminum chloride treatment have not been well established. That being said, due to
improved tissue calcification as compared to Glut/Al/TA, tannins appear to show more
promise as an elastin-stabilizing agent when used without metal ions such as aluminum.
More studies investigating this relationship, and the use of ferric chloride in vivo, are
required to gain a better understanding of each agent’s mechanism of action.

5.5 Conclusions
Glutaraldehyde (Glut) fixation does not adequately protect vascular tissues from
degradation and calcification. The addition of tannic acid (TA) to the Glut fixation
process dramatically increases the biostability of Glut-fixed aortic wall without hindering
collagen crosslinking. TA is chemically compatible with Glut fixation and efficiently
complements the beneficial effects of Glut fixation.

This stabilization of elastin

significantly decreases calcification of treated aorta implanted in the rat subdermal
model. Studies on the stability of interactions between tannins and aortic wall show that
a portion of TA originally bound to the tissue may be partially reversible. Aluminum and
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iron, metals shown to inhibit tissue calcification, were mostly ineffective in enhancing the
beneficial effects of tannin treatment. The present study suggests that the use of TA as an
elastin-stabilizing agent for bioprosthetic heart valves is both practical and feasible, and
has a strong potential to extend the clinical durability of these cardiovascular devices.
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CHAPTER 6
SAFETY AND STRUCTURAL REQUIREMENTS OF TANNIN-MEDIATED
ELASTIN STABILIZATION

6.1 Introduction
It has been shown that pure elastin, with or without chemical fixation processes,
may be vulnerable to enzymatic degradation1 and calcification.2,3

Since these are

common problems associated with the failure of tissue-derived cardiovascular devices
and the progression of vascular pathologies like abdominal aortic aneurysms, a
technology targeting elastin stabilization may be beneficial.
In work presented within Chapters 4 and 5, we have demonstrated that tannic acid
(TA), a naturally occurring plant polyphenol, binds to elastin and in doing so, protects it
from in vitro digestion by elastase. In addition, treatment of porcine aorta with TA
resulted in improved resistance to degradation and in vivo calcification in a rat subdermal
model.4 However, we have also provided evidence for the partial instability of TA after
long-term interaction with vascular elastin. This undesirable property may limit longterm elastin stabilization and may also contribute to implant toxicity, as it has been
shown that the by-products of TA hydrolysis are toxic.5,6 Such effects could obviously
limit the safety, and therefore clinical applicability, of TA treated devices.
Tannic acid is composed of a central glucose molecule derivatized at its hydroxyl
groups with one or more galloyl residues (Figure 6.1, and also portrayed in Figure 2.14).
We hypothesized that the polyphenolic nature of TA, along with its relatively
hydrophobic “core” and hydrophilic “shell” are features responsible for the elastin-
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stabilizing action of TA.

We also believe that the partial instability of TA-elastin

interactions may be due to hydrolyzable ester (depsidic) bonds (highlighted in Figure 6.1)
within the structure of TA.

In present studies, we evaluated the elastin-stabilizing

potential and cytotoxicity of the individual components of TA as well as derivatives of
TA, such as acetylated TA (AcTA), pentagalloyl glucose (PGG, grey circle in Figure
6.1), free gallic acid (Gall) and glucose (Glc). This study provides evidence that the main
structural groups essential to the TA-elastin interactions are polyphenolic hydroxyl
groups. In addition, we show that PGG, the core of tannic acid, possesses elastinstabilizing characteristics similar to TA, yet is much less cytotoxic than TA. As a result,
PGG could exhibit more promising potential as an elastin-stabilizing agent for
cardiovascular bioprostheses and abdominal aortic aneurysms.

Figure 6.1 Chemical structure of tannic acid (TA), consisting of a central glucose
molecule esterified at all five hydroxyl moieties with two gallic acid molecules. The
shaded circle highlights pentagalloyl glucose (PGG), the core structure of TA.
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6.2 Methods

6.2.1 Materials
The following chemicals were purchased from the noted suppliers and used in
current studies: glutaraldehyde (50% solution), acetic anhydride (98%), and tannic acid
(Sigma-Aldrich; St. Louis, MO); pyridine (99%), diethyl ether, and glucose (Acros
Organics; Morris Plains, NJ); ethyl acetate (EM Science; Gibbstown, NJ); gallic acid
(MP Biomedicals, Inc.; Aurora, OH); high purity porcine pancreatic elastase (EC134, 135
U/mg) and elastin-orcein (Elastin Products Company, Inc.; Owensville, MO); Dulbecco’s
modified Eagle media (DMEM) and fetal bovine serum (FBS) (Cellgro; Herndon, VA);
penicillin-streptomycin for cell culture (Invitrogen; Carlsbad, CA); CellTiter 96® AQueous
One Solution Reagent, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt (MTS) (Promega; Madison, WI); LIVE/DEAD®
Viability/Cytoxicity Kit (Molecular Probes; Eugene, OR).

6.2.2 Tissue Preparation
Ascending porcine aortas (supravalvular segments, approximately 3 cm in length)
were collected fresh at a local USDA-approved slaughterhouse and transported to the
laboratory on ice. Aorta was cleaned of fat and extraneous tissue, rinsed exhaustively in
cold physiological saline, and cut into 4 mm x 4 mm squares for elastase digestion and
cytotoxicity testing and into rings for residual stress analysis (see below, Section 6.2.7).
For tensile testing, dumbbell shapes (40 mm long, 10 mm wide at each end, 5 mm wide
in center) were used, with the long axis of the dumbbell being parallel to the
circumferential direction of the aorta.
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Details of tissue treatment groups, which are discussed in the following sections,
are also summarized in Table 6.1.

6.2.3 Acetylated Tannic Acid
The hydroxyl groups of tannic acid were replaced with acetyl groups as described
by Hagerman7 and Porter,8 thus producing acetylated tannic acid (AcTA). Briefly, a
50:50 mixture of acetic anhydride and pyridine was added dropwise to tannic acid (10
mL per 2 g of TA). Upon mixing this solution with water, a solid formed which was
thoroughly rinsed with a series of washes in dilute acetic acid (to remove pyridine) and
water. The resultant solid, consisting of AcTA, was then lyophilized and the loss of free
hydroxyl groups (normally represented by a peak at ~3400 cm-1) was confirmed using
fourier transform infrared (FTIR) spectroscopy analysis.
Samples of porcine aorta were treated in a solution of 0.3% acetylated tannic acid
and compared with fresh aortic wall or tissue treated with Glut and/or TA, as described in
Table 6.1. The resulting groups (Fresh, Glut, TA, Glut/TA, AcTA, Glut/AcTA; n=6 per
group) were then exposed to porcine pancreatic elastase digestion (see below, Section
6.2.7) to assess elastin-stabilizing capabilities of each treatment.
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Table 6.1 Fixation conditions used to stabilize porcine aorta.
Group ID

Treatment details

Glut

0.6% glutaraldehyde (1 day) followed by 0.2% glutaraldehyde
(7 days), in 50 mM Hepes buffered saline, pH 7.4

TA

0.3% tannic acid (1.78 mM, 4 days) in 50 mM Na2HPO4
buffered saline, pH 5.5

Glut/TA

Glut (as listed above) followed by 0.3% tannic acid (4 days) in
50 mM Na2HPO4 buffered saline containing 0.6%
glutaraldehyde, pH 5.5

AcTA

0.3% acetylated tannic acid (4 days) dissolved in a mixture of
dimethyl sulfoxide:isopropanol:ddH2O (3:3:1)

Glut/AcTA

Glut followed by 0.3% acetylated tannic acid dissolved in a
mixture of dimethyl sulfoxide:isopropanol:ddH2O (3:3:1) with
0.6% glutaraldehyde

Gall

8.9 mM gallic acid (4 days) in 50 mM Na2HPO4 buffered saline,
pH 5.5

Glut/Gall

Glut followed by 8.9 mM gallic acid (4 days) in 50 mM
Na2HPO4 buffered saline containing 0.6% glutaraldehyde, pH
5.5

Glc

1.78 mM glucose (4 days) in 50 mM Na2HPO4 buffered saline,
pH 5.5

Glut/Glc

Glut followed by 1.78 mM glucose (4 days) in 50 mM Na2HPO4
buffered saline containing 0.6% glutaraldehyde, pH 5.5

PGG

0.15% PGG (4 days) in 50 mM Na2HPO4 buffered saline, pH
5.5, containing 20% isopropanol

Glut/PGG

Glut followed by 0.15% PGG with 0.6% glutaraldehyde (4
days) in 50 mM Na2HPO4 buffered saline, pH 5.5, containing
20% isopropanol
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6.2.4 Individual Components of Tannic Acid
The individual components of tannic acid, gallic acid (Gall) and glucose (Glc),
were used to treat porcine aortic wall.

Gallic acid treatment of porcine aorta was

performed at a concentration of 8.9 mM in order to create equimolar amounts of unbound
gallic acid in comparison to TA. Likewise, the concentration of Glc used (1.78 mM)
correlated to equimolar amounts of glucose in TA (one glucose per tannic acid molecule).
Similar to studies with acetylated tannic acid, fresh samples and those fixed with Glut
and/or TA were also used for comparative purposes. The subsequent tissue groups (Glut,
Glut/TA, Gall, Glut/Gall, Glc, Glut/Glc; Table 6.1) were exposed to in vitro elastase
digestion to investigate elastin fiber stability.

6.2.5 Pentagalloyl Glucose Synthesis
Pentagalloyl glucose (PGG) was prepared from tannic acid as outlined by
Hagerman et al.9 Initially, TA was methanolyzed using a solution of 70% methanol in
acetate buffer (0.1 M acetic acid, pH 5.0). Methanolysis was performed at 65oC for 15
hours. Following this incubation period, the reaction was stopped by immediately raising
the solution’s pH to 6.0. Methanol was then removed by rotary evaporation and replaced
with ddH2O. A series of separate extractions involving diethyl ether (3 extractions) and
ethyl acetate (3 extractions) were performed. Following each set of extractions, the
resulting products were rotary evaporated to remove the ether and ethyl acetate,
respectively. Once cooled to 4oC, a precipitate resulted which was rinsed in a series of
washes with dilute methanol (thrice in 2% methanol in ddH2O) and ddH2O (once). The
resulting precipitate was centrifuged after each rinse, and the end product ultimately
lyophilized.

The purity of PGG was confirmed by matrix-assisted laser
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desorption/ionization (MALDI) mass spectroscopy and nuclear magnetic resonance
(NMR).10 PGG, which was insoluble in water, was dissolved in isopropanol, then diluted
in buffered saline (0.145 M NaCl, 50 mM Na2HPO4, pH 5.5) to yield final concentrations
of 0.15% PGG in a 20% isopropanol solution. This concentration of PGG, which is
approximately half the molecular weight of TA (depending on the length of the gallic
acid “tails” extending from TA), was used to create molar concentrations of PGG
equivalent to TA.
PGG, alone or in conjunction with Glut, was used to treat aortic wall samples, as
described in Table 6.1 and compared with fresh tissue and that treated with Glut and/or
TA. Once treated, elastin stability experiments (resistance to elastase) were performed,
as well as tests for mechanical properties and cytotoxicity.

6.2.6 Efficacy of Pentagalloyl Glucose
6.2.6.1 Elastin Stability
Resistance to elastolysis was evaluated using the elastase digestion assay that we
developed to test for elastin stability.1,4 Samples of porcine aorta (4 mm x 4 mm) were
either left untreated (fresh) or fixed with one of the aforementioned treatments (Glut, TA,
Glut/TA, PGG, Glut/PGG, as described in Table 6.1; n=6 per group), rinsed 3 times (1
hour each) in 100 mL ddH2O at room temperature, and lyophilized to record dry weight.
Each sample (~15 to 25 mg dry weight) was incubated with 1.0 mL of porcine pancreatic
elastase (20 U/mL in 100 mM Tris buffer, 1 mM CaCl2, 0.02% NaN3, pH 7.8) for 48
hours at 37oC with orbital shaking at 650 rpm. This optimized assay results in nearly
complete removal of unstabilized elastin fibers, as exhibited in Chapter 4. Samples were
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then centrifuged (10000 rpm, 10 minutes, 4oC) and supernatants retained to assess
enzyme activity (see below). Residual tissue samples were rinsed 3 times in 1 mL
ddH2O, centrifuged (as above), lyophilized to obtain dry weight, and the percent of
digested tissue after elastase was calculated. To evaluate the possible direct inhibitory
effects of any of the chemicals (that may have leached from the treated tissues) on
elastase activity, the elastase solutions retrieved were checked for activity using an
elastin-orcein assay.11
The in vitro system previously used to test the stability of TA-elastin interactions
(the propensity of TA to leach out from the treated tissue) was also implemented to
evaluate the stability or reversibility of PGG binding. Aortic wall samples (n=6) were
treated with Glut or Glut/PGG, as described in Table 6.1. Following treatment, they were
rinsed 3 times (1 hour each) in 100 mL ddH2O, then shaken reciprocally at 120 rpm in
phosphate buffered saline (PBS), 0.02% NaN3, pH 7.4 for 14 days at 37oC (50 ml per 6
tissue samples). After subjecting tissues to this system, samples were rinsed, lyophilized
to record dry weight, and subjected to the elastase digestion assay as described above.
6.2.6.2 In Vivo Calcification
Tissue calcification was investigated using a standard accelerated in vivo model,
which was also presented in studies within Chapter 5. For this model, male juvenile
Sprague-Dawley rats (25-35 days old, weighing ~50 g, Harlan Laboratories; Indianapolis,
IN) were sedated with acepromazine (0.5 mg/kg, Ayerst Laboratories, Rouses Point, NJ)
and maintained on 2% isoflurane throughout surgery. A small incision was made on the
backs of the rats and three subdermal pouches were created. Glut and Glut/PGG treated
samples of aortic wall (4 mm x 4 mm; treatment descriptions in Table 6.1) were
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implanted into these subdermal pouches (16 implants per group).

The rats were

euthanized by CO2 asphyxiation at 7 and 21 days and capsule-free samples were retrieved
for calcium analysis and histology. The animal protocol was approved by the Animal
Research Committee at Clemson University and NIH guidelines for the care and use of
laboratory animals (NIH publication #85-23 Rev. 1985) were observed throughout the
experiment.
For calcium analysis, explants (n=8 per group per time point) were rinsed in
saline, cut approximately in half, and lyophilized to obtain dry weight (10 to 15 mg each).
The samples were then individually hydrolyzed in 6 N hydrochloric acid (HCl) at 95oC
for approximately 8 hours. Following hydrolysis, they were dried under a continuous
stream of nitrogen gas and subsequently reconstituted in 1.0 mL of 0.01 N HCl. These
tissue hydrolysates were diluted in the range of 30-fold to 100-fold in an atomic
absorption matrix (0.5% lanthanum oxide in 0.3 N HCl) and assayed for calcium content
using atomic absorption spectrophotometry.12
For histology studies, explanted samples were placed in Karnovsky’s fixative and
paraffin embedded sections (5 μm) were stained using Alizarin red for calcium deposits
and hematoxylin and eosin for general morphology.

6.2.7 Mechanical Testing
6.2.7.1 Residual Stress Measurements
Porcine aorta was cut transversely into ring segments approximately 1 cm in
height. The rings were kept intact (unopened) and left untreated (Fresh) or treated with
Glut, Glut/TA, Glut/PGG, TA, or PGG (n=5 per group) as described in Table 6.1. After
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fixation was completed, the aortic rings were immersed in ddH2O with the cross section
of the aorta facing upward, allowing free movement of the sample. As described by
Gratzer and Lee13 and Liu and Fung,14 the rings were cut once in the radial direction,
allowed to “relax” and open for 15 minutes under water, and then digitally photographed.
These digital photographs were used to calculate the opening angle of each aortic ring
graphically using Adobe Photoshop 7.0.
6.2.7.2 Tensile Testing
Porcine aorta was cut into dumbbell shapes in the circumferential direction and
tensile testing was performed, as described in Chapter 5. Briefly, samples were either left
untreated (fresh) or fixed by Glut, Glut/TA, Glut/PGG, TA, or PGG.

Stress-strain

analysis was performed on each group (n=4) at a constant uniaxial strain rate of 0.2
mm/sec using a 10-Newton load cell on a Synergie 100 testing apparatus from MTS
Systems Corporation (Eden Prairie, MN).

For each sample, elastic modulus was

calculated as the slope of the stress-strain curve between 0 and 5% strain.

6.2.8 Cytotoxicity Testing of Tissue Extracts
The cytotoxicity of treated aorta was tested using rat skin fibroblasts exposed to
tissue extracts, similar to that described in ISO 10993-5, a set of testing standards for
evaluating the safety of medical devices. To obtain these extracts, aortic wall was treated
with Glut, Glut/TA, Glut/Glc, Glut/Gall, or Glut/PGG as described in Table 6.1. After
fixation, samples were rinsed 3 times (1 hour each) in 100 mL ddH2O, and then
underwent orbital shaking at 120 rpm in phosphate buffered saline (PBS) with 0.02%
sodium azide, pH 7.4 for 14 days at 37oC (50 mL per 6 tissue samples, 4 mm x 4 mm).
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This wash solution of PBS, with its potential extracts included, was the agent specifically
applied to cells and tested for cytotoxicity. This method (vigorously washing in PBS for
14 days) was previously used to test the propensity of tannins to leach from the treated
tissue, as described above.
Primary rat skin fibroblasts were isolated from the skins of adult male SpragueDawley rats (Harlan Laboratories; Indianapolis, IN) using a cell explant method. For our
studies, the fibroblasts were seeded onto 24-well plates (50,000 cells per well) in 1 mL
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin. Cells were maintained in a humidified incubator
at 37oC with 5% CO2. After 24 hours, the media was removed and replaced with one of
the PBS extracts diluted 10-fold in fresh culture medium. PBS and ethanol (EtOH; 70%
in ddH2O) were also used as negative and positive cytotoxicity controls, respectively.
The cells were incubated with these solutions for 2 hours and then rinsed with 1 mL PBS.
At this point, the viability of the cells was assessed by LIVE/DEAD® assay, in which live
cells fluoresce green and dead cells fluoresce red. Digital micrographs of cells were
taken 45 minutes after exposure to the LIVE/DEAD® reagent. Separately, cell viability
and metabolism was also measured by MTS assay (n=3 per group for each test) using
MTS reagent diluted 5-fold in culture medium. After 90 minutes, absorbance was read at
490 nm in a microplate reader.

This absorbance is proportional to dehydrogenase

enzyme activity within metabolically active cells, thus creating the correlation between
absorbance and cell viability. Samples were blanked to controls containing media and
MTS reagent without cells.

158
6.2.9 Data Analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.

6.3 Results

6.3.1 Acetylated Tannic Acid
To investigate the mechanisms of binding between tannic acid and elastin, the
hydroxyl groups of TA were replaced by acetyl groups. The complete loss of these
hydroxyls was confirmed by FTIR analysis, specifically by the disappearance of a broad
peak at 3400 cm-1 (Figure 6.2).

Samples of porcine aortic wall were treated with

acetylated tannic acid (AcTA) and tested for resistance to elastase. The elastase digestion
values were compared with those obtained from untreated aorta as well as samples
treated with Glut and/or TA (Figure 6.3). As previously exhibited in Chapter 5, Gluttreated aorta was slightly less susceptible to elastase digestion than fresh aorta (p<0.05),
but the conventional Glut treatment still yielded a tissue that lost approximately 70% of
its dry mass via enzyme digestion. The implementation of TA, particularly in the case of
Glut/TA, decreased the susceptibility of elastin to enzymatic degradation (p<0.05). In the
absence of hydroxyl groups (as in AcTA), TA lost its ability to resist elastase-mediated
digestion, as evidenced by the nearly seven-fold increase in mass loss of Glut/AcTAtreated aorta versus Glut/TA-treated aorta (p<0.05). These data suggest that the phenolic
hydroxyl groups of TA are required to achieve stabilization of vascular elastin.
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Figure 6.2 FTIR scans of normal tannic acid (TA) and acetylated tannic acid. The broad
band at 3400 cm-1 (black arrow) is representative of the outer hydroxyl groups of TA.
The absence of this band within acetylated TA confirms removal of these hydroxyl
groups and subsequent acetylation.
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Figure 6.3 By modifying the hydroxyl groups of TA by acetylation (AcTA), TA lost its
ability to provide the tissue with resistance to elastase digestion both alone (AcTA) and in
combination with glutaraldehyde (Glut/AcTA) in comparison to TA and Glut/TA,
respectively (p<0.05 for AcTA vs. TA and Glut/AcTA vs. Glut/TA).

6.3.2 Individual Components of Tannic Acid
To better understand the requirements for elastin stabilization, the individual
components of TA were also used to treat aortic samples and tested for resistance to
elastase digestion. The simple alcohols, gallic acid (Gall) and glucose (Glc), appeared to
have no stabilizing effect on the tissue, neither alone or in combination with Glut, in
comparison to TA (Figure 6.4; p<0.05). Note that the percent mass loss values for
Glut/Gall and Glut/Glc alone are similar to those obtained for samples treated with Glut
alone (p>0.05). Since elastase-mediated digestion indicated that Gall, Glc, and AcTA did
not assist in preventing elastin degradation, we focused our studies on investigating
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pentagalloyl glucose (PGG), the core polyphenol of TA, as a potential elastin-stabilizing
agent and its comparison with TA.

Figure 6.4 Efficacy of individual tannic acid components as elastin-stabilizing agents.
Neither gallic acid (Gall) nor glucose (Glc), whether alone or in conjunction with
glutaraldehyde (Glut/Gall, Glut/Glc), exhibited elastin-stabilizing capabilities as
compared to Glut/TA (p<0.05 for all Gall or Glc groups vs. Glut/TA).

6.3.3 Pentagalloyl Glucose
6.3.3.1 Pentagalloyl Glucose: Elastin Stabilizing Efficacy
The purity of pentagalloyl glucose (PGG) was verified by MALDI mass
spectroscopy and NMR (data not shown). The implementation of PGG as a fixative or
pretreatment clearly enhanced the ability of the tissue to resist elastase-mediated
degradation in comparison to glutaraldehyde alone (Figure 6.5; p<0.05). Results from
elastase digestion of PGG-treated aorta were similar to those treated with tannic acid
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alone (p>0.10). In addition, the combination of glutaraldehyde and PGG (Glut/PGG)
treatment yielded tissue just as resistant to enzymatic degradation as that treated with
Glut/TA (p>0.05), providing further evidence that PGG stabilizes aortic wall to the same
degree as TA. For all elastase degradation studies performed, enzyme solutions were
retrieved after digestion of tissue samples and displayed similar activities using an
elastin-orcein assay (data not shown).

This implies that none of the leachable

components resulting from the treatments/fixatives had direct inhibitory effects on the
activity of the enzyme.

Figure 6.5 Efficacy of pentagalloyl glucose (PGG) as an elastin-stabilizing
agent. Aortic samples treated with PGG resisted elastase-mediated degradation just as
well as those treated with TA, both alone (TA vs. PGG; p>0.10) and in combination with
glutaraldehyde (Glut/TA vs. Glut/PGG; p>0.10).

We previously observed in Chapter 5 that TA-treated tissues lost a portion of their
elastin stabilizing capabilities when exposed to a long-term vigorous shaking model (14
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days in PBS, 120 rpm), likely indicative of a partial reversibility in the TA-tissue
interactions.

Although it was believed that PGG may improve upon this with its

improved chemical structure and stability, a similar trend was observed for Glut/PGGtreated tissues when exposed to the same prolonged model (Figure 6.6). Approximately
twice as much PGG-treated tissue was digested by elastase following this in vitro
“leaching” model as compared to PGG-treated tissue exposed to elastase immediately
following fixation. However, the digestion values for tissues subjected to the 14 day in
vitro shaking model were significantly lower for PGG-treated aorta as compared to TAtreated aorta (p<0.05). Additionally, as was the case for Glut/TA, Glut/PGG treatment
yielded a tissue that was much more resistant to enzymatic degradation that Glut alone
even when exposed to the prolonged model (p<0.05 for Glut vs. Glut/PGG).

Figure 6.6 Following exposure to a prolonged model of vigorous shaking, PGG
appeared to exhibit the same partial reversible binding that was observed for TA. It
should be noted, however, that the values for PGG (for “14 days in vitro”) were
statistically different in comparison to TA (p<0.05).
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6.3.3.2 Pentagalloyl Glucose: In Vivo Calcification
The addition of PGG to the fixation step, as in Glut/PGG treated tissue,
significantly reduced in vivo tissue calcification in the rat subdermal model (Figure 6.7).
These differences were statistically significant from tissue treated with Glut alone, both
for 7 and 21 day explants (p<0.05). These calcium results are similar to those found for
TA treated tissue, which also revealed a decreased propensity to calcify as compared to
Glut (Chapter 5). Alizarin red staining of 21 day explants confirmed the quantitative
results shown in Figure 6.7, revealing that Glut treated aorta (Figure 6.8A) had more
calcium deposits than Glut/PGG treated aorta (Figure 6.8B). These results suggest that
PGG-mediated elastin stabilization translated into improved resistance to in vivo
calcification as well.

Figure 6.7 Calcium analysis on treated aorta following 7 days or 21 days implantation in
the rat subdermal model. Similar to treatment with tannic acid, the use of PGG resulted
in significantly reduced calcification as compared to glutaraldehyde alone (Glut) at both
time points (p<0.05), most likely due to PGG’s ability to stabilize elastin.
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A

B

Figure 6.8 Calcium deposition within 21 day explants was confirmed by histological
analysis with Alizarin red staining (calcium deposits = red). Glutaraldehyde treated
tissue (A) showed significantly more calcium deposits than Glut/PGG treated aorta (B).

6.3.3.3 Pentagalloyl Glucose: Mechanical Testing
In order to further investigate the interaction between elastin and polyphenolic
tannins, mechanical properties such as elastic modulus and opening angle (residual stress)
were evaluated for untreated aorta (Fresh) and tissues treated with Glut, TA alone, PGG
alone, Glut/TA, and Glut/PGG. For tensile testing experiments, a representative stressstrain graph from each group is displayed in Figure 6.9, while the calculated elastic
moduli are shown in Table 6.2. Expectedly, stress-strain analysis revealed that fresh
aorta was markedly less stiff than all other groups that underwent fixation (p<0.05),
particularly for those groups treated with glutaraldehyde. Treatment with Glut/TA and
Glut/PGG significantly increased the modulus (and subsequently the stiffness) of the
tissue in comparison to Glut alone (p<0.05), indicating that TA and PGG both bind to
elastin fibers within the aortic tissue. Overall, TA and PGG treatment resulted in tissues
with similar stiffness and distensibility (p>0.05 for both cases of TA alone vs. PGG alone
and Glut/TA vs. Glut/PGG), suggesting their interactions with aortic wall are similar.
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Figure 6.9 Representative stress-strain behavior of porcine aorta treated with
glutaraldehyde and/or tannins. As compared to fresh aorta, all stabilization treatments
reduced distensibility of the tissue. The implementation of TA and PGG into the Glut
fixation process (Glut/TA and Glut/PGG) significantly increased tissue stiffness. With or
without Glut, treatment with TA and PGG yielded comparable mechanical properties,
suggesting TA and PGG interact with the tissue similarly.

Table 6.2 Elastic moduli of treated porcine aortic wall.
Treatment Group

Elastic modulus (Average ± SEM)

Fresh

0.17 ± 0.01 MPa

Glut

1.28 ± 0.04 MPa

Glut/TA

4.85 ± 0.30 MPa

Glut/PGG

4.61 ± 0.40 MPa

TA

0.85 ± 0.07 MPa

PGG

0.89 ± 0.13 MPa
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In regards to opening angle, the implementation of any one of the fixatives (Glut
alone, tannins alone, or Glut and tannins combined) drastically reduced the opening angle
of aortic rings as compared to fresh tissue (Figure 6.10; p<0.05). A representative picture
of an opened aorta from each treatment group is shown in Figure 6.11. Fresh aorta nearly
opened to a straight line (~180o) while Glut-fixed tissue possessed an opening angle
approximately 5 times less.

All groups fixed with tannins, whether alone or in

conjunction with Glut, were relatively similar and opened significantly less than Glut
alone (p<0.05), further solidifying the idea that TA and PGG have a similar effect on
aortic elastin fibers.

Figure 6.10 Opening angle measurements of fresh and fixed aorta. The opening angles
of fresh aortic rings were significantly larger than the treated samples. In addition, rings
treated with tannins opened less than those treated with Glut alone (p<0.05). TA and
PGG, both of which interact with aortic wall elastin, exhibited similar opening angles
when used to treat tissue.
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Figure 6.11 Representative opening angle pictures from each group showing aortic rings
after cutting and unaided opening due to internal residual stress.

6.3.4 Cytotoxicity Testing
The cytotoxicity of tissue extracts obtained after fixation was assessed both
qualitatively (Live/Dead assay) and quantitatively (MTS assay).

Results of the

Live/Dead assay revealed that the cells exposed to extracts from Glut, Glut/Glc,
Glut/Gall, and Glut/PGG-treated tissue remained viable after 2 hours of exposure (Figure
6.12). In addition, it appeared that the very small concentration of sodium azide used in
the wash solutions had little to no effect on cytotoxicity in this time frame, as suggested
by the presence of live cells in the PBS control group. However, cells which were
exposed to extracts from Glut/TA-treated aorta experienced a notable amount of cell
death. As expected, the positive control (EtOH) essentially left no viable cells remaining.
Quantitative analyses from the MTS assay confirmed Live/Dead results (Figure
6.13). The absorbance values for cells exposed to Glut extracts were comparable to those
from the PBS control group (p>0.05). Likewise, Glut/PGG extracts were relatively
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similar to the PBS group (p>0.05), suggesting that neither Glut nor PGG treatments
produce tissue that may leach toxic components in these conditions. On the other hand,
Glut/TA extracts yielded an absorbance of nearly half that of these groups (p<0.05),
suggesting that TA is nearly twice as toxic as PGG at equimolar concentrations.

Figure 6.12 Cytotoxicity of extractables obtained from treated aorta. Qualitative
Live/Dead assay (live cells green, dead cells red) shows that application of Glut/TA
extracts resulted in fewer live cells than all other groups, with the exception of the
positive ethanol control (EtOH). Note the large number of live cells associated with
Glut/PGG, indicating virtually no cytotoxic effects. Original magnification, 200x.
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Figure 6.13 Quantitative viability assay of rat skin fibroblasts after being exposed to
extractables from fixed tissues. MTS results are reported as absorbances at 490 nm,
which are proportional to cell viability. Glut, Glut/Glc, Glut/Gall, and Glut/PGG extracts
were not more toxic than the PBS negative control (p>0.05). However, Glut/TA extracts
resulted in about half the number of viable cells in comparison to Glut/PGG (p<0.05).

6.4 Discussion
Our long-term goal is to develop a fixation or stabilization technology targeted at
elastin. Utimately, we believe this could (1) benefit the longevity of tissue derived
cardiovascular implants by presenting a more effective pretreatment or fixation process
for these devices, and (2) be developed as a therapy to halt the progression of abdominal
aortic aneurysms. In Chapters 4 and 5, we have previously shown that tannic acid (TA)
may be a suitable candidate for this stabilization as it binds to both pure aortic elastin and
intact aortic wall. For the purpose of a bioprosthetic heart valve pretreatment, the use of
TA has been shown to be effective in the presence of glutaraldehyde (Glut), the
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conventional fixative used for these devices historically and currently, without hindering
the beneficial attributes of Glut cross-linking. In addition, Glut/TA-treated aortic wall,
when implanted in the rat subdermal model as presented in Chapter 5, exhibited
significantly less calcification than Glut-treated aortic wall, most likely due to the elastinstabilizing capabilities of TA. While these studies promote TA as an excellent stabilizing
agent, little was known about the interactions between TA and elastin. Furthermore,
partial instability in the binding between TA and vascular elastin was observed in the data
presented in Chapter 5. This undesirable property may limit the efficacy of elastin
stabilization and contribute to possible implant toxicity.
Therefore, the aim of this study was to investigate the structural requirements of
tannins as elastin-stabilizing agents, and to evaluate the efficacy and safety of TA
treatment of porcine aorta. To assess the significance of phenolic hydroxyl groups, we
examined the ability of TA to maintain its elastin-stabilizing qualities when its hydroxyl
groups were replaced by acetyl groups (as in the case of AcTA). In the absence of its
hydroxyl groups, TA essentially lost all elastin-stabilizing capabilities, as evidenced by
the poor resistance to elastase digestion exhibited by AcTA (Figure 6.3). Along these
lines, similar tests were performed on the simple components of TA (gallic acid and
glucose) to determine if one particular factor was responsible for elastin stabilization
(Figure 6.4). Similar to results obtained for AcTA, Gall and Glc provided no resistance
to elastase-mediated degradation. The fact that AcTA had no effect on resistance to
elastase implies that multiple polyphenolic hydroxyl groups are a requirement for elastin
binding and stabilization. It is important to note that Gall, which possesses similar
phenolic hydroxyl groups, is apparently not able to bind to elastin in the same fashion as
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the polyphenolic tannin, TA. Glucose, which also has its own hydroxyl groups, similarly
had no effect on resistance to enzymatic degradation. When considered together, these
results suggest that the presence of polyphenolic hydroxyl groups is a clear requirement
for an elastin-stabilizing agent.
Pentagalloyl glucose (PGG), consisting of a central glucose molecule and one
gallic acid bound to each hydroxyl moiety, could also be considered a component of
tannic acid. In contrast to the other components of TA, PGG treatment of aortic wall
provided a level of elastin stabilization, as indicated by resistance to elastase, similar to
that of TA (Figure 6.5). The structure of PGG is comparable to TA with its outer
hydroxyl groups; however, PGG possesses only one layer of gallic acid residues on each
“tail” extending from the core, suggesting that elastin stabilization is independent of the
length of these tails (as measured by the number of gallic acid residues).
Since PGG proved to be effective in protecting elastin from elastase-mediated
degradation, further tests were performed to compare the properties of TA-treated aorta
versus PGG-treated aorta.

Specifically, we investigated the long-term stability or

reversibility of PGG-tissue interactions, the propensity of PGG-treated aorta to calcify in
vivo, and the effects of PGG on tissue mechanical properties.
By exposing Glut/TA treated tissue to a prolonged in vitro model with vigorous
shaking (14 days in PBS, 120 rpm), we previously observed in Chapter 5 that the
interactions between TA and tissue were partially reversible. As this model progressed,
the TA-treated tissue became more vulnerable to enzymatic degradation, indicative of a
portion of the TA leaching from the tissue and, therefore, no longer providing as much
elastin stabilization as was originally observed. PGG, which we believed may partially
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circumvent this reversibility due to an improved chemical structure, also became more
vulnerable to elastase-mediated digestion with time and vigorous shaking (Figure 6.6).
Although this was not desirable, the overall results are still encouraging since elastase
digestion of tissue treated with Glut/PGG and exposed to the prolonged in vitro model
revealed that: (1) Glut/PGG treatment still exhibited significantly improved elastin
stabilization as compared to Glut alone, and (2) Glut/PGG yielded tissue slightly more
resistant to elastase that Glut/TA following this long-term model.
In addition to resistance to elastase, Glut/PGG was also similarly effective in
regards to resisting in vivo tissue calcification as compared to Glut-treated aorta (Figures
6.7 and 6.8), a trend which was also seen in Chapter 5 for Glut/TA-treated implants. This
is likely directly related to the ability of PGG and TA to preserve elastin, and therefore
resist elastin-oriented calcification. This is especially noteworthy since calcification is
one of the primary modes of failure of bioprosthetic heart valves; furthermore, it is also
often observed as a pathological characteristic of abdominal aortic aneurysms.
The idea behind tannin-mediated elastin stabilization and other treatments (such
as Glut) is to bind to components of the extracellular matrix; since these components
(namely elastin and collagen) play a significant role in tissue biomechanics, it is natural
to assume that successful fixation will result in a change in mechanical properties in
comparison to fresh or native tissue. This is especially true in the case of Glut treatment,
which results in significantly increased stiffness in comparison to native tissue.

In

present studies, we investigated tissue distensibility (via elastic modulus) and residual
stress (via ring opening angles). In the case of elastic modulus, Glut treatment yielded a
tissue that was significantly less distensible than fresh tissue, as expected and noted
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previously in Chapter 5. Meanwhile, treatment with Glut/TA or Glut/PGG yielded the
least amount of distensibility (Figure 6.6). This change in elastic modulus for Glut/TA
and Glut/PGG treated tissues can likely be attributed to a high degree of binding to
elastin, which does not occur with Glut alone. The decreased distensibility observed in
Glut/TA or Glut/PGG treated tissues may be undesirable for bioprosthetic heart valve
tissue, although its exact implications are unclear. Glut has long been vindicated for its
effect on tissue stiffness within these devices, however, continues to be widely used
today.15,16 Porcine aorta treated with TA or PGG alone was more distensible (less stiff)
than Glut treated tissue, but less distensible than fresh aorta. The fact that TA alone and
PGG alone both increased stiffness (and strength) in comparison to fresh tissue may be
important in regards to using these tannins as a therapy for abdominal aortic aneurysms.
The weakened architecture associated with aneurysmal tissues may benefit from this
increased stiffness and strength.
Similar to those changes observed in elastic modulus, the opening angles (residual
stress) of the fixed tissue groups were also drastically different than fresh tissue (Figures
6.7 and 6.8). Opening angles, previously used as an approximation of residual stress
within vessel walls,14,17 represent the unaided release of the inner circumferential stress,
which is likely a result of extended elastic fibers. Glutaraldehyde treatment, which
mainly crosslinks collagen fibers, resulted in a tissue that opens much less than fresh
tissue, while the tannin treated samples (Glut/TA, Glut/PGG, TA, PGG) clearly yielded
the smallest opening angles. By binding to elastin, the implementation of TA or PGG
likely fixes or “locks” the orientation of these fibers, resulting in a decreased residual
stress. While these inherent residual stresses are believed to be vital to the native aortic
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wall,18 their role in fixed tissues is less clear. Related opening angle experiments have
been performed previously to assess alternative fixatives, such as polyepoxy
compounds,19 as well as Glut in various buffers and their effect on elastin.13 Overall, we
believe that our studies on mechanical properties suggest that (1) TA and PGG bind to
elastin, thus decreasing the distensibility of the tissue, and (2) the binding mechanisms
and efficacy are similar for TA and PGG.
Decades ago, tannic acid was used as a standard topical treatment of burns due to
its ability to bind to tissues, consequently fixing burn toxins into the wound area and
preventing their further distribution throughout the patient’s body.20

However, this

practice was relatively short-lived due to suspected issues of hepatotoxicity. Since gallic
acid is the suspected culprit, this toxicity is likely attributable to poor TA purity
(particularly in older preparations of TA) and/or the instability of TA.5 The root of TA’s
instability can be traced to the depsidic ester bonds between gallic acid molecules (Figure
6.1), which are hydrolyzable and can lead to the release of toxic gallic acid residues.6
While the topic of TA and hepatotoxicity has been and still is heavily debated, a
significant amount of research has recently been dedicated to assessing the validity of
these issues and the use of potential alternatives, such as TA “mimics”6,21 and high purity
TA.22
For our purposes, the potential toxic by-products of tannic acid stabilization are
certainly an important factor to take into account, especially considering that we have
previously demonstrated the partial reversibility of binding between TA and aortic wall.
By using PGG (which does not possess outer gallic acid residues bound by the depsidic
bonds associated with these compounds) it is reasonable to assume that we may be able
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to drastically reduce or even eliminate any toxic effects of tannic acid, while maintaining
the elastin stabilization potential of polyphenolic tannins. In the work presented here, we
tested this hypothesis by investigating the cytotoxicity of tissue extracts resulting from
vigorous long-term shaking. In addition to TA and PGG extracts, we also analyzed the
toxicity of Glut/Gall and Glut/Glc extracts, neither of which displayed any significant
toxicity towards the cells as exhibited by both Live/Dead (Figure 6.9) and MTS (Figure
6.10) assays. Since these individual components of TA, gallic acid and glucose, had no
stabilizing effect on the tissue (Figure 6.4), it is likely that they do not bind to the elastinrich tissue as TA and PGG do. This likely explains why no toxic effects were observed
in these groups, particularly in the case of gallic acid. While glucose would not be
expected to elicit any toxic effects, free gallic acid, as mentioned above, has been
associated with TA toxicity. However, if Gall does not bind to the tissue to begin with, it
obviously would not be a factor in the tissue extracts we tested for cytotoxicity.
Conversely, PGG apparently did bind to aortic wall, resulting in improved resistance to
elastase (similar to TA), but also exhibited virtually no toxic effects in comparison with
controls. Meanwhile, it was apparent that tissue treated with TA released components
more toxic than those resulting from the PGG treated tissue, as evidenced by the 2-fold
increase in viability for cells exposed to PGG extracts as compared to TA. Similar
studies have been conducted on by-products of TA-treated biomaterials in which their
cytotoxic behavior was confirmed.23
Since PGG has elastin-stabilizing capabilities similar to that of TA and is less
cytotoxic, PGG holds the advantage over TA as a promising elastin-stabilizing agent.
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6.5 Conclusions
The main structural groups essential to the interaction between tannic acid (TA)
and elastin are polyphenolic hydroxyl groups. Furthermore, the components of TA
(gallic acid and glucose) provide no protection from enzymatic degradation individually,
but participate synergistically within the polyphenolic tannin structures to generate
compounds that bind to elastin. Pentagalloyl glucose (PGG), which is the core of TA,
possesses the same unique elastin-stabilizing qualities of TA and endows aortic tissue
with similar mechanical properties. PGG, due to the lack of easily hydrolyzable ester
bonds between gallic acid residues, is more stable and less cytotoxic than TA, and thus
could exhibit potential use as an elastin-stabilizing agent for cardiovascular
bioprostheses. For these same reasons, PGG is a more suitable candidate as a therapy for
abdominal aortic aneurysms. The safety and efficacy of PGG for this application will be
investigated in greater detail in Chapter 7.
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CHAPTER 7
ELASTIN STABILIZATION AS A TREATMENT FOR
ABDOMINAL AORTIC ANEURSYMS

7.1 Introduction
Abdominal aortic aneurysms (AAAs) are disorders defined by an increase in
aortic diameter which is associated with impaired aortic wall integrity. Progression of
this vascular pathology can lead to further dilatation of the artery and eventual fatal
rupture. In addition to arterial dilatation, AAAs are typically characterized by an overall
degeneration of the arterial architecture, presence of matrix-degrading enzymes,
inflammatory infiltration, and often calcification. The loss of structural integrity of the
aortic wall is primarily explained by enzyme-mediated degeneration of extracellular
matrix components such as elastin and collagen. Notably, diseased tissues obtained from
AAA patients exhibit decreased medial elastin content, elastic lamellae disruption or
fragmentation, and increased levels of elastolytic activities.1-3 Numerous studies have
been undertaken to further investigate the role of proteinases in AAA formation. While
serine proteases, cathepsins, and plasminogen activators may also contribute to this
proteolysis, matrix metalloproteinases (MMPs) are apparently the group of enzymes most
closely related to arterial wall weakening, elastin degeneration, and AAA formation and
expansion.4 As a result of its multi-factorial pathogenesis, anti-inflammatory agents,
proteinase inhibitors, and genetic and pharmacologic inhibition of MMPs have been
tested as potential AAA treatments in experimental animals.5-8 Since long-term, adequate
control of local inflammation and MMP activities may be difficult to achieve and may be
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accompanied by adverse systemic side effects,9 therapeutic treatments targeted at directly
stabilizing or protecting elastin against the action of elastin-degrading enzymes may be
useful.
Based on their known properties, we have investigated tannins as novel elastinstabilizing agents for this purpose. In work presented in the previous chapters, we have
shown that tannins bind to arterial elastin in vitro, rendering tissues resistant to enzymatic
degradation, which could be useful in possibly prolonging the durability of bioprosthetic
heart valves.10-12 Among the different polyphenolic tannins investigated, pentagalloyl
glucose (PGG), a compound consisting of a central glucose core with one gallic acid
bound to each hydroxyl moiety, has been employed in current studies. By virtue of its
elastin-stabilizing properties, we hypothesized that in vivo delivery of PGG to aortic
segments would interfere with AAA formation and progression.
To this point, we have shown numerous studies exhibiting the in vitro efficacy of
tannins in regards to elastin stabilization of porcine aortic wall, primarily for the purpose
of bioprosthetic heart valves. In current studies, PGG was investigated for its effect on
aneurysm development within a widely accepted AAA rat model, which will be
described in greater detail later in this chapter. In view of this, we performed in vitro
efficacy studies of PGG on rat aorta, similar to some of the primary experiments
previously done for porcine aorta (ring opening angle and resistance to elastase).
Additionally, since PGG will be applied directly to living tissue within the in vivo
aneurysm model, it was necessary to evaluate the cytotoxic effects of PGG when directly
applied to cells. For all of these in vitro experiments, varying concentrations of PGG
were used to target the optimal concentration for efficacy and safety of this application.
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PGG was then applied to our in vivo AAA model, allowing us to provide evidence that
periarterial treatment with non-cytotoxic levels of PGG hinders aneurysmal dilatation of
the abdominal aorta and preserves elastin fiber integrity, providing a platform for
potential development of safe and effective treatments for this degenerative disease.

7.2 Methods

7.2.1 Materials
The following chemicals were purchased from the noted suppliers and used in
studies presented here: high purity porcine pancreatic elastase (EC134, 135 Units/mg)
and elastin-orcein (Elastin Products Company, Inc.; Owensville, MO); Dulbecco’s
modified Eagle media (DMEM) and fetal bovine serum (FBS) (Cellgro; Herndon, VA);
penicillin-streptomycin for cell culture (Invitrogen; Carlsbad, CA); CellTiter 96® One
Solution

Reagent,

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium, inner salt (MTS) (Promega; Madison, WI); Live/Dead®
Viability/Cytotoxicity Kit (Molecular Probes; Eugene, OR). Pentagalloyl glucose was
synthesized by methanolyis of tannic acid, as described previously in Chapter 6.

7.2.2 In Vitro Studies
7.2.2.1 Cytotoxicity of Pentagalloyl Glucose
Varying concentrations of pentagalloyl glucose (PGG) were applied directly to rat
skin fibroblasts (RSFBs) and rat aortic smooth muscle cells (RASMCs) separately to
assess toxicity of PGG. It should be noted that these studies, in which cells are directly
exposed to solutions of PGG, differ from the cytotoxicity experiments described in
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Chapter 6, where extracts from PGG treated tissue (aorta) were tested for their effects on
cell viability. This was necessary since PGG would be directly applied to native living
tissue in situ within in our animal model.
Primary fibroblasts and smooth muscle cells were isolated from the skins and
aortae, respectively, of adult male Sprague-Dawley rats (Harlan Laboratories;
Indianapolis, IN) using a cell explant method. Each cell type was separately seeded onto
24-well plates (25,000 cells per well) in 1 mL Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin. Cells were maintained in a humidified incubator at 37oC with 5% CO2.
Media was refreshed after 24 hours, and removed and replaced with one of the PGG
solutions 48 hours later (for a total of 72 hours after cells were seeded). For these
solutions, PGG was dissolved and diluted in sterile phosphate buffered saline (PBS) to
yield final concentrations of 0.03%, 0.06%, 0.10%, 0.12%, or 0.15% PGG. Cells were
also incubated with PBS as negative controls and with 70% ethanol as positive (toxic)
controls. Cells, both fibroblasts and smooth muscle cells, were directly exposed to these
solutions (1 mL per well) for 15 minutes, then rinsed twice with sterile PBS.
Cell viability was assessed by Cell Titer 96® AQueous One Solution Reagent, 3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-4-sulfophenyl-2H-tetrazolium,
inner salt (MTS) assay (Promega, Madison, WI; n=3 per group per cell type) as well as
Live/Dead staining (Molecular Probes, Eugene, OR; n=3 per group per cell type). For
MTS, cells were exposed to MTS reagent diluted 5-fold in culture media. After 90
minutes of incubation with the reagent, absorbance was read at 490 nm in a microplate
reader.

This absorbance is proportional to dehydrogenase enzyme activity within
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metabolically active cells, thus creating the correlation between absorbance and cell
viability. Samples were blanked to controls containing media and MTS reagent without
cells. For Live/Dead staining, digital micrographs of cells were taken 45 minutes after
exposure to the Live/Dead reagent. Cell viability is expressed visually through this
assay, as live cells fluoresce green while dead cells fluoresce red.
7.2.2.2 Opening Angle of Treated Rat Aorta
Fresh rat abdominal aorta (infrarenal) was collected from adult male SpragueDawley rats (Harlan Laboratories; Indianapolis, IN) and transported to the laboratory in
physiological saline. The tissue was cut transversely into rings segments approximately 2
mm in length. Aortic rings were carefully cleaned of extraneous tissue with the aid of a
stereomicroscope. The rings were kept intact (unopened) and left untreated (Fresh) or
treated with varying concentrations of PGG (0.03%, 0.06%, 0.10%, 0.30%) dissolved in
unbuffered saline (5 mL per aortic sample). Treatments were performed at 37oC and for
just 15 minutes in an attempt to simulate the in vivo treatments applied within our
aneurym animal model. Following treatment, rat aortic samples were rinsed in saline at
room temperature (3 times, 1 hour per rinse). The aortic rings (n=5) were then immersed
in ddH2O with the cross section of the aorta facing upward, allowing free movement of
the sample. The rings were cut once in the radial direction under a stereomicroscope,
allowed to “relax” and open for 15 minutes under water, and then photographed through
the stereomicroscope at a magnification of ~20x. The resulting images were used to
calculate the opening angle of each aortic ring using Adobe Photoshop 7.0. This opening
angle method is similar to that described for porcine aorta in Chapter 6 and has been used
by others for both porcine13 and rat14 arteries.
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7.2.2.3 Resistance to Elastase
The efficacy of varying concentrations of PGG on rat aorta was tested using a
variation of the elastase digestion assay we developed for porcine vascular elastin and
aortic wall.10,11 Using the fresh abdominal aorta harvested from adult rats, aortic tissue
samples (~5 mm in length) were left untreated (Fresh) or treated with 0.03%, 0.06%,
0.10%, or 0.30% PGG. PGG treatments were identical to those described above for
opening angle experiments (PGG in unbuffered saline, 15 minutes, 37oC, 5 mL per
sample). After treatment, samples were rinsed in saline at room temperature (3 times, 1
hour each) and subsequently lyophilized. The samples of rat aorta (n=5) were then
subjected to 1.0 mL of high purity porcine pancreatic elastase (1.0 Unit/mL in 100 mM
Tris buffer, 1 mM CaCl2, 0.02% NaN3, pH 7.8) for 24 hours at 37oC with mild orbital
shaking at 400 rpm. Following exposure to this enzyme, elastase solutions were retrieved
for desmosine analysis (see below), samples were centrifuged (10000 rpm, 10 minutes,
4oC), and residual tissue was rinsed exhaustively in 100 mL ddH2O (3 times, 1 hour each)
and ultimately lyophilized. Tissue samples were then individually hydrolyzed in 6 N
hydrochloric acid (HCl) at 95oC for approximately 8 hours. After hydrolysis, they were
dried under a continuous stream of nitrogen gas (~45 minutes) and subsequently
reconstituted in 1.0 mL of 0.01 N HCl.
The resulting hydrolysates (n=5) were assayed for desmosine content using a
radioimmunoassay,15,16 as described and performed by our collaborator, Dr. Barry
Starcher at the University of Texas Health Center at Tyler. Desmosine, an amino acid
specific to elastin, can be used to express elastin content. Therefore, preservation or
degradation of elastin after exposure to elastase was quantified by this desmosine
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analysis. Using these same tissue hydrolysates, the ninhydrin-based method for total
amino acid content was used in order to normalize desmosine values to total protein.17
Similarly, desmosine analysis was performed on the retrieved enzyme solutions
(n=5) following the elastase digestion assay described above. Identical to the hydrolysis
performed on aortic samples, elastase solutions were hydrolyzed with 6 N HCl, dried
under nitrogen, and finally reconstituted in 1.0 mL of 0.01 N HCl.

The

radioimmunoassay for desmosine was again performed on the resulting hydrolysates,
with results normalized to total protein in solution.
7.2.2.4 Histology Stain for Tannin Binding
To test for concentration-dependent PGG binding with rat aortic tissue, histology
was performed on samples of treated rat aorta using a stain specific for polyphenols such
as PGG. Fresh abdominal aorta was harvested from adult rats and transported to the
laboratory in physiological saline. Segments of aorta were cut to approximately 2 mm in
length and subsequently treated with 0.03%, 0.06%, 0.10%, or 0.30% PGG. Treatments
with PGG were consistent with those described above (PGG in unbuffered saline, 15
minutes, 37oC, 5 mL per sample). After PGG treatment, samples were rinsed in ddH2O
at room temperature (3 times, 1 hour each), then stained with ferric chloride (10% FeCl3
in ddH2O, 5 minutes), followed by another series of rinses in ddH2O (3 times, 15 minutes
each). The ferric chloride step specifically stains phenols black. Once staining and
rinsing were complete, tissue was embedded and frozen in OCT cryosectioning medium
(Sakura Finetek, Torrance, CA), sectioned at 6 µm, and counterstained with light green.
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7.2.3 Animal Surgeries
7.2.3.1 Experimental Design for In Vivo Aneurysm Studies
Two separate experiments were designed to evaluate the in vivo efficacy of PGG
in hindering AAA formation and development in a rat model for aortic aneurysms. The
schematic in Figure 7.1 depicts a timeline of each study and the stages of AAA
development in the abdominal aorta injury model. For this model, calcium chloride
(CaCl2) is applied directly to the rat abdominal aorta, thus causing a chemical injury.
This model has been effective in progressively causing aneurysm formation in rabbits,
mice, and rats.18-22 In addition to progressive expansion of the aorta, the model also
elicits other AAA traits (localized inflammation, elastin degeneration, and increased
protease activity). Within 28 days after application of CaCl2 injury, AAA develops and
further progresses with time.
In the first experiment, prevention of AAA formation was attempted by
periadventitial delivery of PGG just prior to the CaCl2-mediated injury (at day 0).
Twenty-eight days after application of PGG and CaCl2, the animal’s abdominal aorta was
evaluated for AAA formation.
In the second experiment, CaCl2-mediated injury was performed and AAA
allowed to form unhindered. At 28 days after injury, PGG was applied to aneurysmal
aorta in an attempt to halt or slow aneurysm progression.
monitored for another 28 days after PGG treatment.

AAA development was
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Figure 7.1 Experimental design for in vivo aneurysm experiments. In Experiment 1,
PGG was applied to abdominal aorta immediately prior to CaCl2-mediated injury and
AAA formation evaluated 28 days later. In Experiment 2, PGG was applied to
aneurysmal aorta (28 days after CaCl2-mediated injury) and development of advanced
AAA monitored for another 28 days.

7.2.3.2 Experiment 1: Aneurysm Formation
Adult male Sprague-Dawley rats (weighing ~300 g; Harlan Laboratories;
Indianapolis, IN) were sedated with acepromazine (0.5 mg/kg; Ayerst Laboratories;
Rouses Point, NJ) and maintained under general anesthesia (2% to 3% isoflurane)
throughout surgery. The infrarenal aorta between the renal artery and iliac bifurcation
was exposed via laparatomy (Figure 7.2) and photographed with a digital camera
alongside a 10 mm x 1.1 mm (length x diameter) solid segment of stainless steel wire for
initial diameter measurements (see below). For PGG treatment, a strip (1.5 cm x 0.5 cm)
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of 8-ply sterile cotton gauze presoaked in 0.03% PGG in saline was placed on top of the
abdominal aorta and maintained for 15 minutes. The gauze was then removed and the
area rinsed three times with warm saline. The aortas then underwent chemical injury by
applying 0.5 M CaCl2 solution to the abdominal aorta with presoaked gauze for 15
minutes, a treatment which induces aneurysm formation.

Throughout all steps of

surgery, exposed internal organs were kept moist with periodic application of warm
physiological saline. As controls, rat aortas were treated with physiological saline for 15
minutes (rather than PGG), rinsed, and then subjected to CaCl2. After treating with
CaCl2 (for both PGG and control groups), the gauze was removed, and the incision closed
(abdominal intramuscular suture, subcutaneous suture, and final skin closure with
surgical staples). The rats recovered and had access to water and chow ad libitum.

Figure 7.2 Surgical steps for the abdominal aortic aneurysm model (Experiment 1).
Black arrows denote abdominal aorta.
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The rats (n=12 per group) were anesthetized after 28 days, at which point the
abdominal aorta was cleaned of adhesions, exposed, and digitally photographed. The
diameters of both the aorta and the steel wire were measured in three areas using SPOT
software (Diagnostic Instruments, Sterling Heights, MI) for each rat by two independent
investigators blinded to the identity of the samples. The true external aortic diameter was
calculated from the ratio of the true diameter of the steel wire and the diameter measured
on digital pictures. After photographing the aorta at this day 28 time point, the animals
were humanely euthanized by CO2 asphyxiation. The abdominal aorta was subsequently
excised and segments from each aorta processed for analysis of elastin content and
integrity, PGG content, extent of calcification and inflammation, and matrix
metalloproteinase (MMP) activity, as described below. Upon euthanasia, liver was also
collected (n=4 per group) to study effects of PGG on hepatotoxicity. Samples of liver
were immediately embedded in OCT cryosectioning medium (Sakura Finetek; Torrance,
CA) and frozen on dry ice. Sections (6 µm) were stained with hematoxylin and eosin
(H&E) to assess general cell and tissue morphology.
Elastin Integrity Assessment
Following euthanasia, rat aortas from control (saline) and PGG-treated rats (n=12
per group) were collected 28 days after CaCl2-mediated injury and assayed for
desmosine. Desmosine is an amino acid specific to elastin which can be used to express
elastin content in tissues.23,24 Normal rat aortas, which did not undergo surgery, were
used as controls (n=6) and similarly assayed for desmosine. Segments of abdominal
aorta (~2 mm in length) were lyophilized to obtain dry weight, individually hydrolyzed in
6 N hydrochloric acid (HCl) at 95oC for approximately 8 hours, dried under nitrogen gas
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for approximately 45 minutes, and reconstituted in 1.0 mL of 0.01 N HCl. These
hydrolysates were analyzed for desmosine content by radioimmunoassay15 and results
expressed as picomoles of desmosine per mg dry aorta.
Elastin integrity in aortic explants was also verified by histology. Aortic tissue
samples were retrieved immediately following euthanasia (n=6), embedded in OCT
cryosectioning medium (Sakura Finetek; Torrance, CA), and frozen on dry ice. Sections
(6 µm) were stained with Verhoeff van Giesson’s procedure (VVG, Poly Scientific; Bay
Shore, NY) for elastic tissue (elastin fibers stain black while collagen stains red/pink) to
assess aortic elastin integrity.
Pentagalloyl Glucose Binding Studies
Upon euthanasia, rat abdominal aortas (n=3) retrieved 28 days after PGG
treatment were rinsed and lyophilized to obtain dry weight. Segments of the aorta (~2
mm in length) were crushed in liquid nitrogen and PGG extracted with 80% methanol
(0.5 mL, 3 extractions, 15 minutes each, at 4oC).25 Following each extraction, samples
were centrifuged (12000 rpm, 5 minutes, 4oC), extracts collected, and pellets re-extracted
with methanol. For each sample, the three resulting extracts were pooled, dried under
nitrogen gas at room temperature, and reconstituted in 0.2 mL saline. Samples were then
assayed in triplicates for phenol content with the Folin-Denis reaction using a calibration
curve with 0 to 150 µg PGG/mL.26 Results were normalized to sample dry weights. As
controls, rat aortas were treated with 0.03% PGG in situ with presoaked gauze for 15
minutes.

Immediately following treatment, aortas were rinsed with saline, rats

euthanized, tissue collected, and PGG extracted as described above. These controls
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represented the original amount of PGG that would bind to rat aorta at day 0. Samples
were also stained for phenols with FeCl3 as described above.
Calcification Assessment
Twenty-eight days after CaCl2 injury, rats were euthanized and aortic samples
were retrieved for calcium analysis. Samples (n=12) were lyophilized to obtain dry
weight, individually hydrolyzed in 6 N HCl at 95oC for approximately 8 hours, dried
under nitrogen gas for 45 minutes, and ultimately reconstituted in 1.0 mL of 0.01 N HCl.
Calcium content was then measured within these hydrolysates using atomic absorption
spectrophotometry as described before.27 Samples of aorta were also embedded in OCT
cryosectioning medium (Sakura Finetek; Torrance, CA), frozen on dry ice, and sectioned
(6 µm). These sections were stained with Alizarin red for calcium deposits, with light
green as a counter stain, to verify quantitative calcium values.27
Immunohistochemical Staining for Inflammation (Macrophages)
Aortic tissues from control (saline) and PGG-treated rats were embedded in OCT
cryosectioning medium immediately after euthanasia. Sections (6 µm) were fixed in cold
acetone for 5 minutes and incubated with 0.1% proteinase K for antigen unmasking.
Following two rinses in Tris-buffered saline (5 minutes each), sections were blocked with
0.3% hydrogen peroxide in 0.3% normal sera in Tris-buffered saline for 5 minutes to
neutralize endogenous peroxidase activity. Sections were then incubated with mousederived anti-rat monocyte/macrophage monoclonal antibody (Chemicon International;
Temecula, CA) diluted in TNB blocking buffer (1:200 dilution) at room temperature for 1
hour.28 TNB buffer alone was used as a negative control. Following another series of
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rinses in Tris-buffered saline, staining (and visualization of the stain) were performed
using rat-adsorbed biotinylated anti-mouse IgG secondary antibody (5 µg/mL in Trisbuffered saline; Vector Laboratories; Burlingame, CA), avidin-biotin-horseradish
peroxidase complex (Vectastain Elite kit, Vector Laboratories), and diaminobenzidine
substrate (DAB Substrate kit, Vector Laboratories). Sections were counterstained with
hematoxylin in order to demonstrate cell nuclei. As a positive control for the stain,
normal rat spleen, a tissue rich in macrophages, was subjected to this same procedure.
MMP and TIMP Quantification
MMP activities within control (saline) and PGG-treated rat aortas (n=6 per group)
retrieved 28 days after CaCl2 injury were analyzed using gelatin zymography, as
described previously.29 Aortic samples were homogenized and proteins were extracted
with buffered guanidine-HCl (50 mM Tris, 0.2% Triton X-100, 10 mM CaCl2, 2 M
guanidine-HCl, pH 7.5). Protein within resulting extracts was dialyzed (3500 molecular
weight cutoff dialysis tubing) against a buffered solution of 50 mM Tris, 0.2% Triton X100, pH 7.5, and subsequently quantified with the bicinchoninic (BCA) assay (Pierce;
Rockford, IL). For zymography, each lane was loaded with 5 µg of protein. Following
staining and development, densities of light bands on a dark background were quantified
for MMP-2 (68 and 72 kDa) and MMP-9 (82 kDa) using Gel-Pro Analyzer software
(Media Cybernetics, Inc.; Silver Spring, MD) and reported as relative density units
(RDU).
Levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) within these same
protein extracts (n=6 per group) were analyzed by enzyme-linked immunosorbent assay
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(ELISA; TIMP-2 Biotrak Assay kit, Amersham Biosciences; Piscataway, NJ) according
to manufacturer’s guidelines and results expressed as ng per mg of protein.
7.2.3.3 Experiment 2: Aneurysm Progression
Adult rats (n=24) were sedated and maintained under general anesthesia as
described above for Experiment 1. The infrarenal aorta between the renal artery and iliac
bifurcation was exposed via laparatomy, photographed for diameter measurements,
treated with 0.5 M CaCl2 to induce aneurysm formation as described above, and rats
closed and allowed to recover. All rats had access to water and chow ad libitum. After
28 days, rats were exposed to a second surgery and randomly divided into two groups,
PGG treatment group (n=12) and controls (saline; n=12). For this second procedure, rats
were anesthetized, the abdominal aorta exposed (Figure 7.3), cleaned of adhesions, and
digitally photographed for diameter measurements. In the PGG treatment group, aortas
were treated with 0.06% PGG in saline for 15 minutes using same gauze application
technique described above.

The higher PGG concentration was selected for this

experiment (as compared to Experiment 1) because of expected higher degree of elastin
degeneration in the pathological (aneurysmal) aortas.

In the control saline group,

exposed rat aortas were treated with physiological saline for 15 minutes. After rinsing,
incisions were closed and rats allowed to recover with free access to food and water. At
28 days after the second surgery (totaling 56 days after initial CaCl2 injury), all rats were
anesthetized, abdominal aorta exposed, cleaned of adhesions, and again photographed for
diameter measurements. These photographs allowed us to track diameter changes (and
aneurysm development) for each rat, from aneurysm induction (calcium chloride at day
0) to treatment or intervention with PGG (day 28) to our endpoint (day 56).
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Figure 7.3 Surgical steps for the abdominal aortic aneurysm model (Experiment 2). For
this experiment, a second surgery was performed 28 days after the first in an attempt to
halt or slow aneurysm progression. Black arrows denote abdominal aorta.

Five rats from each group (PGG-treated and saline controls) were perfusion-fixed
with formalin in order to fix the tissues into place under pressure and evaluate
histomorphometry.

Following anesthesia and photography (for aortic diameter

measurement), heparin (0.2 mL of 1000 Units/mL) was administered through
subcutaneous injection. Once the heparin circulated for 20 minutes, the animals were
humanely euthanized by CO2 asphyxiation. A catheter inserted into the thoracic aorta
allowed the vasculature to be washed/flushed (250 mL saline with 2000 Units/L heparin)
and fixed in situ (150 mL of 10% neutral buffered formalin) under 100 mm Hg pressure,
to imitate physiological pressure in blood vessels. Flow rates of wash and fixative
solutions were both approximately 10 mL/minute.

Once perfusion fixation was

complete, aortas were digitally photographed again. Those rats which were not perfusion
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fixed were euthanized by CO2 asphyxiation immediately following digital photography of
their abdominal aorta.
Samples were collected from each aorta, whether perfusion fixed or not, and
processed for assessment of elastin content and integrity, as well as calcium analysis.
Histology on the perfusion fixed aortic samples was used for morphometric measurement
of external and internal diameters, as described below. All animals received humane care
in compliance with protocols approved by the Clemson University Animal Research
Committee as formulated by the NIH (Publication No. 86-23, revised 1985).
Histomorphometric Diameter Measurement
For those aortas which were perfusion fixed in situ under physiological pressure
(n=5 per group), aortic samples (~3 mm in length) were stored in 10% neutral buffered
formalin and processed for histology. Paraffin embedded sections (5 µm) were stained
with hematoxylin and eosin (H&E). Low magnification pictures (25x) were used to
determine the external diameter, internal diameter, and thickness of the arterial media.
These digital measurements were performed using the trace feature in Image-Pro Plus 5.1
(Media Cybernetics; Silver Spring, MD).
Elastin Integrity Assessment
Following euthanasia, rat aortas were collected and assayed for desmosine content
(an amino acid specific to elastin) to express elastin content in tissues, as described
above. Normal rat aortas, which did not undergo surgery, were again used as controls
(n=6). Briefly, segments of abdominal aorta (~2 mm in length) were lyophilized to
obtain dry weight, acid hydrolyzed, and ultimately analyzed for desmosine content by
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radioimmunoassay.15 This analysis was performed on all collected rat aortas, whether
perfusion fixed or not. Results were expressed as picomoles of desmosine per mg dry
aorta. Elastin integrity in aortic explants was also verified by histology using VVG stain
for elastin fibers, as described above.

In addition to this elastin-specific stain,

hematoxylin and eosin (H&E) was also performed to investigate general structure of the
aortic tissue.

7.2.4 Data Analysis
Results are expressed as means ± standard error of the mean (SEM). Unless
otherwise noted, statistical analyses of the data were performed using single-factor
analysis of variance (ANOVA). Subsequently, differences between means were
determined using the least significant difference (LSD) with an alpha value of 0.05.

7.3 Results

7.3.1 In Vitro Safety and Efficacy
In anticipation of the animal studies, several studies were performed in vitro to
evaluate the effects of a single, 15-minute application of pentagalloyl glucose (PGG) on
cell viability and arterial extracellular matrix components, specifically elastin.
Cytotoxicity tests were performed by direct exposure of rat aortic smooth muscle
cells and rat skin fibroblasts to increasing concentrations of PGG at 37oC. MTS results,
reported as absorbance values which are directly proportional to cell viability, showed
that exposure of smooth muscle cells (Figure 7.4) and fibroblasts (Figure 7.6) to PGG
concentrations of up to 0.06% had minimal cytotoxic effects. For each cell type, greater
than 80% of the cells remained viable after exposure to this concentration of PGG. It
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should be noted that exposure to 0.03% and 0.06% PGG, the two concentrations used for
in vivo experiments, did not significantly (p>0.10) alter cell viability for smooth muscle
cells or fibroblasts. In general, MTS results were confirmed visually by Live-Dead assay
(Figure 7.5 for rat aortic smooth muscle cells, Figure 7.7 for rat skin fibroblasts), which
fluoresces live cells green and dead cells red.

Figure 7.4 Rat aortic smooth muscle cells were exposed to varying concentrations of
PGG, and cytotoxicity measured using the MTS assay (absorbance values are directly
proportional to number of viable cells). Phosphate buffered saline (PBS) and 70%
ethanol (EtOH) were used as negative and positive controls, respectively. Cells exposed
to 0.03% and 0.06% PGG did not exhibit significantly different viability (p>0.10).
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Figure 7.5 Viability of rat aortic smooth muscle cells was visualized with Live/Dead
staining (live cells = green, dead cells = red), indicating that PGG up to 0.10% resulted in
little to no cell death. PBS = phosphate buffered saline, EtOH = 70% ethanol.

Figure 7.6 Rat skin fibroblasts were exposed to varying concentrations of PGG, and
their viability assessed using the MTS assay. Concentrations of PGG up to 0.06% had
minimal effects on fibroblast viability. The number of viable cells exposed to 0.03%
PGG was not significantly less than those exposed to the negative PBS control (p>0.10).
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Figure 7.7 Effect of varying concentrations of PGG on rat skin fibroblast viability was
confirmed by Live-Dead staining (live cells = green, dead cells = red). PBS = phosphate
buffered saline, EtOH = 70% ethanol.

As a test for elastin stabilization, PGG-treated samples of rat aorta were exposed
to an in vitro accelerated model for enzyme-mediated elastolytic degradation. Following
digestion with elastase, elastin content within the tissue was determined by desmosine
assay (Figure 7.8). As expected, results showed a trend of increasing resistance to
elastase with increasing PGG concentrations used for treatment of rat aorta. The samples
treated with PGG showed concentration-dependent retention of desmosine (and thus
elastin). Concentrations of 0.06% PGG and higher yielded aortic tissue that retained
significantly more desmosine than saline controls (p<0.05).
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Figure 7.8 To test for elastin stabilization in rat aorta, samples were treated with varying
concentrations of PGG for 15 minutes in vitro and then exposed to pure elastase. Elastin
content was measured in the aortic tissues by desmosine analysis, revealing that PGG was
able to protect elastin from degradation in a concentration-dependent manner.

In addition to investigating the tissue, desmosine, which may have been released
due to significant elastin degradation, was also assayed within the retrieved enzyme
solutions. These results correlated well with those in Figure 7.8, revealing that greater
elastin stabilization (with increasing PGG concentrations) resulted in less detected
desmosine in solution (Figure 7.9). The amount of desmosine in these “used” solutions
was significantly less within the higher concentration PGG groups (0.10% and 0.15%) as
compared to saline controls (p<0.05). Although not statistically significant from these
controls (p>0.05), aortas treated with 0.03% or 0.06% PGG also appeared to reduce the
elastase-mediated release of desmosine into solution.
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Figure 7.9 Desmosine analysis on elastase solutions revealed that rat aorta treated with
PGG correlated into significantly less desmosine being released into solution as a result
of its elastin stabilizing capabilities.

It was believed that this observed elastin stabilization within rat aorta was
attributable to PGG’s ability to bind directly to elastin within the tissue. This was
confirmed by showing PGG binding to rat aortic elastin using a specific phenol stain
(Figure 7.10). Results showed specific staining of elastic fibers, with the intensity of the
black stain progressively increasing with increasing concentrations of PGG. Therefore,
PGG clearly binds to rat aortic elastin in a concentration-dependent pattern, thus
endowing the tissue resistance to elastolytic degradation.

203

Figure 7.10 For histological confirmation of PGG binding to rat aortic elastin, PGGtreated aortic tissues were stained with a phenol-specific stain (PGG=black) and
counterstained with light green. L=lumen, bar=100 µm, arrows point to elastic lamellae.

For further proof of interactions of PGG with arterial elastic fibers, the ringopening test was performed on PGG-treated rat aorta (Figures 7.11 and 7.12). Native
untreated aortic rings, when allowed to open by a single incision, extended to more than
75 degrees, revealing the natural elastic recoil properties of aortic tissues. Rings that
were exposed to increasing concentrations of PGG exhibited smaller opening angles,
suggestive of the direct interaction of PGG with elastic fibers. With the exception of
0.03% PGG, all PGG-treated tissues opened significantly less than saline controls
(p<0.05).

The opening angles of aorta treated with 0.03% and 0.06% PGG, the

concentrations used in vivo, were not statistically different from one another (p>0.10).
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Figure 7.11 To test elastin recoil, aortic rings were treated for 15 minutes with
increasing concentrations of PGG and subjected to ring opening analysis. Opening
angles were measured graphically, as depicted by the white lines (bottom left corner).

Figure 7.12 Mean opening angles of rat aorta for each treatment group are shown as a
function of PGG concentration. The decreased opening angles associated with higher
PGG concentrations are likely indicative of increased PGG binding to elastin.
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Having established that a 15-minute exposure to PGG solutions of up to 0.06% is
not cytotoxic and effectively stabilizes aortic tissue by binding to elastic fibers, two
experiments were designed to test the in vivo efficacy of PGG in hindering AAA
formation and progression (Figure 7.1). In Experiment 1, prevention of AAA formation
was achieved by periadventitial delivery of PGG to healthy abdominal aorta concomitant
with the onset of AAA. In a more clinically relevant Experiment 2, PGG was applied to
pathologic (aneurysmal) aorta and this treatment significantly hindered chronic AAA
progression.

7.3.2 Effect of Pentagalloyl Glucose on Aneurysm Formation
In Experiment 1, perivascular application of CaCl2 to the infrarenal abdominal
aorta induced significant changes in aortic diameter at 28 days after injury (Figures 7.13
and 7.14). Comparative measurements of the external aortic diameter of control (salinetreated) rats at day zero and 28 days after surgery (1.395 ± 0.052 mm and 1.939 ± 0.112
mm, respectively) revealed a mean increase in diameter of 42 ± 10 % (p<0.05, n=12). By
comparison, aortas that were exposed to PGG exhibited minimal (8 ± 7 %; Figure 7.14)
increase in diameter after 28 days (from 1.564 ± 0.064 mm to 1.676 ± 0.097 mm). Figure
7.13 shows representative digital images of control rat aorta at day zero (prior to
treatment or chemical injury), saline-treated aorta 28 days after chemical injury, and
PGG-treated aorta 28 days after chemical injury.
Considering an arbitrary threshold of 20% diameter increase as aneurysmal in this
experimental model, 8 out of 12 rats exhibited aneurysms in the control group (66.7%)
and only 2 out of 11 rats were aneurysmal in the PGG group (18.2%, Table 7.1). Chisquared categorical analysis (with an alpha value of 0.05) revealed that these proportions
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were statistically different from one another. These results indicate that PGG application
just prior to arterial injury with CaCl2 effectively hindered development of aneurysms in
this experimental model.

Figure 7.13 External diameter of the infrarenal abdominal aorta between the renal artery
(top) and iliac bifurcation (bottom) was measured by digital photography at day 0 and 28
days after injury in the control group (saline-treated) and in the PGG group. Black
dashed lines were added to aid in identification of aortic anatomy.
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Figure 7.14 Mean percent change in diameter at 28 days (relative to day 0) revealed that
local delivery of PGG prevented abdominal aortic aneurysm formation. Black arrow
denotes time of PGG (or saline) application.

Table 7.1 Aneurysm occurrence (defined as a 20% increase in aortic diameter)
Aneurysm
Occurrence

% Aneurysmal

Saline

8 / 12

66.7

PGG

2 / 11

18.2

As shown above, such exposure to PGG for 15 minutes had minimal cytotoxic
effects on rat smooth muscle cells and fibroblasts. In our experiment, PGG-treated rats
did not exhibit significant changes in weight gain during the 28-day test period (mean
gain of 42.33 ± 3.47 g in control group vs. 44.25 ± 3.69 g in PGG group, p<0.05, n=12).
Liver samples collected from each group did not exhibit any noticeable histological
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changes indicative of hepatotoxicity (Figure 7.15). Taken together, these results suggest
that periarterial application of PGG did not elicit conspicuous local, organ, or cell toxicity
in this experimental model.

Figure 7.15 Histology on rat liver revealed that PGG treatment had no hepatotoxic
effects when delivered locally within the abdominal aortic aneurysm model.
Hematoxylin and eosin stain, original magnification 100x.

7.3.2.1 Elastin Integrity
Along with aortic dilatation, perivascular application of CaCl2 induced major
changes in vascular elastin content and integrity as shown by desmosine analysis (Figure
7.16) and histology (Figure 7.17). As compared to non-surgery control aorta collected
from age-matched rats, aortic elastin content in the control (saline-treated) group
diminished by almost 50%, as suggested by the drastic drop in desmosine content (Figure
7.16). Histology on this same group exhibited characteristic flattening and fragmentation
of the elastic laminae at 28 days after injury (Figure 7.17). Conversely, aortas from the
PGG group exhibited minimal decrease in elastin content (Figure 7.16) as compared to
normal non-surgery control aorta (less than 15% loss of desmosine, p>0.05) and excellent
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preservation of elastic laminae integrity and waviness (Figure 7.17), suggesting that PGG
delivery effectively prevented elastin degeneration in this animal model.

Figure 7.16 Desmosine analysis was performed on non-surgery control rat aorta (day 0)
and compared to aorta collected 28 days after chemical injury. The PGG group exhibited
excellent elastin preservation after 28 days as compared to saline-treated aorta (p<0.05).
Black arrow denotes time of PGG (or saline) application.
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Figure 7.17 Elastin integrity at day 0 and day 28 was also evaluated by histology using
VVG stain (elastin = black). The natural wavy architecture of elastin fibers remained
intact for PGG-treated aorta while saline-treated controls displayed significant elastin
fiber fragmentation after 28 days. L = lumen, bar = 50 µm.

7.3.2.2 In Vivo Binding of Pentagalloyl Glucose
The affinity of phenolic tannins towards elastin has been well established in
previous chapters, particularly for porcine vascular elastin. In order to validate PGG
binding to rat aortic elastin in vivo, we quantified amounts of PGG present in explanted
rat aortas (Figure 7.18). As compared to day 0 (1.88 ± 0.6 µg PGG/dry tissue), aortas
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explanted 28 days after PGG application contained slightly lower, but not statistically
different amounts of PGG (1.23 ± 0.4 µg PGG/dry tissue; p>0.05), indicating that in vivo
binding of PGG to rat aortic tissues is stable for a minimum of 28 days in this accelerated
animal model.

Figure 7.18 Quantitative analysis of PGG content in explanted aorta shows the presence
of significant amounts of PGG incorporated into the tissue. The majority of this PGG
remained bound even after 28 days in the accelerated animal model (p>0.05 as compared
to day 0).

7.3.2.3 Model-Related Pathogenesis
The primary pathogenic characteristics of this experimental model are similar to
those found in human aortic aneurysms, namely medial calcification,30 inflammation,22
and matrix degeneration.20,31 To investigate the effect of periadventitial PGG application
on these aspects, calcium content, macrophage infiltration, MMP activities, and

212
expression of TIMP were analyzed in aortas from both groups (PGG-treated and salinetreated controls).
Aortic Calcification
Expectedly, perivascular application of CaCl2 induced substantial tissue
calcification after 28 days (Figure 7.19). Alizarin red staining of aorta showed that this
calcium was localized mainly in the media (Figure 7.20).

Although slightly lower

calcium values were observed for PGG-treated aortas, these results were not statistically
different from saline-treated controls (p>0.10). In addition, tissue distribution of calcium,
as seen by histology, also appeared to be similar for both groups.

Figure 7.19 Aortic calcification at 28 days after CaCl2 injury was evaluated by analysis
of calcium content, which revealed that PGG treatment did not significantly alter this
pathological trait of the model (p>0.10).
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Figure 7.20 Calcium analysis results were confirmed by histology with Alizarin red
staining (calcium deposits = red). PGG appeared to have little effect on the degree of
calcification as compared to saline-treated controls. L = lumen, bar = 100 µm.

Inflammation
Immunohistochemical (IHC) staining for macrophages revealed comparable
inflammatory infiltrates in both groups (Figure 7.21). As a positive control for the stain,
sections of spleen were subjected to the same IHC procedure, confirming the brown
staining of macrophages (data not shown).

Figure 7.21 Immunohistochemistry for macrophages (positive reaction brown) revealed
comparable inflammatory infiltrates in both groups, thus suggesting that PGG does not
reduce inflammation. L = lumen, bar = 100 µm.
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Activity of Matrix-Degrading Enzymes
Activities of MMP-2 and MMP-9, enzymes which digest matrix components such
as elastin and collagen, were assessed by gelatin zymography. MMP-2 and MMP-9
activities were not different between saline controls and PGG-treated aortas (p>0.10,
Figure 7.22).

In addition, expression of TIMP-2, a potential inhibitor of the

aforementioned MMPs, was also analyzed by ELISA (Figure 7.22).

Again, no

differences were observed in TIMP-2 for the two groups (p>0.10), suggesting that tissues
in both groups were exposed to similar proteolytic environments.
Taken together, these results (calcification, inflammation, and activity of matrixdegrading enzymes) suggest that PGG treatment did not interfere with the pathogenic
mechanisms typical to this experimental model. Instead, PGG apparently works by
directly binding to and stabilizing elastin.

Figure 7.22 After 28 days, MMP-2 and MMP-9 enzymatic activities, as well as TIMP-2
levels, were not statistically different in the two groups (p>0.10). This data suggests that
PGG does not interfere with (inhibit) the MMP activity associated with this model.
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7.3.3 Effect of Pentagalloyl Glucose on Aneurysm Progression
7.3.3.1 Aortic Diameter
In Experiment 2, rat aortas were treated with CaCl2 and abdominal aortic
aneurysms (AAAs) were allowed to develop for 28 days. At this time point, a second
surgery was performed and PGG was applied to aneurysmal aortas in the PGG group and
saline was applied to aneurysmal aortas in the control group. AAA progression was
monitored for another 28 days in both groups. Figure 7.23 shows representative pictures
of perfusion-fixed aorta from each group (PGG-treated and saline-treated controls) at this
time point. Additionally, Table 7.2 displays the number of individual rats from each
group whose aortic diameter increased (aneurysm progression), experienced little or no
relative change (stationary), or decreased (regression) at day 56 as compared to day 28.
As expected, perivascular application of CaCl2 at day 0 induced a progressive
diameter expansion, reaching a mean increase of 47.1 ± 11.8% at 56 days in the salinetreated control group (Figure 7.24).

Approximately half of the aneurysmal aortas

increased in diameter from day 28 to day 56 in the saline-treated control group (Table
7.2), indicative of chronic AAA progression in this animal model.
By comparison, aneurysmal aortas that were exposed to PGG at day 28 exhibited
no increase in mean diameter at 56 days (23.2 ± 4.1% diameter increase relative to day 0)
as compared to day 28 mean values (33.6 ± 5.4% diameter increase relative to day 0). In
other words, the average diameter of the PGG-treated aorta actually decreased in
comparison to its diameter at day 28, although this difference was not statistically
significant (p>0.05). The change in diameter at 56 days for saline-treated controls (47.1
± 5.4%), however, was significantly greater (p<0.05) than that observed for PGG-treated
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(23.2 ± 4.1%). It is also noteworthy that 100% (11 out of 11) of aortas in the PGG group
maintained the same diameter or exhibited a slight decrease in aortic diameter (56 vs. 28
days; Table 7.2). Overall, these results indicate that PGG application to aneurysmal
aortas effectively hindered AAA progression in this experimental model.

Figure 7.23 External diameter of the infrarenal aorta between the renal artery (top) and
iliac bifurcation (bottom) was measured by digital photography after perfusion fixation in
both groups 56 days after chemical injury (28 days after treatment with PGG or saline).
Black dashed lines were added to aid in identification of aortic anatomy.
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Figure 7.24 Mean percent change in external aortic diameter at 28 days (time of second
surgery and application of PGG or saline, as denoted by black arrow) and 56 days,
relative to day 0. Values in the two groups were significantly different at 56 days
(p<0.05).

Table 7.2 State of aneurysm development at day 56 following treatment with PGG or
saline at day 28. Values represent actual numbers of individual rats that exhibited
increased, stationary, or reduced diameters at 56 days, as compared to 28 days.
Diameter increase

Saline

PGG

Progression (>40%)

5

0

Stationary (25% to 40%)

3

5

Regression (<25%)

3

6
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Using low magnification histology images of perfusion-fixed cross-sections of rat
aorta, like those shown in Figure 7.25, morphometric analysis was performed to calculate
internal and external diameters of the aortic media, as well as media thickness (Figure
7.26). For external and internal diameter, values were smaller for the PGG group,
although this difference was not significant (p>0.05). At the same time, thickness of
aortic media was found to be substantially smaller in the PGG treatment group (p<0.05,
Figure 7.26). While the meaning of this increased thickness for the saline controls is not
well understood, it may be indicative of arterial matrix degeneration, resulting in a loss of
tissue “compactness”.
Taken together, these results suggest that PGG treatment of aneurysmal aortas
effectively prevented chronic diameter expansion in this animal model.

Figure 7.25 Low magnification pictures taken from each H&E stained aortic crosssection were used for histomorphometric measurement of external and internal diameters,
as well as thickness of arterial media using digital imaging. In the representative pictures
shown here, PGG-treated aorta possessed a slightly smaller internal diameter, external
diameter, and thickness. Bar = 1000 µm.
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Figure 7.26 Histomorphometric measurement of medial inner and outer diameters, as
well as medial thickness. Diameters and thickness were smaller in the PGG group,
although only thickness measurements were statistically significant (p<0.05).

7.3.3.2 Elastin Integrity
After 56 days, animals were sacrificed and aortas were visually examined for
elastin integrity by VVG staining. This elastin-specific stain displayed marked flattening,
extensive fragmentation, and complete degeneration of the elastic laminae in extended
areas in the saline control group (Figure 7.27). Moreover, overall tissue architecture
(H&E stain) was indicative of severe tissue degeneration as outlined by numerous empty
spaces, bestowing the aneurysmal aorta with a “spongy” aspect (Figure 7.28). This trait
likely coincides with the increased medial thickness and loss of tissue compactness
observed during histomorphometric analysis of saline-treated controls, as described
above. In contrast, PGG-treated aortas exhibited visibly better preservation of elastic
laminae integrity and waviness (Figure 7.27) and overall tissue architecture (Figure 7.28).
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Figure 7.27 Aortic elastin integrity was evaluated by histology using VVG stain (elastin
= black), showing preservation of the natural wavy architecture of elastin fibers in the
PGG-treated samples. L = lumen, bar = 50 µm.

Figure 7.28 General tissue architecture was also examined by H&E staining. Salinetreated controls, those more prone to aneurysm progression, apparently experienced
severed tissue degradation, as suggested by the spongy aspect seen in the aortic wall.
L = lumen, bar = 50 µm.
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Desmosine analysis of aortic tissues at 56 days post-injury in both PGG and saline
control groups revealed no significant differences in elastin content (p>0.05, Figure
7.29). Moreover, these elastin values were not statistically different from the 28-day
values, indicating that the severe elastin degradation observed at 28 days has reached a
steady-state and has not changed significantly as AAA progressed from 28 to 56 days. In
view of the fact that major elastin degradation (flattening and fragmentation) was seen
through histology (Figures 7.27 and 7.28), it may be a case where quantity of elastin was
not affected by PGG treatment, but preservation of elastin quality was maintained.

Figure 7.29 Desmosine analysis on explanted aorta revealed that elastin content in PGGtreated aorta was not different than saline-treated samples (p>0.05). Furthermore, 56 day
values (for both groups) were not significantly different than 28 day controls, suggesting
that the majority of elastin degradation may have occurred prior to intervention with
PGG. Black arrow indicates time of intervention with PGG (or saline as control).
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7.4 Discussion
Aneurysms arise from irreversible, chronic pathological changes that involve
MMP-mediated degeneration of structural matrix components, namely elastin and
collagen. The role of MMP/TIMP imbalances in AAA initiation and development have
been irrevocably demonstrated by studies using MMP and TIMP-knockout mice.20,31-33
Degeneration and loss of elastin are trademarks of AAA development, which apparently
lead to progressive dilatation of the aorta. Therefore, the work presented here focused on
chemical stabilization of vascular elastin as a novel approach to limit aneurysmal
degeneration.
Currently, the only options for treating late-stage AAAs entail surgical procedures
such as endovascular stent graft repairs or complete replacement of the diseased section
of the aorta with an artificial mesh vascular graft. Non-surgical approaches to suppress
aneurysmal degeneration in experimental animals include use of anti-inflammatory
agents, proteinase inhibitors, and genetic and pharmacologic inhibition of MMPs.
Doxycycline, an antibiotic and MMP inhibitor, showed initial promising results in a
clinical study.34,35 Recent studies have also reported that the systemic pharmacologic
inhibition of c-Jun N-terminal kinase (JNK), an intracellular signaling switch that
controls MMP production, might block AAA progression and stimulate aneurysm
regression.36

Such approaches have been effective when delivered systemically;

however, the high doses required for systemic use could ultimately lead to adverse side
effects. For instance, doxycycline use in this manner has been associated with muscle
pains, cutaneous photosensitivity, and gastrointestinal problems.37
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While numerous attempts have focused on proteolytic inhibition for AAA
treatment, our novel approach is based on periadventitial delivery of phenolic tannins
such as PGG to stabilize elastin and render it resistant to enzymatic degradation. In
previous chapters, we have shown that tannins are excellent candidates for such an
approach for their ability to bind to and stabilize vascular elastin. PGG, a more stable
derivative of tannic acid, was chosen for these studies since its improved structure
virtually eliminates any toxic implications that have been associated with tannic acid, as
shown in Chapter 6. Our hypothesis was that the ability of PGG to stabilize elastin
would extend to rat aorta as well. To verify our hypothesis, we performed a series of in
vitro safety and efficacy studies followed by in vivo validation in a rat AAA model.
As demonstrated in the previous chapters, PGG exhibits an outstanding affinity
towards elastin, possibly binding to hydrophobic areas, which are known to be
susceptible to protease-mediated elastolysis. In current studies we have validated PGG
binding to rat aortic elastin in vivo and provided evidence that the binding is stable for a
minimum of 28 days in this accelerated AAA experimental model. In previous chapters,
we have also provided ample in vitro evidence that binding of PGG to arterial elastin
provides an outstanding resistance to proteolytic degeneration.10-12 Since the natural
elastin turnover is exceptionally low,38 we hypothesize that PGG may remain bound to
aortic wall (by way of elastin) for extended periods of time after application, sufficient to
maintain resistance to enzymes and deter AAA progression.

7.4.1 Experiment 1: Pentagalloyl Glucose Hinders Aneurysm Formation
Traditionally, increase in aortic diameter is considered the defining characteristic
of AAA. Numerous investigators studied AAA formation in the CaCl2 injury model in
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mice,21 rabbits,18,19 and rats.22 In Experiment 1, application of 0.5 M CaCl2 to the rat
infrarenal abdominal aorta induced a mean increase in diameter of 42% at 28 days after
application. The extent of aneurysmal dilatation observed in our studies is in good
correspondence with other published studies using CaCl2 injury, which consistently
reported a 25% to 75% increase in diameter in rodents, depending on the time periods
evaluated and concentration of CaCl2 used.20,22,31,39
Conversely, mean aortic diameter increase in the PGG group was less than 10%,
which is traditionally not considered indicative of aneurysm formation. The overall AAA
incidence in the PGG group was less than 20%, indicating that in this experimental
model, PGG prevented aneurysm formation in more than 8 out of 10 animals. While the
detailed mechanisms of this successful approach are not entirely known, it apparently
involves PGG-mediated elastin stabilization and effective prevention of proteolytic
degeneration.
A second major characteristic of AAA is progressive damage to the arterial elastin
component. In our experimental model, periadventitial application of CaCl2 induced a
decrease of more than 50% in aortic elastin content at 28 days after application, as
compared to non-surgery control aorta.

Earlier studies have shown that elastin

degeneration starts within the first days after the CaCl2 injury and this chronic process is
related to an over-expression of MMPs within the aortic extracellular matrix.30 These
quantitative desmosine results were confirmed by histological analysis of tissue
architecture using an elastin-specific stain.

Typically, aortic samples that were

characterized by low elastin content also exhibited characteristic flattening and
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fragmentation of the naturally wavy elastic lamellae.

This histological aspect is

characteristic of the aortic pathology in CaCl2-treated aorta.36
Periadventitial treatment of aorta with PGG resulted in remarkable preservation of
elastin integrity. Quantitative desmosine results showed that elastin content in the PGG
group was not statistically different from the non-surgery controls (p<0.05), indicating
little to no elastin degradation.

This was accompanied by excellent histological

preservation of elastic lamellae integrity and waviness. Other published studies utilizing
this experimental model, including the current data shown here, indicate that elastin
preservation was consistently associated with absence of aneurysm initiation or
progression.20,31,36 This indicates that elastin stabilization by PGG treatment may be
effective as a potential AAA treatment.
Within days after CaCl2 application, medial calcification and matrix degeneration
occurs in this animal model as a result of increased MMP activities and inflammation
within the aortic wall.30 In our studies, application of non-cytotoxic doses of PGG to rat
aortas did not alter the calcification or inflammation processes and did not influence the
levels of aortic MMPs and TIMP. This is significant, as it provides insight into the
working mechanisms of PGG treatment for this application.

It suggests that PGG

treatment does not directly interfere with model-related pathogenesis; rather, PGGmediated inhibition of AAA development is apparently due to direct stabilization of
elastin and not by inhibition of enzyme activities. Inhibition of MMPs, enzymes which
are required for many normal physiological remodeling processes, could lead to
undesirable side effects, as mentioned previously.
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7.4.2 Experiment 2: Pentagalloyl Glucose Limits Aneurysm Progression
In a more clinically relevant experiment, PGG was directly applied to aneurysmal
aortas and AAA progression was followed after this surgical intervention. While most
control aneurysmal aortas (periadventitially treated with saline) continued to expand in
diameter, every one of the PGG-treated aneurysmal aortas maintained the same diameter
or exhibited a decrease in aortic diameter at the end of the experiment (56 days). In our
experiments, diameter expansion in aneurysmal controls was associated with changes in
medial thickness and integrity, including severe tissue degeneration. In an experimental
setup similar to the studies we are reporting here, Yoshimura et al. reported comparable
inhibition of AAA progression after the onset of AAA in rodent animal models, as a
result of systemic pharmacologic inhibition of JNK.

Since JNK is an intracellular

signaling switch that controls MMP production, JNK inhibition may have temporarily
inhibited MMP production and thus prevented degeneration of the vascular matrix.36 To
our knowledge, this is the only study (besides our current work) which has shown the
ability to halt aneurysm progression by intervening with a treatment weeks after
aneurysm onset. Since JNK inhibition apparently works by limiting MMP production
and activity, the feasibility of using this technology as a systemic clinical treatment may
be limited due to the same unfavorable effects of MMP inhibition.
Histological analysis of aneurysmal aortas at day 56 showed a significant decline
in elastin integrity in the control group indicating that elastin degeneration is a chronic
pathogenic aspect characteristic to this AAA model. Hallmarks of this process were
elastic fiber flattening, fragmentation, and lack of elastic laminae staining in extended
areas in almost all samples (5 out of 6). Aortas from the PGG group exhibited improved
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preservation of elastic laminae integrity and waviness in most samples (4 out of 6).
Desmosine analysis for this experiment revealed little differences for the PGG group as
compared to controls, possibly due to high biological variability in this experimental
model.

Another possible explanation for these conflicting results (histology and

desmosine analysis) is that elastin quantity is maintained for both groups, while the
quality of elastin within the PGG group is better preserved. Taken together, however, our
data suggest that PGG-mediated elastin stabilization in aneurysmal aortas has the
potential to significantly hinder elastin degradation and AAA development.

7.5 Conclusions
Maintaining the integrity of the aortic wall is vital in preventing AAA
development. Acute localized periadventitial delivery of non-cytotoxic concentrations of
PGG inhibits elastin degeneration, attenuates aneurysmal diameter expansion, and
hinders development of AAA in an established animal model without interfering with the
pathogenic mechanisms typical to this model. PGG binds strongly and specifically to
arterial elastin and in doing so, it preserves elastic laminae integrity and architecture
despite the presence of high levels of matrix-degrading enzymes. Approaches that target
stabilization of the aortic extracellular matrix in aneurysm-prone arterial segments hold
great potential towards development of safe and effective therapies for AAAs.
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CHAPTER 8
CONCLUSIONS AND RECOMMENDATIONS

8.1 Conclusions
Elastin is an extracellular matrix protein found in abundance within vascular and
cardiovascular tissues.

Protecting elastin from degeneration associated with matrix-

degrading enzymes may be beneficial in (1) improving the clinical longevity of tissuederived cardiovascular devices such as bioprosthetic heart valves, and (2) halting or
limiting development of abdominal aortic aneurysms. These ideas were tested in the
work presented here, allowing us to draw the following conclusions:
•

Tannins, such as tannic acid and pentagalloyl glucose (PGG), bind to vascular
elastin, resulting in improved resistance to elastolytic degradation.1

•

Elastin stabilization may be beneficial as a pretreatment for bioprosthetic heart
valves. Tannin treatment for this purpose appeared to be safe, effective, and
feasible.2

•

Polyphenolic hydroxyl groups, such as those found in tannic acid and PGG, are
required for interaction with and stabilization of elastin. PGG, the core of tannic
acid, possesses the same unique elastin-stabilizing capabilities of tannic acid and
endows aortic tissue with similar mechanical properties. However, PGG is more
chemically stable than tannic acid, thus making it less cytotoxic as well.3

•

By binding to vascular elastin and protecting it from degeneration, PGG appears
to inhibit abdominal aortic aneurysm formation and progression in an
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experimental animal model, making it a promising therapeutic agent for aneurysm
patients.

8.2 Recommendations

8.2.1 Elastin Stabilization in Bioprosthetic Heart Valves
The studies listed below are recommended for future work in implementing
tannins as an elastin stabilizing tissue pretreatment for bioprosthetic heart valves. For
these studies, we suggest using PGG rather than tannic acid as a bioprosthetic heart valve
pretreatment due to its improved chemical structure and relative lack of toxicity.
1. Examine the effects of tannin treatment on porcine aortic cusp tissue. The
majority of the research presented here for bioprosthetic heart valves was on tannintreated porcine aortic wall. Aorta was used not only because it possesses an abundance
of elastin (thus providing an elastin-rich model tissue), but also because it is an important
component of stentless bioprosthetic heart valves. That being said, elastin is also present
within cusp tissue, just to a lesser degree. Stabilizing elastin within these tissues may still
be beneficial towards preserving mechanical properties4,5 and resisting tissue
calcification.6,7 As such, tannin treatment applied to cusps should be investigated for
stabilizing efficacy and effect on mechanical properties and in vivo calcification.
2. Further investigate the possibility of creating a tissue pretreatment for these
devices with both tannins (PGG) and anti-calcific metal ions (aluminum or iron).
Apparently, a small portion of tannic acid which bound to elastin is partially reversible.
This same property was observed for PGG as well, although to a somewhat lesser extent.
Using our long-term in vitro model, these metal ions (in combination with tannic acid)
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appeared to alleviate this reversibility or instability. However, in the case of aluminum,
this same preservation of elastin-tannin interactions was not observed for in vivo studies.
Further studies on the long-term in vitro and in vivo efficacy of PGG and metal ions
(particularly iron) may be beneficial.

The relationship between the two could be

valuable, as it is well documented that tannins and metals have a very high binding
affinity for one another.8
3. Expose tannin-treated bioprosthetic heart valves to long-term cyclic fatigue
testing. We have shown that by binding to elastin, tannin treatment alters the mechanical
properties of tissue; however, we do not know what effect this will have in the cyclic
operation of the valve. Fatigue testing, performed at accelerated rates in the range of 400
to 1200 cycles per minute, can provide insight into the resistance to tissue tears as well as
the maintenance (or loss) of extracellular matrix components such as elastin and
collagen.9,10
4. Ultimately, tannin-treated bioprosthetic heart valves will need to be implanted
in more complex, functional animal models.

These models involve actual valve

replacement (often in the mitral valve position) in “higher-order” animals such as sheep,
canines, calves, goats, and pigs.11 Such tests would provide pivotal insight into the in
vivo efficacy and safety of elastin stabilization within a blood-contacting model.

8.2.2 Elastin Stabilization in Abdominal Aortic Aneurysms
The following studies are recommended for future work in implementing tannins
as a treatment for abdominal aortic aneurysms:
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1. Investigate the effect of PGG application on other aneurysm animal models.
To date, the only model used to induce aneurysms for our studies has been calcium
chloride-mediated injury of rat abdominal aorta. While we have provided evidence that
PGG is indeed working by directly stabilizing elastin rather than by inhibiting pathogenic
characteristics of the model (such as MMP activities, calcification, and inflammation), it
would be beneficial to confirm that this technology is applicable and effective in a variety
of models. In addition to perivascularly administering calcium chloride to rats, other well
documented options include intraluminal elastase perfusion in rodents,12,13 systemic
angiotensin-II delivery in mice,14,15 and genetically altered (blotchy, copper-deficient)
mice.16 Perivascular delivery of elastase to rabbit aortas has been attempted and reported,
but with conflicting results.17,18 Ideally, the technology would be extended to higherorder animals such as pigs or canines, however, information on such models is scarce.
Luminal elastase perfusion has been attempted on pigs19 and canines,20,21 but did not
appear to elicit true aneurysm formation in these cases. The development of such a
model in large animals would be extremely helpful in advancing the idea of PGGmediated elastin stabilization as a treatment for aneurysms.
2. Examine potential delivery methods for PGG applied to abdominal aortic
aneurysms. The high doses needed for systemic delivery of PGG would likely not be
tolerable (although this is yet to be determined), meaning optimization of a local delivery
method for PGG is apparently necessary. The use of PGG as an aneurysm treatment
could ultimately fall into one of two categories: (1) in conjunction with endovascular
stent grafts, or (2) as a stand-alone treatment, including for aneurysms at the early and
moderate stages for which there is no current option other than imaging surveillance.
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In regards to endovascular stent grafts, PGG could potentially be bound to these
luminal bypass devices and slowly released in the months or years following device
implantation. By delivering PGG to the area (as depicted in Figure 8.1A), we may be
able to limit any further elastolytic degradation in or around the aneurysmal sac. This
would be particularly useful near the neck of the stent graft, potentially reducing distal
migration and/or loss of graft fixation which are serious problems with these devices.
The efficacy and feasibility of such a combinatorial device needs to be investigated.
As a stand-alone treatment, PGG could be delivered perivascularly through a slow
release drug delivery system.

Polymers such as polyhydroxybutyrate22 and

polycaprolactone23 have been suggested and used as long-term (greater than one year)
drug delivery systems. These are just two examples of the types of polymers that could
be incorporated with PGG and developed into a “tube” device that wraps around the
diseased aorta, similar to Figure 8.1B. PGG may be able to be delivered as a stand-alone
treatment through the lumen as well, with the aid of a non-invasive catheter-driven device
which would release a single dose of the elastin-stabilizing agent. Again, the feasibility
and efficacy of such delivery devices would need to be evaluated.
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Figure 8.1 Conceptual depiction of potential aneurysm products for endovascular (A)
and perivascular (B) delivery of PGG to the diseased aorta.

3. Implement a time course study to evaluate in vivo binding of PGG within
animal models. Using any of the animal models mentioned above, the amount of PGG
which binds, and remains bound, needs to be documented long-term (at least 6 months).
This would aid in determining if (or how often) multiple PGG treatments would need to
be administered to properly hinder aneurysm progression, as well as potentially providing
insight on the necessary concentration of PGG. The use of radiolabelled PGG may be
beneficial for this purpose, as it would allow for monitoring of PGG content within the
tissue over a given time period.

Such studies could initially be done with current

experimental methods on rats, but would ideally be implemented with an optimized
delivery method for PGG, as described above.
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